<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Biomolecules</journal-id>
<journal-id journal-id-type="iso-abbrev">Biomolecules</journal-id>
<journal-id journal-id-type="publisher-id">biomolecules</journal-id>
<journal-title-group>
<journal-title>Biomolecules</journal-title>
</journal-title-group>
<issn pub-type="epub">2218-273X</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32369911</article-id>
<article-id pub-id-type="pmc">7277112</article-id>
<article-id pub-id-type="doi">10.3390/biom10050702</article-id>
<article-id pub-id-type="publisher-id">biomolecules-10-00702</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Oxidative Stress in DNA Repeat Expansion Disorders: A Focus on NRF2 Signaling Involvement</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9723-2363</contrib-id>
<name>
<surname>La Rosa</surname>
<given-names>Piergiorgio</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Petrillo</surname>
<given-names>Sara</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9276-4590</contrib-id>
<name>
<surname>Bertini</surname>
<given-names>Enrico Silvio</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1825-9347</contrib-id>
<name>
<surname>Piemonte</surname>
<given-names>Fiorella</given-names>
</name>
<xref ref-type="corresp" rid="c1-biomolecules-10-00702">*</xref>
</contrib>
</contrib-group>
<aff id="af1-biomolecules-10-00702">Unit of Muscular and Neurodegenerative Diseases, Bambino Gesù Children’s Hospital, IRCCS, 00146 Rome, Italy; <email>piergiorgio.larosa@opbg.net</email> (P.L.R.); <email>sara.petrillo@opbg.net</email> (S.P.); <email>enricosilvio.bertini@opbg.net</email> (E.S.B.)</aff>
<author-notes>
<corresp id="c1-biomolecules-10-00702"><label>*</label>Correspondence: <email>fiorella.piemonte@opbg.net</email>; Tel.: +39-06-6859-2102</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>5</month>
<year>2020</year>
</pub-date>
<volume>10</volume>
<issue>5</issue>
<elocation-id>702</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>4</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>4</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>DNA repeat expansion disorders are a group of neuromuscular and neurodegenerative diseases that arise from the inheritance of long tracts of nucleotide repetitions, located in the regulatory region, introns, or inside the coding sequence of a gene. Although loss of protein expression and/or the gain of function of its transcribed mRNA or translated product represent the major pathogenic effect of these pathologies, mitochondrial dysfunction and imbalance in redox homeostasis are reported as common features in these disorders, deeply affecting their severity and progression. In this review, we examine the role that the redox imbalance plays in the pathological mechanisms of DNA expansion disorders and the recent advances on antioxidant treatments, particularly focusing on the expression and the activity of the transcription factor NRF2, the main cellular regulator of the antioxidant response.</p>
</abstract>
<kwd-group>
<kwd>DNA repeat expansion disorders</kwd>
<kwd>NRF2</kwd>
<kwd>oxidative stress</kwd>
<kwd>FXTAS</kwd>
<kwd>fragile X syndrome</kwd>
<kwd>Friedreich’s ataxia</kwd>
<kwd>myotonic dystrophy</kwd>
<kwd>spinocerebellar ataxia</kwd>
<kwd>Huntington’s disease</kwd>
<kwd>spinal and bulbar muscular atrophy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-biomolecules-10-00702" sec-type="intro">
<title>1. Introduction</title>
<p>Microsatellites are stretches of DNA abundantly interspersed in the genome of prokaryotes and eukaryotes [<xref ref-type="bibr" rid="B1-biomolecules-10-00702">1</xref>,<xref ref-type="bibr" rid="B2-biomolecules-10-00702">2</xref>], including humans, where they account for the 3% of the genome [<xref ref-type="bibr" rid="B3-biomolecules-10-00702">3</xref>]. Their structure consists of short, tandemly repeated duplications of 1–6 base pairs, spanning between 20–100 bases [<xref ref-type="bibr" rid="B4-biomolecules-10-00702">4</xref>] and primarily consisting of mono- and dinucleotides, although tri-, tetra-, penta-, and hexa-nucleotides microsatellite classes are present [<xref ref-type="bibr" rid="B4-biomolecules-10-00702">4</xref>,<xref ref-type="bibr" rid="B5-biomolecules-10-00702">5</xref>]. Their location is ubiquitous, occurring both in protein-coding as well as in non-coding DNA regions, with preference for the latter [<xref ref-type="bibr" rid="B6-biomolecules-10-00702">6</xref>], and their functions range among several biological regulatory processes [<xref ref-type="bibr" rid="B7-biomolecules-10-00702">7</xref>], including alternative splicing [<xref ref-type="bibr" rid="B8-biomolecules-10-00702">8</xref>], transcription start/end site selection [<xref ref-type="bibr" rid="B9-biomolecules-10-00702">9</xref>,<xref ref-type="bibr" rid="B10-biomolecules-10-00702">10</xref>], nucleosome packaging [<xref ref-type="bibr" rid="B11-biomolecules-10-00702">11</xref>], and methylation [<xref ref-type="bibr" rid="B12-biomolecules-10-00702">12</xref>]. One of the most peculiar characteristics of microsatellites is their tendency to mutate. While 10<sup>−9</sup> is the rate of mutations occurring in non-repetitive region of the DNA, microsatellite mutation rate ranges between 10<sup>−2</sup> and 10<sup>−6</sup> [<xref ref-type="bibr" rid="B13-biomolecules-10-00702">13</xref>,<xref ref-type="bibr" rid="B14-biomolecules-10-00702">14</xref>]. Because of this, microsatellites are highly polymorphic, as the number of the repeats in a given locus is relatively unstable and frequently varies between individuals [<xref ref-type="bibr" rid="B15-biomolecules-10-00702">15</xref>]. Due to this feature, deregulated microsatellite expansions are widely known to be the triggering cause of many neurological and neuromuscular diseases and, to date, more than 30 disorders are known to be caused by aberrant expansion of repetitive DNA sequences [<xref ref-type="bibr" rid="B16-biomolecules-10-00702">16</xref>]. Although trinucleotides repeats, in particular GAA, CGG, CAG, and CTG, are commonly known to be responsible for the pathologic manifestation of nucleotide expansion disorders, also tetra- and penta-nucleotides expansions are disease causing [<xref ref-type="bibr" rid="B17-biomolecules-10-00702">17</xref>], thus these diseases are collectively classified as disorders of DNA unstable repeat expansions [<xref ref-type="bibr" rid="B18-biomolecules-10-00702">18</xref>]. Some peculiarities join this variegated group of pathologies: (i) The disease-causing expansion repeats are more unstable in the affected population, with a higher tendency to expand or to contract with respect to the polymorphic repeats of normal people, even if contraction events are rarer [<xref ref-type="bibr" rid="B16-biomolecules-10-00702">16</xref>]. This also occurs as the repeats reach the threshold limit between a normal condition and the pathological state. Thus, even in unaffected families, de novo mutations can determine clinical manifestations [<xref ref-type="bibr" rid="B19-biomolecules-10-00702">19</xref>]. (ii) The dynamic changes in the length of expansions are so marked that differences among patients, as well as in different tissues of the same affected proband, are common [<xref ref-type="bibr" rid="B16-biomolecules-10-00702">16</xref>]. (iii) The more the expansions are transmitted from generation to generation, the earlier the disease symptoms appear in the newly affected individuals, a phenomenon known as clinical anticipation [<xref ref-type="bibr" rid="B20-biomolecules-10-00702">20</xref>,<xref ref-type="bibr" rid="B21-biomolecules-10-00702">21</xref>,<xref ref-type="bibr" rid="B22-biomolecules-10-00702">22</xref>]. (iv) In most disorders, the length of repeat expansions influences the phenotype severity of affected individuals [<xref ref-type="bibr" rid="B23-biomolecules-10-00702">23</xref>,<xref ref-type="bibr" rid="B24-biomolecules-10-00702">24</xref>,<xref ref-type="bibr" rid="B25-biomolecules-10-00702">25</xref>,<xref ref-type="bibr" rid="B26-biomolecules-10-00702">26</xref>,<xref ref-type="bibr" rid="B27-biomolecules-10-00702">27</xref>,<xref ref-type="bibr" rid="B28-biomolecules-10-00702">28</xref>,<xref ref-type="bibr" rid="B29-biomolecules-10-00702">29</xref>]. Consequently, different defects for a given disease can be expressed among patients, including onset of symptoms and co-morbidities. For example, the incidence of diabetes in Friedreich’s ataxia (FA) ranges between 8–32% of patients [<xref ref-type="bibr" rid="B30-biomolecules-10-00702">30</xref>,<xref ref-type="bibr" rid="B31-biomolecules-10-00702">31</xref>,<xref ref-type="bibr" rid="B32-biomolecules-10-00702">32</xref>], but the risk of developing is directly correlated to the number of GAA repeats in the frataxin (<italic>FXN</italic>) gene [<xref ref-type="bibr" rid="B33-biomolecules-10-00702">33</xref>]. In the same way, in myotonic dystrophy (DM), patients carrying small CTG repeats (i.e., between 50–99) are asymptomatic or develop mild defects, such as cataracts, while a severe phenotype occurs in patients with 100–200 repeats [<xref ref-type="bibr" rid="B34-biomolecules-10-00702">34</xref>].</p>
<p>Beside these common features, a high grade of diversity characterizes DNA expansion disorders, as the DNA expanded tracts can affect genes encoding proteins with different roles. Therefore, three different classes have been distinguished, by assembling disorders on the basis of which defects arise from expansions. The first class groups the diseases that are determined by a protein loss of function and are inherited by autosomal recessive or x-linked manner [<xref ref-type="bibr" rid="B19-biomolecules-10-00702">19</xref>]. Typical examples are Fragile X (FXS) or FA, where CGG or GAA repeats determine the loss of the expression of the fragile X mental retardation protein (FMRP) and FXN, respectively [<xref ref-type="bibr" rid="B35-biomolecules-10-00702">35</xref>,<xref ref-type="bibr" rid="B36-biomolecules-10-00702">36</xref>]. The second group belongs to disorders characterized by an autosomal dominant inheritance and in which a protein gain of function occurs [<xref ref-type="bibr" rid="B18-biomolecules-10-00702">18</xref>]. PolyQ diseases, for instance, are determined by CAG expansions in the coding region of 9 distinct genes that lead to the formation of glutamine residues in the final peptide of their encoded product [<xref ref-type="bibr" rid="B37-biomolecules-10-00702">37</xref>]. PolyQ tracts exert a toxic effect mainly by causing aberrant nuclear and cytoplasmic protein aggregation and trapping transcription factors [<xref ref-type="bibr" rid="B38-biomolecules-10-00702">38</xref>,<xref ref-type="bibr" rid="B39-biomolecules-10-00702">39</xref>], chaperons, and proteins belonging to the ubiquitin–proteasome system (UPS) [<xref ref-type="bibr" rid="B40-biomolecules-10-00702">40</xref>]. The third group of disorders are characterized by gain of function involving the transcribed RNA. DM1 and DM2 are respectively caused by the aberrant insertion of CTG and CCTG expansion repeats in the 3′ untranslated region (UTR) of dystrophin myotonic protein kinase (<italic>DMPK</italic>) [<xref ref-type="bibr" rid="B41-biomolecules-10-00702">41</xref>] and in the first intron of zinc-finger protein 9 (<italic>ZNF9</italic>) [<xref ref-type="bibr" rid="B42-biomolecules-10-00702">42</xref>]. Similarly, the CGG triplet expansion in <italic>FMR1</italic> gene, ranging between 60–200 triplets, causes the fragile X–associated tremor ataxia syndrome (FXTAS) [<xref ref-type="bibr" rid="B43-biomolecules-10-00702">43</xref>]. The pathogenic activity, both in DM and in FXTAS, lies on of the respective expanded mRNA molecules, which are able to sequestrate RNA binding proteins, such as muscleblind-like (MBNL) proteins in DM1, determining splicing alterations and impairments in protein expression [<xref ref-type="bibr" rid="B44-biomolecules-10-00702">44</xref>,<xref ref-type="bibr" rid="B45-biomolecules-10-00702">45</xref>,<xref ref-type="bibr" rid="B46-biomolecules-10-00702">46</xref>,<xref ref-type="bibr" rid="B47-biomolecules-10-00702">47</xref>].</p>
<p>Oxidative stress has been widely reported to play a prominent role in neurodegenerative diseases [<xref ref-type="bibr" rid="B48-biomolecules-10-00702">48</xref>,<xref ref-type="bibr" rid="B49-biomolecules-10-00702">49</xref>], including disorders caused by DNA expansion repeats (<xref ref-type="fig" rid="biomolecules-10-00702-f001">Figure 1</xref>). Here, we report the most recent evidences connecting ROS imbalance and DNA expansion disorders, with particular emphasis to the pathway primarily involved in the regulation of cellular antioxidant response, the NF-E2 p45-related factor 2 (NRF2) signaling pathway.</p>
</sec>
<sec id="sec2-biomolecules-10-00702">
<title>2. Oxidative Stress and Cellular Responses</title>
<p>Oxidative stress occurs when the balance between ROS production and elimination cannot be maintained in the cell, thus determining damage on lipids, proteins, and nucleic acids, ultimately leading to cell death [<xref ref-type="bibr" rid="B50-biomolecules-10-00702">50</xref>,<xref ref-type="bibr" rid="B51-biomolecules-10-00702">51</xref>]. Oxidative stress can be determined by exogenous (i.e., UV light or chemicals) and endogenous factors [<xref ref-type="bibr" rid="B52-biomolecules-10-00702">52</xref>], as mitochondrial metabolism and NADH oxidase activity, the major endogenous ROS sources [<xref ref-type="bibr" rid="B53-biomolecules-10-00702">53</xref>,<xref ref-type="bibr" rid="B54-biomolecules-10-00702">54</xref>]. ROS production and elimination are tightly controlled in the cell, as aerobic organisms use O<sub>2</sub> molecules in redox reactions needed for energy demands and oxygen byproducts (superoxide anion, O<sub>2</sub><sup>−</sup>, hydrogen peroxide, H<sub>2</sub>O<sub>2</sub>, hydroxyl radical, HO*) to transduce regulatory signals [<xref ref-type="bibr" rid="B55-biomolecules-10-00702">55</xref>,<xref ref-type="bibr" rid="B56-biomolecules-10-00702">56</xref>,<xref ref-type="bibr" rid="B57-biomolecules-10-00702">57</xref>,<xref ref-type="bibr" rid="B58-biomolecules-10-00702">58</xref>]. Thus, an efficient antioxidant cellular machinery is essential to mitigate adverse effects and to permit a correct signaling cascade modulation. This variety of endogenous defenses consists of antioxidant enzymes, including superoxide dismutases (SODs) [<xref ref-type="bibr" rid="B59-biomolecules-10-00702">59</xref>], catalase [<xref ref-type="bibr" rid="B60-biomolecules-10-00702">60</xref>], glutathione peroxidases (GPXs) [<xref ref-type="bibr" rid="B61-biomolecules-10-00702">61</xref>], and scavenger molecules, such as glutathione (GSH), ubiquinol (CoQ10), uric acid, and others [<xref ref-type="bibr" rid="B62-biomolecules-10-00702">62</xref>].</p>
<p>GSH, in particular, represents the most important endogenous antioxidant for its dual function, as a direct ROS scavenger [<xref ref-type="bibr" rid="B63-biomolecules-10-00702">63</xref>,<xref ref-type="bibr" rid="B64-biomolecules-10-00702">64</xref>] and as cofactor in reactions catalyzed by antioxidant enzymes (e.g., glutathione reductase, GR, GPXs) [<xref ref-type="bibr" rid="B65-biomolecules-10-00702">65</xref>] and in those involved in the elimination of xenobiotics (glutathione-S transferases, GSTs) [<xref ref-type="bibr" rid="B66-biomolecules-10-00702">66</xref>]. The GSH synthesis occurs in 2 steps, the first uses cysteine and glutamate as substrates and is catalyzed by the glutamate cysteine ligase (GCL), while the second, catalyzed by the glutathione synthetase (GSS), binds glycine to the pre-synthesized dipeptide [<xref ref-type="bibr" rid="B67-biomolecules-10-00702">67</xref>,<xref ref-type="bibr" rid="B68-biomolecules-10-00702">68</xref>].</p>
<p>Under physiological conditions, a basal expression of this antioxidant machinery is available in cells. However, to promptly answer to redox imbalance that ranges from mild to high pathologic- induced oxidative stress [<xref ref-type="bibr" rid="B69-biomolecules-10-00702">69</xref>,<xref ref-type="bibr" rid="B70-biomolecules-10-00702">70</xref>], cells evolved the transcription-independent activation of NRF2, able in turn to modulate the expression of several antioxidant enzymes (SODs, catalase, GPXs), to ensure the GSH synthesis (by GCL expression) and to reduce toxic quinones by the action of NAD(P)H: quinone oxidoreductase (NQO1) [<xref ref-type="bibr" rid="B70-biomolecules-10-00702">70</xref>,<xref ref-type="bibr" rid="B71-biomolecules-10-00702">71</xref>,<xref ref-type="bibr" rid="B72-biomolecules-10-00702">72</xref>].</p>
</sec>
<sec id="sec3-biomolecules-10-00702">
<title>3. NRF2 Pathway and Its Regulation</title>
<p>NRF2 is a transcription factor belonging to the cap ‘n’ collar (CNC) basic leucine zipper (bZip) proteins [<xref ref-type="bibr" rid="B73-biomolecules-10-00702">73</xref>,<xref ref-type="bibr" rid="B74-biomolecules-10-00702">74</xref>]. In the nucleus, it dimerizes with the small musculoaponeurotic fibrosarcoma (sMAF) proteins, particularly with F, G, and K isoforms [<xref ref-type="bibr" rid="B75-biomolecules-10-00702">75</xref>,<xref ref-type="bibr" rid="B76-biomolecules-10-00702">76</xref>]. The NRF2-sMAF heterodimer binds to specific 16 base long DNA stretches (the antioxidant responsive elements, ARE), acting as enhancer for gene transcription [<xref ref-type="bibr" rid="B77-biomolecules-10-00702">77</xref>]. NRF2 is able to regulate the expression of at least 250 genes [<xref ref-type="bibr" rid="B78-biomolecules-10-00702">78</xref>] and, besides being the master regulator of cellular antioxidant defense, its activity participates to the modulation of different cellular processes, including metabolism, survival, differentiation, inflammation, mitochondrial biogenesis, and mitophagy [<xref ref-type="bibr" rid="B69-biomolecules-10-00702">69</xref>,<xref ref-type="bibr" rid="B78-biomolecules-10-00702">78</xref>,<xref ref-type="bibr" rid="B79-biomolecules-10-00702">79</xref>,<xref ref-type="bibr" rid="B80-biomolecules-10-00702">80</xref>,<xref ref-type="bibr" rid="B81-biomolecules-10-00702">81</xref>,<xref ref-type="bibr" rid="B82-biomolecules-10-00702">82</xref>,<xref ref-type="bibr" rid="B83-biomolecules-10-00702">83</xref>,<xref ref-type="bibr" rid="B84-biomolecules-10-00702">84</xref>]. For this reason, the NRF2 activity and expression are subjected to a tight and fine-tuned control mechanism, to avoid unwanted gene expression upregulation and, at the same time, determining a fast response in case of need. Upon oxidative stress, the induction of NRF2 occurs by regulating its stability and localization in the cell [<xref ref-type="bibr" rid="B72-biomolecules-10-00702">72</xref>], and modulating the amount of its mRNA transcript [<xref ref-type="bibr" rid="B81-biomolecules-10-00702">81</xref>,<xref ref-type="bibr" rid="B85-biomolecules-10-00702">85</xref>].</p>
<p>Under physiological condition, NRF2 has a short half-life, spanning between 15–40 min, and its cellular localization is restricted to the cytoplasm [<xref ref-type="bibr" rid="B86-biomolecules-10-00702">86</xref>]. Soon after translation, NRF2 interacts with the ubiquitin ligase adaptor KEAP1 (Kelch-like ECH-associated protein 1) that sequesters the transcription factor and mediates its proteasomal degradation [<xref ref-type="bibr" rid="B87-biomolecules-10-00702">87</xref>]. In parallel, free NRF2 can be phosphorylated by the GSK3β kinase, which increases the NRF2 proteasomal-mediated turnover [<xref ref-type="bibr" rid="B71-biomolecules-10-00702">71</xref>,<xref ref-type="bibr" rid="B86-biomolecules-10-00702">86</xref>]. These two mechanisms work in conjunction to regulate NRF2 activity, in response to different cellular cues. Under redox imbalance, the KEAP1–NRF2 interaction is disrupted, as result of ROS-induced conformational changes of KEAP1 [<xref ref-type="bibr" rid="B88-biomolecules-10-00702">88</xref>]. Conversely, the activation of growth factor receptors determines the AKT/PI3K-induced inhibitory phosphorylation of GSK3β, thus allowing NRF2 accumulation [<xref ref-type="bibr" rid="B89-biomolecules-10-00702">89</xref>]. This regulatory system points to the NRF2/ARE axis as one of the most important signaling pathway in cells. Indeed, being ARE sequences implicated in the regulation of more than 1% of human genes [<xref ref-type="bibr" rid="B86-biomolecules-10-00702">86</xref>], impairments of NRF2 signaling network may interfere with multiple cellular processes and determine redox imbalance, a condition commonly encountered in cancers [<xref ref-type="bibr" rid="B90-biomolecules-10-00702">90</xref>,<xref ref-type="bibr" rid="B91-biomolecules-10-00702">91</xref>,<xref ref-type="bibr" rid="B92-biomolecules-10-00702">92</xref>] and in neurological disorders. Re-establishing NRF2 signaling homeostasis can be essential to improve the pathological phenotypes, especially in neurodegenerative diseases [<xref ref-type="bibr" rid="B93-biomolecules-10-00702">93</xref>,<xref ref-type="bibr" rid="B94-biomolecules-10-00702">94</xref>,<xref ref-type="bibr" rid="B95-biomolecules-10-00702">95</xref>].</p>
<p>Recent evidences increasingly highlight a dual role of NRF2 in the diseases’ pathogenesis. In cancer, for instance, the activation of Nrf2 appears correlated with progression and chemo-resistance, and its downregulation has attracted growing attention as alternative cancer therapy [<xref ref-type="bibr" rid="B96-biomolecules-10-00702">96</xref>]. Several studies have clearly demonstrated that the hyper-activation of the NRF2 pathway may create an environment favoring the survival of malignant cells, protecting them against oxidative stress, chemotherapeutic agents, and radiotherapy [<xref ref-type="bibr" rid="B97-biomolecules-10-00702">97</xref>,<xref ref-type="bibr" rid="B98-biomolecules-10-00702">98</xref>]. Indeed, although a transient NRF2 activation in response to stress may be beneficial for health, a persistent induction can confer therapeutic resistance in cancer cells and more aggressive tumorigenicity, leading to poor prognoses in patients. In this light, the inhibition of NRF2 is a promising therapeutic approach in cancer and NRF2 inhibitors are being actively developed [<xref ref-type="bibr" rid="B99-biomolecules-10-00702">99</xref>]. Contrariwise, NRF2 appears inhibited in many neurodegenerative disorders, such as Huntington’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, multiple sclerosis and FA, where its activation has been proven mitigating pathogenic processes by upregulating antioxidant defenses, decreasing inflammation, and improving mitochondrial function [<xref ref-type="bibr" rid="B80-biomolecules-10-00702">80</xref>,<xref ref-type="bibr" rid="B100-biomolecules-10-00702">100</xref>,<xref ref-type="bibr" rid="B101-biomolecules-10-00702">101</xref>,<xref ref-type="bibr" rid="B102-biomolecules-10-00702">102</xref>,<xref ref-type="bibr" rid="B103-biomolecules-10-00702">103</xref>]. Therefore, a dual face of Nrf2 in cancer and neurodegenerative diseases has to be recognized, making its role in the pathogenesis’ mechanisms even more attractive.</p>
</sec>
<sec id="sec4-biomolecules-10-00702">
<title>4. Oxidative Stress in Loss of Function DNA Expansion Disease</title>
<sec id="sec4dot1-biomolecules-10-00702">
<title>4.1. Friedreich’s Ataxia (FA)</title>
<p>(FA) is an autosomal recessive neurodegenerative disease caused by a homozygous GAA trinucleotide repeat expansion in the first intron of the FXN gene, encoding for the mitochondrial FXN protein [<xref ref-type="bibr" rid="B36-biomolecules-10-00702">36</xref>,<xref ref-type="bibr" rid="B104-biomolecules-10-00702">104</xref>]. The GAA repeated expansions cause histones deacetylation and abnormal DNA conformation, leading to decreased mRNA levels and FXN amount [<xref ref-type="bibr" rid="B105-biomolecules-10-00702">105</xref>]. FA is clinically characterized by progressive ataxia, diabetes, cardiomyopathy, skeletal deformations, altered central and peripheral nervous system with lesions in the dorsal root ganglia, dentate nuclei of the cerebellum, corticospinal tracts, and sensory peripheral nerves [<xref ref-type="bibr" rid="B106-biomolecules-10-00702">106</xref>,<xref ref-type="bibr" rid="B107-biomolecules-10-00702">107</xref>,<xref ref-type="bibr" rid="B108-biomolecules-10-00702">108</xref>]. Actually, the FXN function is still unclear, although it is well known to be involved in iron–sulphur cluster biogenesis and in heme biosynthesis. The FXN deficiency increases the mitochondrial iron content, altering activities of iron–sulphur (Fe-S) cluster enzymes in mitochondria and causing oxidative stress in affected tissues [<xref ref-type="bibr" rid="B109-biomolecules-10-00702">109</xref>,<xref ref-type="bibr" rid="B110-biomolecules-10-00702">110</xref>,<xref ref-type="bibr" rid="B111-biomolecules-10-00702">111</xref>]. Oxidative stress is a leading hypothesis in the pathogenesis of FA, since the identification of the gene in 1996 and later supported and confirmed by several studies in human and mouse FA models [<xref ref-type="bibr" rid="B112-biomolecules-10-00702">112</xref>,<xref ref-type="bibr" rid="B113-biomolecules-10-00702">113</xref>,<xref ref-type="bibr" rid="B114-biomolecules-10-00702">114</xref>,<xref ref-type="bibr" rid="B115-biomolecules-10-00702">115</xref>].</p>
<p>Several studies have demonstrated an impairment of the NRF2 pathway in FA [<xref ref-type="bibr" rid="B116-biomolecules-10-00702">116</xref>,<xref ref-type="bibr" rid="B117-biomolecules-10-00702">117</xref>,<xref ref-type="bibr" rid="B118-biomolecules-10-00702">118</xref>,<xref ref-type="bibr" rid="B119-biomolecules-10-00702">119</xref>] and alterations of systemic redox markers have been evidenced in patients. An increased oxidative damage on nuclear and mitochondrial DNA has been found in peripheral blood cells, together with high levels of plasma malondialdehyde and of urine 8-hydroxy-2-desoxiguanosine [<xref ref-type="bibr" rid="B120-biomolecules-10-00702">120</xref>,<xref ref-type="bibr" rid="B121-biomolecules-10-00702">121</xref>]. A decrease of glutathione levels and of antioxidant enzymes activities (SOD and GST) have been also reported in fibroblasts and in blood of patients [<xref ref-type="bibr" rid="B122-biomolecules-10-00702">122</xref>,<xref ref-type="bibr" rid="B123-biomolecules-10-00702">123</xref>]. Recently, lipid peroxidation and ferroptosis have also been suggested as responsible for the FA pathophysiology [<xref ref-type="bibr" rid="B124-biomolecules-10-00702">124</xref>,<xref ref-type="bibr" rid="B125-biomolecules-10-00702">125</xref>,<xref ref-type="bibr" rid="B126-biomolecules-10-00702">126</xref>]. It is important to note that two ferroptosis-triggering enzymes (GPX4 and cysteine/glutamate transporter system, xC-/xCT) are downstream targets of NRF2 [<xref ref-type="bibr" rid="B127-biomolecules-10-00702">127</xref>]. For all these findings, NRF2 has recently attracted attention for novel therapeutic strategies in FA [<xref ref-type="bibr" rid="B72-biomolecules-10-00702">72</xref>,<xref ref-type="bibr" rid="B94-biomolecules-10-00702">94</xref>,<xref ref-type="bibr" rid="B128-biomolecules-10-00702">128</xref>,<xref ref-type="bibr" rid="B129-biomolecules-10-00702">129</xref>]. Among the main pharmacological NRF2 activators, we can mention the Sulforaphane (SFN), a natural blood–brain-barrier permeable antioxidant, and the dimethyl fumarate (DMF), an ester of fumaric acid recently approved for the treatment of multiple sclerosis [<xref ref-type="bibr" rid="B130-biomolecules-10-00702">130</xref>,<xref ref-type="bibr" rid="B131-biomolecules-10-00702">131</xref>,<xref ref-type="bibr" rid="B132-biomolecules-10-00702">132</xref>,<xref ref-type="bibr" rid="B133-biomolecules-10-00702">133</xref>] and promising for adrenoleukodystrophy [<xref ref-type="bibr" rid="B134-biomolecules-10-00702">134</xref>]. The efficacy of these NRF2 inducers has been verified on several FXN deficient models [<xref ref-type="bibr" rid="B81-biomolecules-10-00702">81</xref>,<xref ref-type="bibr" rid="B85-biomolecules-10-00702">85</xref>,<xref ref-type="bibr" rid="B135-biomolecules-10-00702">135</xref>], where they significantly increased NRF2 mRNA levels [<xref ref-type="bibr" rid="B85-biomolecules-10-00702">85</xref>], re-balanced the GSH/GSSG ratio [<xref ref-type="bibr" rid="B85-biomolecules-10-00702">85</xref>,<xref ref-type="bibr" rid="B135-biomolecules-10-00702">135</xref>], and up-regulated the FXN gene expression [<xref ref-type="bibr" rid="B85-biomolecules-10-00702">85</xref>,<xref ref-type="bibr" rid="B135-biomolecules-10-00702">135</xref>,<xref ref-type="bibr" rid="B136-biomolecules-10-00702">136</xref>,<xref ref-type="bibr" rid="B137-biomolecules-10-00702">137</xref>] (<xref ref-type="fig" rid="biomolecules-10-00702-f002">Figure 2</xref>).</p>
<p>Currently, clinical FA trials are focused on improving mitochondrial function and reducing oxidative stress [<xref ref-type="bibr" rid="B138-biomolecules-10-00702">138</xref>]. Idebenone (Raxone<sup>®</sup>/Catena<sup>®</sup>), for instance, is proven to be effective on the mitochondrial function. But, despite an initial optimism on its cardiac impact, the neurological benefit in FA is still under evaluation [<xref ref-type="bibr" rid="B139-biomolecules-10-00702">139</xref>,<xref ref-type="bibr" rid="B140-biomolecules-10-00702">140</xref>,<xref ref-type="bibr" rid="B141-biomolecules-10-00702">141</xref>]. RTA408 (Omaveloxolone), a specific NRF2 inducer [<xref ref-type="bibr" rid="B142-biomolecules-10-00702">142</xref>], is currently being tested in a 12 months placebo-controlled trial (<uri xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</uri>). EPI-743 (vatiquinone), another highly promising drug for FA [<xref ref-type="bibr" rid="B143-biomolecules-10-00702">143</xref>], was approved in 2011 for children with genetically confirmed inherited respiratory chain diseases, but still not clinically tested in FA, although it has been proven to activate NRF2 and increase the expression of FXN in fibroblasts of FA patients [<xref ref-type="bibr" rid="B85-biomolecules-10-00702">85</xref>].</p>
</sec>
<sec id="sec4dot2-biomolecules-10-00702">
<title>4.2. X-Fragile (FXS)</title>
<p>FXS syndrome is caused by the absence or deficiency of FMRP, the gene product of <italic>FMR1</italic> [<xref ref-type="bibr" rid="B144-biomolecules-10-00702">144</xref>]. In most cases, CGG trinucleotide expansions at the <italic>FMR1</italic> promoter determine its transcriptional silencing, giving rise to the disease [<xref ref-type="bibr" rid="B145-biomolecules-10-00702">145</xref>]. More than 200 CGG repeat expansions determine the FXS phenotype, while premutation alleles, bearing 55–200 CGG tracts, are recognized to cause FXTAS. Mutations or deletions in the <italic>FMR1</italic> gene have been also reported in FXS patients [<xref ref-type="bibr" rid="B146-biomolecules-10-00702">146</xref>,<xref ref-type="bibr" rid="B147-biomolecules-10-00702">147</xref>], as well as mosaicisms of repeat length (i.e., some cells harboring the full mutation in one allele and others containing the premutation allele), or of methylation [<xref ref-type="bibr" rid="B148-biomolecules-10-00702">148</xref>]. FXS represents the most common form of inherited intellectual disability [<xref ref-type="bibr" rid="B145-biomolecules-10-00702">145</xref>], affecting 1:5000 males and 1:4000–8000 females [<xref ref-type="bibr" rid="B144-biomolecules-10-00702">144</xref>], often associated with autism spectrum disorder comorbidities, estimated in about 50% patients [<xref ref-type="bibr" rid="B149-biomolecules-10-00702">149</xref>]. Clinical FXS manifestations include language development delays, hyperactivity, anxiety, and physical dysmorphic features [<xref ref-type="bibr" rid="B150-biomolecules-10-00702">150</xref>,<xref ref-type="bibr" rid="B151-biomolecules-10-00702">151</xref>]. Females’ phenotype is usually less severe, due to the presence of the second X chromosome that can restore FMRP expression in approximately 50% of cells [<xref ref-type="bibr" rid="B152-biomolecules-10-00702">152</xref>].</p>
<p>FMRP is a RNA-binding protein forming a ribonucleoproteic complex that associates to polyribosomes and regulates mRNA metabolism, acting as a translation suppressor [<xref ref-type="bibr" rid="B153-biomolecules-10-00702">153</xref>]. Its expression is particularly high in neurons, where it shuttles between nucleus and axons or dendrites [<xref ref-type="bibr" rid="B154-biomolecules-10-00702">154</xref>,<xref ref-type="bibr" rid="B155-biomolecules-10-00702">155</xref>] and carries out its function, especially at postsynaptic sites, where it transports mRNA cargos [<xref ref-type="bibr" rid="B156-biomolecules-10-00702">156</xref>,<xref ref-type="bibr" rid="B157-biomolecules-10-00702">157</xref>] and where its activity is tightly regulated by synaptic receptors [<xref ref-type="bibr" rid="B158-biomolecules-10-00702">158</xref>,<xref ref-type="bibr" rid="B159-biomolecules-10-00702">159</xref>,<xref ref-type="bibr" rid="B160-biomolecules-10-00702">160</xref>,<xref ref-type="bibr" rid="B161-biomolecules-10-00702">161</xref>,<xref ref-type="bibr" rid="B162-biomolecules-10-00702">162</xref>]. The absence of FMRP mostly determines an increase of translation rate of its targets [<xref ref-type="bibr" rid="B163-biomolecules-10-00702">163</xref>,<xref ref-type="bibr" rid="B164-biomolecules-10-00702">164</xref>,<xref ref-type="bibr" rid="B165-biomolecules-10-00702">165</xref>,<xref ref-type="bibr" rid="B166-biomolecules-10-00702">166</xref>] and impairs the synaptic development and plasticity in specific brain areas [<xref ref-type="bibr" rid="B158-biomolecules-10-00702">158</xref>,<xref ref-type="bibr" rid="B167-biomolecules-10-00702">167</xref>].</p>
<p>Oxidative stress in FXS has been suggested by a number of indirect evidences: (i) aging-dependent oxidative stress increase is responsible for impairments in long-term (LTP) potentiation in the hippocampus [<xref ref-type="bibr" rid="B168-biomolecules-10-00702">168</xref>], a condition described in FXS [<xref ref-type="bibr" rid="B158-biomolecules-10-00702">158</xref>,<xref ref-type="bibr" rid="B169-biomolecules-10-00702">169</xref>]. (ii) Anxiety and autism, which are strongly linked to ROS impairments, are common conditions in the pathology [<xref ref-type="bibr" rid="B170-biomolecules-10-00702">170</xref>,<xref ref-type="bibr" rid="B171-biomolecules-10-00702">171</xref>,<xref ref-type="bibr" rid="B172-biomolecules-10-00702">172</xref>]. (iii) As in Alzheimer’s disease, where oxidative stress is a recognized contributing factor in progression and pathogenesis of the disorder [<xref ref-type="bibr" rid="B48-biomolecules-10-00702">48</xref>], in models of FXS amyloid beta (Aβ) expression is increased, probably as a consequence of FMRP-mediated dysregulation of amyloid precursor protein (APP) translation [<xref ref-type="bibr" rid="B173-biomolecules-10-00702">173</xref>]. Despite these evidences, only a moderate increase of oxidative stress has been documented in FXS. Biochemical markers of oxidative stress have been detected in the brain of Fmrp1 KO mice, where increased ROS levels, high content of lipid peroxidation byproducts (i.e., thiobarbituric acid reactive substances, TBARS), enhanced carbonyl protein content, and imbalance of the GSH/GSSG redox ratio have been found in 2–4 months old mice, although these markers appeared to normalize over time [<xref ref-type="bibr" rid="B174-biomolecules-10-00702">174</xref>]. Moreover, although FMRP favors the translation of SOD1 mRNA [<xref ref-type="bibr" rid="B175-biomolecules-10-00702">175</xref>,<xref ref-type="bibr" rid="B176-biomolecules-10-00702">176</xref>] and, consequently, Fmr1 null mice display a strongly reduced expression of SOD1 [<xref ref-type="bibr" rid="B176-biomolecules-10-00702">176</xref>], to date, definitive proofs on oxidative stress depending on SOD1 decreased activity are still lacking in FXS. These apparent inconsistencies could be related to an indirect redox regulation operated by FMRP on NRF2. Indeed, the lack of FMRP increases the synthesis and the activity of the small Rho GTPase RAC1 [<xref ref-type="bibr" rid="B177-biomolecules-10-00702">177</xref>], which exerts a role in ROS modulation and in the inflammatory response [<xref ref-type="bibr" rid="B178-biomolecules-10-00702">178</xref>] by inducing NRF2 and up-regulating HO-1 expression [<xref ref-type="bibr" rid="B177-biomolecules-10-00702">177</xref>]. RAC1 is known to participate in the activation of PI3K and MAPKs signaling pathways [<xref ref-type="bibr" rid="B179-biomolecules-10-00702">179</xref>,<xref ref-type="bibr" rid="B180-biomolecules-10-00702">180</xref>], thus suggesting that the modulation of NRF2 activity may depend on the RAC1 mediated AKT/PI3K-induced inhibitory phosphorylation of GSK3β [<xref ref-type="bibr" rid="B89-biomolecules-10-00702">89</xref>,<xref ref-type="bibr" rid="B181-biomolecules-10-00702">181</xref>], possibly rebalancing oxidative and inflammatory responses in FXS [<xref ref-type="bibr" rid="B177-biomolecules-10-00702">177</xref>].</p>
</sec>
</sec>
<sec id="sec5-biomolecules-10-00702">
<title>5. Oxidative Stress in CAG/polyQ Diseases</title>
<sec id="sec5dot1-biomolecules-10-00702">
<title>5.1. Spinobulbar Muscular Atrophy (SBMA)</title>
<p>SBMA, also known as Kennedy’s disease, is a neuromuscular X-linked disorder, which exclusively affects adult males [<xref ref-type="bibr" rid="B182-biomolecules-10-00702">182</xref>]. Patients display progressive cramps, fasciculation, tremor, and weakness of skeletal muscles (especially bulbar, facial, and limb ones) [<xref ref-type="bibr" rid="B183-biomolecules-10-00702">183</xref>], together with a mild androgen insensitivity syndrome (AIS) and sensory loss [<xref ref-type="bibr" rid="B184-biomolecules-10-00702">184</xref>,<xref ref-type="bibr" rid="B185-biomolecules-10-00702">185</xref>]. SBMA is due to spinal and bulbar motor neurons death, triggered by an expansion of more than 38 glutamine residues in the androgen receptor (AR) protein [<xref ref-type="bibr" rid="B186-biomolecules-10-00702">186</xref>], a ligand activated transcriptional factor that mediates the cellular effects of the sex hormone testosterone and its metabolites [<xref ref-type="bibr" rid="B187-biomolecules-10-00702">187</xref>]. The pathogenic mechanism in SBMA is unique respect to the other polyQ diseases. Nuclear and cytoplasmic inclusions of poliQ AR, UPS components, heat shock proteins (HSPs), and AR coactivators can be found in SBMA [<xref ref-type="bibr" rid="B188-biomolecules-10-00702">188</xref>,<xref ref-type="bibr" rid="B189-biomolecules-10-00702">189</xref>], however, other mechanisms participate to the pathogenicity of this disorder. PolyQ AR retains most of its functionality, but the region in which glutamine expansion occurs localizes in the N-terminal domain that is responsible for multiple protein–protein interactions [<xref ref-type="bibr" rid="B190-biomolecules-10-00702">190</xref>]. This lead to partial loss of transcriptional activity [<xref ref-type="bibr" rid="B191-biomolecules-10-00702">191</xref>], sequestration of transcription activators [<xref ref-type="bibr" rid="B192-biomolecules-10-00702">192</xref>], and block of the AR-dependent non genomic signaling cascades [<xref ref-type="bibr" rid="B189-biomolecules-10-00702">189</xref>]. Moreover, the pathogenic activity of polyG expanded AR seems to heavily depend on its ligands. Indeed, females homozygous for glutamine expanded AR display mild sings of SBMA [<xref ref-type="bibr" rid="B193-biomolecules-10-00702">193</xref>] and studies in SBMA animal models demonstrated their androgen dependence [<xref ref-type="bibr" rid="B194-biomolecules-10-00702">194</xref>,<xref ref-type="bibr" rid="B195-biomolecules-10-00702">195</xref>]. Moreover, it has been proposed that WT AR signaling could play a role in the regulation of the expression of neurotrophins and growth factors known to support neuronal survival [<xref ref-type="bibr" rid="B182-biomolecules-10-00702">182</xref>,<xref ref-type="bibr" rid="B196-biomolecules-10-00702">196</xref>], a function that should be lost in the mutant receptor. Low expression of GDNF, for instance, was encountered in SBMA patients [<xref ref-type="bibr" rid="B197-biomolecules-10-00702">197</xref>] and GDNF, IGF-1, and VEGF reduced expression was assessed in mouse models of the pathology [<xref ref-type="bibr" rid="B198-biomolecules-10-00702">198</xref>,<xref ref-type="bibr" rid="B199-biomolecules-10-00702">199</xref>].</p>
<p>Part of the SBMA pathogenic mechanism could be explained by increased ROS levels [<xref ref-type="bibr" rid="B200-biomolecules-10-00702">200</xref>] and mitochondrial dysfunction [<xref ref-type="bibr" rid="B201-biomolecules-10-00702">201</xref>]. Under physiological conditions, AR regulates the expression of several nuclear- and mitochondrial-DNA encoded proteins [<xref ref-type="bibr" rid="B202-biomolecules-10-00702">202</xref>]. Thus, in cells expressing polyQ AR, numerous genes implicated in mitochondrial function are altered [<xref ref-type="bibr" rid="B200-biomolecules-10-00702">200</xref>]. Moreover, mutant AR has been found to associate with the mitochondria in MN-1 cells, where it activates the intrinsic apoptotic pathway [<xref ref-type="bibr" rid="B200-biomolecules-10-00702">200</xref>], and, in HeLa cells transfected with AR receptor bearing 48 glutamine expansions, mitochondria were sequestered in polyQ AR inclusions [<xref ref-type="bibr" rid="B203-biomolecules-10-00702">203</xref>]. Although the toxicity of cytoplasmic AR aggregates has been questioned, [<xref ref-type="bibr" rid="B204-biomolecules-10-00702">204</xref>,<xref ref-type="bibr" rid="B205-biomolecules-10-00702">205</xref>] and mitochondrial sequestration was not found in polyQ AR expressing NSC34 motor neurons [<xref ref-type="bibr" rid="B206-biomolecules-10-00702">206</xref>], mutant AR aggregates-mediated impairment of mitochondria transport along the neurites has been hypothesized in SBMA [<xref ref-type="bibr" rid="B206-biomolecules-10-00702">206</xref>]. Another cause of mitochondrial impairment could be the androgen-dependent association of polyQ AR with the respiratory chain enzyme cytochrome c oxidase subunit Vb (COXVb), that could be trapped in mutant AR aggregates, interfering with the physiological function of oxidative phosphorylation [<xref ref-type="bibr" rid="B207-biomolecules-10-00702">207</xref>]. It is important to underline that numerous cellular antioxidants are downregulated in SBMA, including proteins belonging to the pathway regulated by NRF2 (SODs, catalase [<xref ref-type="bibr" rid="B200-biomolecules-10-00702">200</xref>], NQO1, and GPX). The expression of NRF2 itself was deeply reduced in motor neurons of mice carrying 100 glutamine expansions in AR with respect to the non-pathogenic 20 polyQ repeats-containing AR mice [<xref ref-type="bibr" rid="B208-biomolecules-10-00702">208</xref>], and in MN-1 cells expressing the mutant AR [<xref ref-type="bibr" rid="B200-biomolecules-10-00702">200</xref>]. Interestingly, some studies attempted to correct protein misfolding-induced aggregates by using curcumin, an antioxidant polyphenol whose activity was neuroprotective [<xref ref-type="bibr" rid="B209-biomolecules-10-00702">209</xref>,<xref ref-type="bibr" rid="B210-biomolecules-10-00702">210</xref>]. Curcumin treatment has been demonstrated to slow the protein aggregation [<xref ref-type="bibr" rid="B211-biomolecules-10-00702">211</xref>] and to induce NRF2 activity [<xref ref-type="bibr" rid="B212-biomolecules-10-00702">212</xref>,<xref ref-type="bibr" rid="B213-biomolecules-10-00702">213</xref>]. A curcumin analog, ASC-J9, tested in cells and in a mouse model of SBMA, demonstrated beneficial effects on mutated AR aggregates, motor impairments, muscular atrophy, and VEGF expression [<xref ref-type="bibr" rid="B214-biomolecules-10-00702">214</xref>]. Another curcumin analog, ASC-JM17, has been tested on cultured SBMA cells and has been found to activate NRF2 and its signaling pathway, determining the transcription of its target genes, including NQO1, HO-1, catalase, and GCL [<xref ref-type="bibr" rid="B215-biomolecules-10-00702">215</xref>]. These evidences support a promising role for this class of molecules to reverse multiple SBMA pathogenic defects.</p>
</sec>
<sec id="sec5dot2-biomolecules-10-00702">
<title>5.2. Huntington’s Disease (HD)</title>
<p>Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disease with defects in the striatum, cerebral cortex, and thalamus [<xref ref-type="bibr" rid="B216-biomolecules-10-00702">216</xref>,<xref ref-type="bibr" rid="B217-biomolecules-10-00702">217</xref>]. The HD disorder is caused by the abnormal expansion of the nucleotide triplet CAG in the gene coding for the protein huntingtin [<xref ref-type="bibr" rid="B218-biomolecules-10-00702">218</xref>]. In the huntingtin gene (HTT) of healthy subjects, the number of trinucleotides CAG repeats varies from 1 to 34, while in HD patients, the CAG triplet expansion ranges between 35–140 repetitions [<xref ref-type="bibr" rid="B219-biomolecules-10-00702">219</xref>]. Clinical features of HD include progressive motor dysfunction, psychiatric disturbance, cognitive decline, dystonia, bradykinesia, and dementia, ultimately leading to death within approximately 15–20 years from the age of onset [<xref ref-type="bibr" rid="B220-biomolecules-10-00702">220</xref>]. The genetic abnormality in the HD gene leads to the formation of a mutant huntingtin protein (mHtt), which is normally involved in the vesicle transport and represents a scaffold for the autophagic machinery [<xref ref-type="bibr" rid="B221-biomolecules-10-00702">221</xref>,<xref ref-type="bibr" rid="B222-biomolecules-10-00702">222</xref>]. The mutant protein exhibits toxic properties, leading to protein aggregation, transcriptional dysregulation, defective energy metabolism, chronic inflammation, and oxidative stress [<xref ref-type="bibr" rid="B223-biomolecules-10-00702">223</xref>,<xref ref-type="bibr" rid="B224-biomolecules-10-00702">224</xref>,<xref ref-type="bibr" rid="B225-biomolecules-10-00702">225</xref>,<xref ref-type="bibr" rid="B226-biomolecules-10-00702">226</xref>]. Inflammation, mitochondrial dysfunction, and oxidative stress are some of the key pathways persistently abnormal in mouse models of HD and in autoptic tissues of patients.</p>
<p>Several pharmacological HD mice models have been developed, resembling defective neuro-motor functions described in human HD patients [<xref ref-type="bibr" rid="B227-biomolecules-10-00702">227</xref>,<xref ref-type="bibr" rid="B228-biomolecules-10-00702">228</xref>,<xref ref-type="bibr" rid="B229-biomolecules-10-00702">229</xref>,<xref ref-type="bibr" rid="B230-biomolecules-10-00702">230</xref>] and supporting oxidative damage as a pathogenic mechanism underlying neurodegeneration in this disease [<xref ref-type="bibr" rid="B231-biomolecules-10-00702">231</xref>,<xref ref-type="bibr" rid="B232-biomolecules-10-00702">232</xref>]. Increased markers of oxidative stress, mitochondrial failure, and chronic inflammation have been found in brain tissue of HD patients. High levels of malondialdehyde, 8-hydroxy-deoxyguanosina, and carbonyls, and lower levels of GSH, SOD1, and GPX, have been detected in plasma and red blood cells of patients [<xref ref-type="bibr" rid="B233-biomolecules-10-00702">233</xref>,<xref ref-type="bibr" rid="B234-biomolecules-10-00702">234</xref>]. Additionally, mitochondrial DNA damage, low levels of oxidative phosphorylation enzymes, and iron-mediated mitochondrial impairment have been shown in autoptic brain tissues of patients [<xref ref-type="bibr" rid="B231-biomolecules-10-00702">231</xref>,<xref ref-type="bibr" rid="B235-biomolecules-10-00702">235</xref>]. In addition, increased amounts of circulating pro-inflammatory cytokines have been reported in patients, whose levels correlated to the severity of the disease [<xref ref-type="bibr" rid="B234-biomolecules-10-00702">234</xref>]. Numerous studies have been focused to reduce oxidative damage in HD by using antioxidants (alpha-tocopherol, CoQ10, vitamin E, vitamin C, N-acetylcysteine (NAC), lipoic acid [<xref ref-type="bibr" rid="B236-biomolecules-10-00702">236</xref>,<xref ref-type="bibr" rid="B237-biomolecules-10-00702">237</xref>,<xref ref-type="bibr" rid="B238-biomolecules-10-00702">238</xref>,<xref ref-type="bibr" rid="B239-biomolecules-10-00702">239</xref>,<xref ref-type="bibr" rid="B240-biomolecules-10-00702">240</xref>,<xref ref-type="bibr" rid="B241-biomolecules-10-00702">241</xref>,<xref ref-type="bibr" rid="B242-biomolecules-10-00702">242</xref>]). Nevertheless, these compounds have shown a moderate effectiveness in counteracting oxidative stress in mouse models, thus leading to hypothesize that a pharmacological upstream activation of NRF2 should be required. Recently, the potent NRF2 inducer SFN has been tested, showing increased mHtt degradation and a significant reduction of cytotoxicity by the NRF2-mediated activation of the ubiquitin–proteasome system [<xref ref-type="bibr" rid="B243-biomolecules-10-00702">243</xref>]. The SFN pre-treatement ameliorated behavioral impairments and reduced pro-inflammatory cytokines in the striatum of a 3-nitropropionic acid (3-NP) mouse model by attenuating neuroinflammation and oxidative stress [<xref ref-type="bibr" rid="B243-biomolecules-10-00702">243</xref>]. High susceptibility to oxidative stress has been also found in human HD neural stem cells, where the genetic correction of the disease-causing mutation restored the redox balance [<xref ref-type="bibr" rid="B244-biomolecules-10-00702">244</xref>]. The protective effect of NRF2 activation in HD patients has been further confirmed in primary monocytes, where the NRF2 induction inhibited the release of pro-inflammatory cytokines (IL-6, IL-1, IL-8, and TNFα) [<xref ref-type="bibr" rid="B244-biomolecules-10-00702">244</xref>]. As in other neurodegenerative diseases, also in HD has been hypothesized a role for ferroptosis in the pathogenic mechanism, mainly as a consequence of increased iron levels that were detected in brain regions of patients [<xref ref-type="bibr" rid="B235-biomolecules-10-00702">235</xref>,<xref ref-type="bibr" rid="B245-biomolecules-10-00702">245</xref>]. Therefore, even in HD, NRF2 can represent a strategic therapeutic target, for its ability in preventing iron overload and regulating ferroptosis-related genes expression [<xref ref-type="bibr" rid="B246-biomolecules-10-00702">246</xref>]. DMF, for instance, exerted beneficial effects on survival and motor functions in R6/2 and YAC128 models of HD, preserving the neuronal integrity in striatum and motor cortex, and slowing degeneration [<xref ref-type="bibr" rid="B247-biomolecules-10-00702">247</xref>]. Additionally, gintonin (GT), a ginseng-derived lysophosphatidic acid receptor ligand, was effective on the NRF2 pathway in the striatum of 3-NPA mice, by protecting the mitochondrial function and reducing the expression of inflammatory mediators (cytokines, COX-2, and iNOS) [<xref ref-type="bibr" rid="B248-biomolecules-10-00702">248</xref>].</p>
</sec>
<sec id="sec5dot3-biomolecules-10-00702">
<title>5.3. Spinocerebellar Ataxias (SCAs)</title>
<p>SCAs comprise more than 40 disorders, all characterized by progressive degeneration of the cerebellum, which determines abnormal coordination and gait impairments [<xref ref-type="bibr" rid="B249-biomolecules-10-00702">249</xref>]. Clinical features have been used to initially subdivide these disorders. Indeed, almost all forms of SCAs are characterized by cerebellar degeneration, with involvement of Purkinje and granule cell layers and neurons of deep cerebellar nuclei [<xref ref-type="bibr" rid="B250-biomolecules-10-00702">250</xref>,<xref ref-type="bibr" rid="B251-biomolecules-10-00702">251</xref>]. However, other regions of the brain can be affected. In all polyQ SCAs, for example, with the exception of SCA6 where Purkinje neurons are exclusively implicated, brainstem is involved [<xref ref-type="bibr" rid="B251-biomolecules-10-00702">251</xref>,<xref ref-type="bibr" rid="B252-biomolecules-10-00702">252</xref>]. Moreover, many forms of SCAs share clinical signs on basal ganglia, spinal cord, cerebral cortex, and peripheral nerves, while epilepsy is restricted to SCA10, and pigmentary retinal degeneration only occurs in SCA7 [<xref ref-type="bibr" rid="B251-biomolecules-10-00702">251</xref>,<xref ref-type="bibr" rid="B252-biomolecules-10-00702">252</xref>,<xref ref-type="bibr" rid="B253-biomolecules-10-00702">253</xref>]. A genetic classification has been developed for these disorders based on heritance (i.e., autosomal dominant, autosomal recessive, X-linked, and mitochondrial) [<xref ref-type="bibr" rid="B254-biomolecules-10-00702">254</xref>] and type of mutation (microsatellite repeat expansion or point mutation [<xref ref-type="bibr" rid="B255-biomolecules-10-00702">255</xref>]. Despite this, the gene or mutation responsible for many SCAs are currently unknown [<xref ref-type="bibr" rid="B253-biomolecules-10-00702">253</xref>]. The pathogenic mechanism appears variegated even among the autosomal dominant forms of SCA. Indeed, while polyQ tracts encoded by CAG repeats are present in at least 7 disorders (SCA1, 2, 3, 6, 7, 17, and DRPLA), tri- penta- or hexanucleotide expansions, located in introns or in the 3′UTR, occur in SCA8, 10, 12, 31, 36, and 37, determining an unclear pathogenic mechanism compatible with the generation of toxic mRNA or transcriptional silencing [<xref ref-type="bibr" rid="B18-biomolecules-10-00702">18</xref>,<xref ref-type="bibr" rid="B255-biomolecules-10-00702">255</xref>]. Only the polyQ SCAs were considered in this review, being the best characterized for their oxidative stress defects. PolyQ SCAs display a wide range of phenotypes due to the great instability of repeat expansion length, also responsible for the clinical anticipation reported for these disorders. This is most evident in the Machado–Joseph disease (SCA3), where the pathologic onset can occur in childhood, in middle-age, or have a late onset, depending on the expansion length. In people with smaller repeats, the disease can present as restless leg syndrome [<xref ref-type="bibr" rid="B251-biomolecules-10-00702">251</xref>,<xref ref-type="bibr" rid="B256-biomolecules-10-00702">256</xref>]. The physiological functions of the proteins responsible for SCAs are highly heterogeneous: ataxin 1, the protein mutated in SCA1, interacts in the nucleus with transcriptional regulators and with the splicing complex [<xref ref-type="bibr" rid="B257-biomolecules-10-00702">257</xref>]; similarly, ataxin 7, TATA-binding protein (TBP) and atrophin 1, whose mutations are the underlying cause of SCA7, SCA17, and DRPLA, are involved in transcriptional regulation processes, but with different roles (e.g., activating or repressing function) and with different interactors [<xref ref-type="bibr" rid="B258-biomolecules-10-00702">258</xref>,<xref ref-type="bibr" rid="B259-biomolecules-10-00702">259</xref>,<xref ref-type="bibr" rid="B260-biomolecules-10-00702">260</xref>]; ataxin 2 (SCA2) regulates translation, by the interaction with poly(a)-binding protein [<xref ref-type="bibr" rid="B261-biomolecules-10-00702">261</xref>]; ataxin 3 (SCA3) is a de-ubiquitination enzyme [<xref ref-type="bibr" rid="B262-biomolecules-10-00702">262</xref>]; Cav2.1α1A (SCA6) is a subunit of the voltage dependent calcium channel [<xref ref-type="bibr" rid="B263-biomolecules-10-00702">263</xref>].</p>
<p>Despite the functional heterogeneity and beside the partial loss of ataxin 1 function observed in SCA1 [<xref ref-type="bibr" rid="B264-biomolecules-10-00702">264</xref>], in all these disorders, the proposed pathogenic mechanism is the same: polyQ expansions promote protein misfolding that results in aggregation [<xref ref-type="bibr" rid="B253-biomolecules-10-00702">253</xref>]. This leads to defective interactions with common partners and determines impairment in shared cellular pathways leading to cerebellar neurons degeneration [<xref ref-type="bibr" rid="B265-biomolecules-10-00702">265</xref>]. The aggregates grow by time, forming big inclusions that may represent a valid biomarker for the disease. However, a discrepancy has been evidenced, as the presence of protein aggregates has been often reported to correlate with neuronal survival rather than to cell death [<xref ref-type="bibr" rid="B251-biomolecules-10-00702">251</xref>]. One hypothesis is that small CAG-expanded protein oligomers, produced at earlier steps of aggregation, are more toxic for the cell than larger ones [<xref ref-type="bibr" rid="B251-biomolecules-10-00702">251</xref>]. As reported for other polyQ diseases, these inclusions are positive for the presence of transcription factors [<xref ref-type="bibr" rid="B192-biomolecules-10-00702">192</xref>], as well as for proteins belonging to the quality control assessment (i.e., chaperons) and to the UPS system [<xref ref-type="bibr" rid="B266-biomolecules-10-00702">266</xref>,<xref ref-type="bibr" rid="B267-biomolecules-10-00702">267</xref>], suggesting that a major pathogenic route in these disorders consists in the derangement of the two cellular systems functioning in the clearance of damaged proteins [<xref ref-type="bibr" rid="B268-biomolecules-10-00702">268</xref>]. In line with this, some studies reported that both polyQ Ataxin 1 and 7 fail to be degraded by the proteasome, as it occurs in normal conditions [<xref ref-type="bibr" rid="B269-biomolecules-10-00702">269</xref>,<xref ref-type="bibr" rid="B270-biomolecules-10-00702">270</xref>]. Moreover, due to its localization near the polyQ expanded tract, the function of the Jospephin domain, which mediates the de-ubiquitinating activity of ataxin 3, could be altered, impairing ataxin 3 association with the proteasome [<xref ref-type="bibr" rid="B271-biomolecules-10-00702">271</xref>] and further exacerbating the activity of the UPS system [<xref ref-type="bibr" rid="B253-biomolecules-10-00702">253</xref>].</p>
<p>Oxidative stress, mitochondrial impairments, and NRF2 involvement are widely reported in SCAs and, due to the fact that Purkinje neurons are among the most energy-demanding cellular types [<xref ref-type="bibr" rid="B272-biomolecules-10-00702">272</xref>], it is not surprising that mitochondrial impairment in these disorders have been proposed to strongly contribute to the disease progression [<xref ref-type="bibr" rid="B273-biomolecules-10-00702">273</xref>]. In the SCA1 mouse model, the mutant ataxin 1 has been found to sequester the high mobility group box1 complex (HMGB1), inhibiting its function [<xref ref-type="bibr" rid="B274-biomolecules-10-00702">274</xref>] and determining the increase of mitochondrial DNA damage [<xref ref-type="bibr" rid="B275-biomolecules-10-00702">275</xref>]. Successive studies performed in Sca1<sup>154Q/2Q</sup> mice evidenced morphological mitochondria alterations, dysfunctional electron transport chain (ETC) enzyme activities, and increased oxidative damage [<xref ref-type="bibr" rid="B273-biomolecules-10-00702">273</xref>]. Importantly, in young Sca1<sup>154Q/2Q</sup> mice, that have not yet exhibited mitochondrial defects, the treatment with a quinone, which is able to modulate NRF2 nuclear translocation and activity (MitoQ) [<xref ref-type="bibr" rid="B276-biomolecules-10-00702">276</xref>], is capable of delaying the onset of motor coordination defects [<xref ref-type="bibr" rid="B273-biomolecules-10-00702">273</xref>]. Likewise, MitoQ administration to mice already displaying the pathologic deficits improves mouse phenotype [<xref ref-type="bibr" rid="B273-biomolecules-10-00702">273</xref>]. In cultured SCA2 patient’s fibroblasts, dysfunctions of mitochondrial network structure, alterations of antioxidant genes transcription and expression, increases of O<sup>−</sup> and H<sub>2</sub>O<sub>2</sub> production, and impaired activities of ETC complex I, II, and III have been further evidenced [<xref ref-type="bibr" rid="B277-biomolecules-10-00702">277</xref>], strongly connecting mitochondrial defects to ROS overload and oxidative stress. Despite many of these defects are rescued by treating SCA2 fibroblasts with CoQ<sub>10</sub> [<xref ref-type="bibr" rid="B277-biomolecules-10-00702">277</xref>], its clinical effect on a cohort of SCA1, 2, 3, and 6 patients is unclear. The drug administration was effective on clinical baseline outcome only in SCA1 and 3 patients, but it did not modify the progression of the disease in the 2 years follow-up trial [<xref ref-type="bibr" rid="B278-biomolecules-10-00702">278</xref>]. Among SCAs, SCA3 is the most common [<xref ref-type="bibr" rid="B279-biomolecules-10-00702">279</xref>] and the best characterized regarding the relationship among ROS, NRF2 imbalance, and neurodegeneration. In cells stably transfected with CAG expanded ataxin 3, a strong reduction of the GSH and GSH/GSSG ratio was observed. Paired to this, reduction of glutathione reductase (GSR), SOD, and catalase activities was reported, determining an increase of mitochondrial DNA damage, also assessed in SCA3 patient’s blood [<xref ref-type="bibr" rid="B280-biomolecules-10-00702">280</xref>]. Reduction of ETC complex II activity is reported in different SCA3 cellular and mouse models and in SCA3 human lymphoblastic cell lines, supporting an increase of ROS generation [<xref ref-type="bibr" rid="B281-biomolecules-10-00702">281</xref>]. The redox imbalance has been demonstrated also in patients. A significant reduction of thiols levels, which include GSH and thioredoxins, has been described in a case-control study enrolling 7 patients with SCA3, although total polyphenols, lipid peroxides, and ROS levels appeared unchanged [<xref ref-type="bibr" rid="B282-biomolecules-10-00702">282</xref>]. Nevertheless, a recent study performed on a larger number of SCA3 patients attested to an increase of ROS levels and the inhibition of SOD, with a parallel reduction of GPX activity that correlated with disease severity [<xref ref-type="bibr" rid="B283-biomolecules-10-00702">283</xref>]. Notably, all these parameters were close to physiological values in the pre-symptomatic group of SCA3 patients [<xref ref-type="bibr" rid="B283-biomolecules-10-00702">283</xref>].</p>
<p>Mutated ataxin 3 activity is connected with oxidative stress impairments in SCA3. Oxidative stress induces the nuclear translocation of ataxin 3 and this occurs both in normal and pathological conditions [<xref ref-type="bibr" rid="B284-biomolecules-10-00702">284</xref>]. However, this acquires a particular importance in the pathologic context, as CAG-expanded repeats-containing proteins exert their toxic effects predominantly at nuclear level [<xref ref-type="bibr" rid="B285-biomolecules-10-00702">285</xref>,<xref ref-type="bibr" rid="B286-biomolecules-10-00702">286</xref>,<xref ref-type="bibr" rid="B287-biomolecules-10-00702">287</xref>,<xref ref-type="bibr" rid="B288-biomolecules-10-00702">288</xref>,<xref ref-type="bibr" rid="B289-biomolecules-10-00702">289</xref>]. Because ROS production increases with age [<xref ref-type="bibr" rid="B290-biomolecules-10-00702">290</xref>], the toxic effect could progressively worsen by time and increase neuronal death. Moreover, ataxin 3 has been found to interact with forkhead box class O 4 (FOXO4), a transcription factor implicated in the regulation of cell response to stress stimuli, including oxidative stress [<xref ref-type="bibr" rid="B291-biomolecules-10-00702">291</xref>]. Under physiological conditions, ataxin 3 binding to FOXO4 is a necessary pre-requisite for SOD2 transcription. Although both normal and mutated ataxin 3 are able to interact with FOXO4, only the wild type protein can activate the FOXO4-dependent binding at SOD2 promoter. As a consequence, SOD2 expression is reduced in SCA3 cells, thus contributing to increase oxidative stress and cytotoxicity [<xref ref-type="bibr" rid="B292-biomolecules-10-00702">292</xref>]. Several studies demonstrated reduced NRF2 levels in HEK293 and SH-SY5Y, after transfection with ataxin 3 mutant cDNA. The expression of NRF2 downstream targets were also reduced, thus determining a further increase of ROS [<xref ref-type="bibr" rid="B293-biomolecules-10-00702">293</xref>,<xref ref-type="bibr" rid="B294-biomolecules-10-00702">294</xref>]. Cell treatment with plant-derived antioxidant compounds were able to rescue these biochemical defects by triggering NRF2 activation and enhancing the expression of NQO1, GCL, GST, and SOD2 [<xref ref-type="bibr" rid="B293-biomolecules-10-00702">293</xref>,<xref ref-type="bibr" rid="B294-biomolecules-10-00702">294</xref>]. Importantly, the NRF2 activation, or its overexpression, reduced the aggregation of mutant ataxin 3 and the activation of the caspase3-dependent apoptotic pathway, while silencing the NRF2 expression led to increased ataxin 3 aggregates formation [<xref ref-type="bibr" rid="B294-biomolecules-10-00702">294</xref>]. The administration of resveratrol and caffeic acid to mutant ataxin 3-expressing human SK-N-SH neuroblastoma cells and to a drosophila model of SCA3 enhanced the NRF2 activity, up-regulating the expression of NQO1, catalase, HO-1, GPX, SOD, and GR and causing a consistent reduction of total and mitochondrial ROS [<xref ref-type="bibr" rid="B295-biomolecules-10-00702">295</xref>]. In parallel, the treatment was also able to induce the NRF2-mediated expression of autophagy-related proteins (i.e., p62), leading to decreased expression of mutant ataxin 3 and its aggregates (<xref ref-type="fig" rid="biomolecules-10-00702-f003">Figure 3</xref>), ultimately determining an extension of mutant flies life span [<xref ref-type="bibr" rid="B295-biomolecules-10-00702">295</xref>].</p>
<p>The link between oxidative stress-induced damage and polyQ mutant protein aggregation was investigated also in SCA7, with similar results obtained in the studies described above. In PC12 cells, stably expressing a mutant ataxin 7 bearing 65 Q residues, oxidative stress is increased, with a parallel reduction of GSH content and dysregulation of catalase, SOD1, and GST protein levels, due to the aberrant activation of the NADPH oxidase (NOX) complex [<xref ref-type="bibr" rid="B296-biomolecules-10-00702">296</xref>]. These defects were ameliorated by the use of two antioxidants, N-acetyl cysteine (NAC) and vitamin E, both known to induce NRF2-dependent transcription [<xref ref-type="bibr" rid="B72-biomolecules-10-00702">72</xref>,<xref ref-type="bibr" rid="B85-biomolecules-10-00702">85</xref>]. Both compounds were able to reduce the level of mutant ataxin 7 aggregation [<xref ref-type="bibr" rid="B296-biomolecules-10-00702">296</xref>]. Notably, by overexpressing SOD1 or RORα, a transcriptional factor that activates the anti-oxidant gene transcription [<xref ref-type="bibr" rid="B297-biomolecules-10-00702">297</xref>], a comparable reduction of mutant ataxin 7 aggregation was observed, further confirming the link between oxidative stress and pathologic polyQ protein [<xref ref-type="bibr" rid="B296-biomolecules-10-00702">296</xref>]. In a mouse model of SCA17, the transcriptional dysregulation induced by CAG expanded TBP determines the downregulation of the heat shock protein beta1 (HSBP1) [<xref ref-type="bibr" rid="B298-biomolecules-10-00702">298</xref>], a protein known to protect cells from oxidative stress in HD [<xref ref-type="bibr" rid="B299-biomolecules-10-00702">299</xref>]. In addition, lymphoblastoid cells obtained from patients with SCA17 resulted highly susceptible to oxidative stress and to the ROS-induced cell death [<xref ref-type="bibr" rid="B300-biomolecules-10-00702">300</xref>]. Proteomic analysis performed on SCA17 lymphoblastoid lines confirmed the involvement of the NRF2 signaling pathway in the disease, as evidenced by NQO1 and HO-1 different expression patterns in cells carrying mutation [<xref ref-type="bibr" rid="B301-biomolecules-10-00702">301</xref>]. The treatment with two NRF2 inducers (resveratrol or genipin) [<xref ref-type="bibr" rid="B72-biomolecules-10-00702">72</xref>,<xref ref-type="bibr" rid="B302-biomolecules-10-00702">302</xref>] was able to rescue the antioxidant genes transcription defects and to low ROS generation [<xref ref-type="bibr" rid="B301-biomolecules-10-00702">301</xref>]. Lastly, the implication of oxidative stress in the DRPLA pathogenic mechanism is poorly investigated to date, however, DNA and RNA oxidative by-products have been found in patients, particularly in a subset of cases showing progressive myoclonus epilepsy (PME) [<xref ref-type="bibr" rid="B303-biomolecules-10-00702">303</xref>]. The SOD2 expression was reduced in 70% of examined patients and this correlated with clinical symptoms of epilepsy [<xref ref-type="bibr" rid="B303-biomolecules-10-00702">303</xref>].</p>
</sec>
</sec>
<sec id="sec6-biomolecules-10-00702">
<title>6. Oxidative Stress in RNA Gain of Function Expansion Disease</title>
<sec id="sec6dot1-biomolecules-10-00702">
<title>6.1. Fragile X–Associated Tremor Ataxia Syndrome (FXTAS)</title>
<p>While a number of CGG repetitions greater than 200 in the FMR1 gene determines FXS, CGG triplets ranging between 55–200 in the fragile X locus, a condition known as pre-mutation state, gives rise to FXTAS [<xref ref-type="bibr" rid="B304-biomolecules-10-00702">304</xref>,<xref ref-type="bibr" rid="B305-biomolecules-10-00702">305</xref>]. FXTAS is a neurodegenerative disorder principally occurring in adult male carriers (50 years or more) and whose penetrance increases with age [<xref ref-type="bibr" rid="B305-biomolecules-10-00702">305</xref>,<xref ref-type="bibr" rid="B306-biomolecules-10-00702">306</xref>]. FXTAS clinical features include late onset and progressive cerebellar gait ataxia and intention tremor, with associated parkinsonism, cognitive deficits, and peripheral neuropathy [<xref ref-type="bibr" rid="B43-biomolecules-10-00702">43</xref>,<xref ref-type="bibr" rid="B305-biomolecules-10-00702">305</xref>,<xref ref-type="bibr" rid="B306-biomolecules-10-00702">306</xref>,<xref ref-type="bibr" rid="B307-biomolecules-10-00702">307</xref>]. Individuals developing FXTAS have normal or relatively low FMR1 protein levels, but increased FMR1 mRNA transcript [<xref ref-type="bibr" rid="B308-biomolecules-10-00702">308</xref>], which accumulates in the nucleus of neurons and astrocytes in ubiquitin-positive inclusions [<xref ref-type="bibr" rid="B309-biomolecules-10-00702">309</xref>,<xref ref-type="bibr" rid="B310-biomolecules-10-00702">310</xref>]. Long CGG expansions in FMR1 mRNA are able to sequestrate numerous proteins that co-localize with the pathologic intranuclear inclusions in FXTAS animal models and patients [<xref ref-type="bibr" rid="B311-biomolecules-10-00702">311</xref>,<xref ref-type="bibr" rid="B312-biomolecules-10-00702">312</xref>,<xref ref-type="bibr" rid="B313-biomolecules-10-00702">313</xref>,<xref ref-type="bibr" rid="B314-biomolecules-10-00702">314</xref>]. FXTAS CGG expanded intranuclear inclusions are dynamic and form structures capable to trap a variety of proteins over time [<xref ref-type="bibr" rid="B47-biomolecules-10-00702">47</xref>]. One of the first proteins to be sequestrated is the splicing factor SAM68 [<xref ref-type="bibr" rid="B47-biomolecules-10-00702">47</xref>], a critical regulator of alternative splicing and polyadenylation in the nervous system [<xref ref-type="bibr" rid="B315-biomolecules-10-00702">315</xref>,<xref ref-type="bibr" rid="B316-biomolecules-10-00702">316</xref>,<xref ref-type="bibr" rid="B317-biomolecules-10-00702">317</xref>]. Nevertheless, a recent work demonstrated that nearly 200 proteins can be found in FXTAS intranuclear inclusions, 36% of them being RNA binding factors, with a strong enrichment of SUMO2, ubiquitin, and p62 proteins, indicating that aggregates are mostly composed of proteins tagged for degradation [<xref ref-type="bibr" rid="B314-biomolecules-10-00702">314</xref>].</p>
<p>Oxidative stress is well known in FXTAS [<xref ref-type="bibr" rid="B318-biomolecules-10-00702">318</xref>,<xref ref-type="bibr" rid="B319-biomolecules-10-00702">319</xref>,<xref ref-type="bibr" rid="B320-biomolecules-10-00702">320</xref>,<xref ref-type="bibr" rid="B321-biomolecules-10-00702">321</xref>] and proteins belonging to redox response have been identified as SUMO2/3 substrates in patients, thus suggesting to be sequestrated in aggregates [<xref ref-type="bibr" rid="B314-biomolecules-10-00702">314</xref>]. A number of mitochondrial dysfunctions has also been reported. A significant decline of oxidative phosphorylation (OXPHOS), increase of lipid peroxidation [<xref ref-type="bibr" rid="B318-biomolecules-10-00702">318</xref>], oxidative biomarkers, and ROS [<xref ref-type="bibr" rid="B321-biomolecules-10-00702">321</xref>] have been evidenced in fibroblasts and blood of FXTAS patients. Abnormal expression and function of mitochondrial proteins were further reported in patient’s brain samples [<xref ref-type="bibr" rid="B320-biomolecules-10-00702">320</xref>,<xref ref-type="bibr" rid="B322-biomolecules-10-00702">322</xref>]. Because of this, oxidative stress has been proposed to participate to the FXTAS pathogenic formation of nuclear aggregates. By this model, a ROS-induced increase of oxidized proteins could exceed the UPS degradative capacity and lead to the accumulation of ubiquitin- and SUMO2/3-tagged proteins with mRNA molecules of FMRP1. In late stages, also the p62-mediated shuttling of aggregates towards autophagosomes would be abrogated, for the excessive enlargement of the inclusions, thus ultimately leading to the nuclear p62 trapping [<xref ref-type="bibr" rid="B314-biomolecules-10-00702">314</xref>].</p>
<p>Some clues suggest the involvement of the NRF2 signalling pathway in this pathology. (i) Reduced expression of mnSOD, which is a NRF2 target gene, was attested in FXTAS [<xref ref-type="bibr" rid="B320-biomolecules-10-00702">320</xref>]. (ii) Alterations of the mitochondrial network in patients [<xref ref-type="bibr" rid="B318-biomolecules-10-00702">318</xref>] and impairments in their density and transport dynamics in mice carrying CGG premutation have been reported [<xref ref-type="bibr" rid="B323-biomolecules-10-00702">323</xref>], both suggesting impairments in cytoskeletal proteins responsible for mitochondrial distribution and cell morphology [<xref ref-type="bibr" rid="B324-biomolecules-10-00702">324</xref>]. These defects resemble the altered NRF2 trafficking observed in FA, where the increase of oxidative stress impairs cytoskeletal organization [<xref ref-type="bibr" rid="B325-biomolecules-10-00702">325</xref>] by causing the mislocalizing of KEAP1-NRF2 complexes, normally bound to actin filaments [<xref ref-type="bibr" rid="B326-biomolecules-10-00702">326</xref>], and leading to the failure of NRF2-mediated transcriptional activity [<xref ref-type="bibr" rid="B117-biomolecules-10-00702">117</xref>]. (iii) As in FA, also in premutation carriers, FXN expression is low [<xref ref-type="bibr" rid="B322-biomolecules-10-00702">322</xref>]. The reduced expression of the zinc transporter ZnT6 alters the zinc availability in FXTAS, impairing its incorporation, the mitochondrial processing peptidase (MPP), and the mitochondrial intermediate peptidase (MIP), two Zn-dependent proteases responsible for the maturation of mitochondrial proteins [<xref ref-type="bibr" rid="B327-biomolecules-10-00702">327</xref>], including FXN [<xref ref-type="bibr" rid="B328-biomolecules-10-00702">328</xref>,<xref ref-type="bibr" rid="B329-biomolecules-10-00702">329</xref>]. The consequent increase of the premature form of FXN, in respect to the mature one, leads to defective iron metabolism and oxidative stress [<xref ref-type="bibr" rid="B322-biomolecules-10-00702">322</xref>], and suggest that the similarities between FA and FXTAS could also be extended to NRF2 signalling pathway.</p>
</sec>
<sec id="sec6dot2-biomolecules-10-00702">
<title>6.2. Myotonic Dystrophy (DM)</title>
<p>DM is an autosomal dominant disorder, which arises from 2 different mutations: DM1, determined by 50-1000 CUG triplets in the 3′UTR of <italic>DMPK</italic> gene [<xref ref-type="bibr" rid="B18-biomolecules-10-00702">18</xref>,<xref ref-type="bibr" rid="B41-biomolecules-10-00702">41</xref>] and DM2, caused by 75–11000 expansions of the tetranucleotide CCTG in the first intron of <italic>ZNF9</italic>. [<xref ref-type="bibr" rid="B18-biomolecules-10-00702">18</xref>,<xref ref-type="bibr" rid="B42-biomolecules-10-00702">42</xref>]. DM1 and DM2 are multisystemic diseases sharing a common symptomatology characterized by myotonia, muscular dystrophy, cardiac defects, cataracts [<xref ref-type="bibr" rid="B330-biomolecules-10-00702">330</xref>], and neurological manifestations [<xref ref-type="bibr" rid="B331-biomolecules-10-00702">331</xref>,<xref ref-type="bibr" rid="B332-biomolecules-10-00702">332</xref>]. Unlike DM1, DM2 does not show congenital forms [<xref ref-type="bibr" rid="B333-biomolecules-10-00702">333</xref>]. DM shows a marked somatic instability of repeat expansions that, in DM1, are reported to increase of about 50–80 repeats per year and, in DM2, appear to be even more pronounced [<xref ref-type="bibr" rid="B330-biomolecules-10-00702">330</xref>,<xref ref-type="bibr" rid="B334-biomolecules-10-00702">334</xref>,<xref ref-type="bibr" rid="B335-biomolecules-10-00702">335</xref>]. Depending on the repeat length, the severity of DM1 and the onset of the pathology range from “mild” manifestation (baldness and cataracts) to a “classic” or “juvenile” form, with worse symptoms [<xref ref-type="bibr" rid="B19-biomolecules-10-00702">19</xref>]. On the contrary, although the same clinical heterogeneity is observed in DM2, the pathologic onset and disease severity do not seem to depend on the size of expansions in this disorder [<xref ref-type="bibr" rid="B336-biomolecules-10-00702">336</xref>]. Clinical anticipation, prominent in DM1 [<xref ref-type="bibr" rid="B337-biomolecules-10-00702">337</xref>], appears mildly in DM2 [<xref ref-type="bibr" rid="B338-biomolecules-10-00702">338</xref>].</p>
<p>Different hypotheses have been proposed to explain the pathogenic mechanism in DM. Early studies suggested that the pathological defects observed in DM1 could be determined by the decrease of DMPK expression, mediated by CUG expansions [<xref ref-type="bibr" rid="B339-biomolecules-10-00702">339</xref>] and/or by the trans-acting effect of the expanded mRNA, able to reduce the processing of WT DMPK mRNA [<xref ref-type="bibr" rid="B340-biomolecules-10-00702">340</xref>]. Clinical similarities led to support a common pathogenic mechanism for DM1 and DM2 and, to date, an RNA toxic gain of function is the most credited. In particular, both CUG triplet containing DMPK mRNA and spliced ZNF9 intron1 containing long CCTG sequences are able to sequestrate in the nucleus the splicing factors MBNL1 and 2 [<xref ref-type="bibr" rid="B341-biomolecules-10-00702">341</xref>,<xref ref-type="bibr" rid="B342-biomolecules-10-00702">342</xref>] and, at the same time, to raise the RNA binding activity of CUG-binding protein 1 (CUG-BP1 or CELF1) [<xref ref-type="bibr" rid="B330-biomolecules-10-00702">330</xref>,<xref ref-type="bibr" rid="B343-biomolecules-10-00702">343</xref>]. This changes the cellular alternative splicing output, determining the defects observed in the disease [<xref ref-type="bibr" rid="B46-biomolecules-10-00702">46</xref>,<xref ref-type="bibr" rid="B344-biomolecules-10-00702">344</xref>].</p>
<p>Many of the clinical features showed in DM, including myotonia, progressive muscle weakness, cataracts, frontal alopecia, and cognitive decline, suggest an increased susceptibility to oxidative stress in this pathology, as observed in premature and accelerated aging [<xref ref-type="bibr" rid="B345-biomolecules-10-00702">345</xref>]. While in DM2, oxidative stress is still poor investigated, a pathogenic involvement of ROS has been evidenced in DM1. Increased sensitivity to oxidative stress and strong activation of the pro-apoptotic p38 and JNKs pathways have been reported in the C2C12 cell line transfected with human mutant MDPK containing a variable number of CTG repeats [<xref ref-type="bibr" rid="B346-biomolecules-10-00702">346</xref>]. On the contrary, in cells having only 5 CTG repeats, ERKs were preferentially activated [<xref ref-type="bibr" rid="B347-biomolecules-10-00702">347</xref>]. Moreover, studies performed in DM patients have demonstrated an increase of lipid peroxidation and ROS levels, with a parallel decrease of the antioxidant CoQ<sub>10</sub> content [<xref ref-type="bibr" rid="B348-biomolecules-10-00702">348</xref>]. Increased oxidative stress and ROS-induced inflammation are known to produce cognitive dysfunctions [<xref ref-type="bibr" rid="B349-biomolecules-10-00702">349</xref>,<xref ref-type="bibr" rid="B350-biomolecules-10-00702">350</xref>] and depressive behaviours [<xref ref-type="bibr" rid="B351-biomolecules-10-00702">351</xref>,<xref ref-type="bibr" rid="B352-biomolecules-10-00702">352</xref>], conditions observed in the MBNL2 KO mouse model of DM1 [<xref ref-type="bibr" rid="B353-biomolecules-10-00702">353</xref>]. In these mice, the chronic administration of methylphenidate (MPH) was able to partially rescue the cognitive defects and depressive-like behaviours, and to reduce the reactive microglia and pro-inflammatory cytokine IL-1β levels [<xref ref-type="bibr" rid="B353-biomolecules-10-00702">353</xref>]. The treatment with MPH was shown to increase NRF2 gene expression in the hippocampus of MBNL2 KO mice and the brain-derived neurotrophic factor (BDNF) levels, which regulates NRF2 nuclear translocation by means of an ERK/PI3K-dependent activation [<xref ref-type="bibr" rid="B354-biomolecules-10-00702">354</xref>]. These findings suggest that the rescue of behavioural defects in MBNL2 KO mice may depend on NRF2-mediated reduction of oxidative stress and inflammation. In line with this, it is important to note that in NRF2 KO mice, an increase of the serum level of pro-inflammatory cytokines and a decrease of the BDNF expression have been reported in association to a depressive-like phenotype [<xref ref-type="bibr" rid="B355-biomolecules-10-00702">355</xref>]. In the same way, NRF2 activation is able to reduce depression and serum content of pro-inflammatory markers induced by lipopolysaccharide (LPS) injections in mice [<xref ref-type="bibr" rid="B356-biomolecules-10-00702">356</xref>]. Cognitive defects [<xref ref-type="bibr" rid="B331-biomolecules-10-00702">331</xref>,<xref ref-type="bibr" rid="B332-biomolecules-10-00702">332</xref>] and depression [<xref ref-type="bibr" rid="B357-biomolecules-10-00702">357</xref>], together with serum increased concentration of the pro-inflammatory IL-6 [<xref ref-type="bibr" rid="B358-biomolecules-10-00702">358</xref>] have been found in DM1 patients, thus the pharmacological NRF2 induction could be very promising in this disease (<xref ref-type="fig" rid="biomolecules-10-00702-f004">Figure 4</xref>).</p>
</sec>
</sec>
<sec id="sec7-biomolecules-10-00702" sec-type="conclusions">
<title>7. Conclusions</title>
<p>Around the first years of the 1990s, the discovery of a new type of unstable mutation, the expansion of DNA microsatellite repeats, was found as the underlying cause of FXS, DM, and SBMA [<xref ref-type="bibr" rid="B359-biomolecules-10-00702">359</xref>], helping to understand the molecular basis of the clinical anticipation concept in heritable diseases and allowing the definition of a new class of disorders, characterized by the earlier onset and severity in succeeding generations. Since then, this class has expanded, making the current subdivision, which accounts for the general pathogenic mechanism (i.e., loss/gain of function of protein or mRNA), necessary. As, to date, DNA expansions are known to cause more than 30 disorders (16), it is somehow surprising that oxidative stress is involved in a major part of such a vast group of pathologies. At the same time, mounting evidence points at ROS imbalance as a common thread in neurodegeneration and a plethora of neurodegenerative conditions share oxidative-related defects [<xref ref-type="bibr" rid="B48-biomolecules-10-00702">48</xref>,<xref ref-type="bibr" rid="B49-biomolecules-10-00702">49</xref>]. Cellular pathways in charge of regulating the oxidative stress defenses are often deregulated in DNA expansion disorders, providing an inadequate response to ROS overload. In line with this, the NRF2-ARE axis has been found to be defective in most of the pathologies we reviewed here and, in some of these, beneficial effects have been observed by modulating NRF2 signaling (<xref ref-type="table" rid="biomolecules-10-00702-t001">Table 1</xref>). Therapeutic interventions aimed at re-establishing the NRF2 pathway can be very promising to ameliorate the patient’s condition by rescuing oxidative stress-induced defects. Notably, NRF2 induction has been demonstrated to partially recover the primary defects in FA [<xref ref-type="bibr" rid="B85-biomolecules-10-00702">85</xref>,<xref ref-type="bibr" rid="B135-biomolecules-10-00702">135</xref>,<xref ref-type="bibr" rid="B136-biomolecules-10-00702">136</xref>,<xref ref-type="bibr" rid="B137-biomolecules-10-00702">137</xref>] and in SCA3, where it mediates the reduction of ataxin 3 aggregates [<xref ref-type="bibr" rid="B294-biomolecules-10-00702">294</xref>,<xref ref-type="bibr" rid="B295-biomolecules-10-00702">295</xref>], thus paving the way for NRF2-targeted therapies.</p>
</sec>
<sec>
<title>Author Contributions</title>
<p>Conceptualization: P.L.R, F.P.; writing of the Huntington’s disease and Friedreich’s ataxia sections: S.P.; writing &amp; editing: P.L.R., E.S.B., F.P.; figures: P.L.R. All authors have read and agreed to the published version of the manuscript.</p>
</sec>
</body>
<back>
<notes>
<title>Funding</title>
<p>This work was supported by Ricerca Corrente of the Italian Ministry of Health. Our Centre belongs to the ERN RND network.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-biomolecules-10-00702">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gur-Arie</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Eitan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shelef</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hallerman</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Kashi</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Simple sequence repeats in Escherichia coli: Abundance, distribution, composition, and polymorphism</article-title>
<source/>Genome Res.
          <year>2000</year>
<volume>10</volume>
<fpage>62</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1101/gr.10.1.62</pub-id>
<pub-id pub-id-type="pmid">10645951</pub-id>
</element-citation>
</ref>
<ref id="B2-biomolecules-10-00702">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamada</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Petrino</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Kakunaga</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>A novel repeated element with Z-DNA-forming potential is widely found in evolutionarily diverse eukaryotic genomes</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1982</year>
<volume>79</volume>
<fpage>6465</fpage>
<lpage>6469</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.79.21.6465</pub-id>
<pub-id pub-id-type="pmid">6755470</pub-id>
</element-citation>
</ref>
<ref id="B3-biomolecules-10-00702">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lander</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Linton</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Birren</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nusbaum</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zody</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Baldwin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Devon</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dewar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Doyle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>FitzHugh</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Initial sequencing and analysis of the human genome</article-title>
<source/>Nature
          <year>2001</year>
<volume>409</volume>
<fpage>860</fpage>
<lpage>921</lpage>
<pub-id pub-id-type="doi">10.1038/35057062</pub-id>
<pub-id pub-id-type="pmid">11237011</pub-id>
</element-citation>
</ref>
<ref id="B4-biomolecules-10-00702">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beckman</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Survey of human and rat microsatellites</article-title>
<source/>Genomics
          <year>1992</year>
<volume>12</volume>
<fpage>627</fpage>
<lpage>631</lpage>
<pub-id pub-id-type="doi">10.1016/0888-7543(92)90285-Z</pub-id>
<pub-id pub-id-type="pmid">1572635</pub-id>
</element-citation>
</ref>
<ref id="B5-biomolecules-10-00702">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toth</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gaspari</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Jurka</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Microsatellites in different eukaryotic genomes: Survey and analysis</article-title>
<source/>Genome Res.
          <year>2000</year>
<volume>10</volume>
<fpage>967</fpage>
<lpage>981</lpage>
<pub-id pub-id-type="doi">10.1101/gr.10.7.967</pub-id>
<pub-id pub-id-type="pmid">10899146</pub-id>
</element-citation>
</ref>
<ref id="B6-biomolecules-10-00702">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Metzgar</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bytof</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wills</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Selection against frameshift mutations limits microsatellite expansion in coding DNA</article-title>
<source/>Genome Res.
          <year>2000</year>
<volume>10</volume>
<fpage>72</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">10645952</pub-id>
</element-citation>
</ref>
<ref id="B7-biomolecules-10-00702">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bagshaw</surname>
<given-names>A.T.M.</given-names>
</name>
</person-group>
<article-title>Functional Mechanisms of Microsatellite DNA in Eukaryotic Genomes</article-title>
<source/>Genome Biol. Evol.
          <year>2017</year>
<volume>9</volume>
<fpage>2428</fpage>
<lpage>2443</lpage>
<pub-id pub-id-type="doi">10.1093/gbe/evx164</pub-id>
<pub-id pub-id-type="pmid">28957459</pub-id>
</element-citation>
</ref>
<ref id="B8-biomolecules-10-00702">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hui</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Heiner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schreiner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Neumuller</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Reither</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Haas</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Bindereif</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Intronic CA-repeat and CA-rich elements: A new class of regulators of mammalian alternative splicing</article-title>
<source/>Embo J.
          <year>2005</year>
<volume>24</volume>
<fpage>1988</fpage>
<lpage>1998</lpage>
<pub-id pub-id-type="doi">10.1038/sj.emboj.7600677</pub-id>
<pub-id pub-id-type="pmid">15889141</pub-id>
</element-citation>
</ref>
<ref id="B9-biomolecules-10-00702">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tseng</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.Z.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>T.S.</given-names>
</name>
</person-group>
<article-title>Modulation of formation of the 3′-end of the human argininosuccinate synthetase mRNA by GT-repeat polymorphism</article-title>
<source/>Int. J. Biochem. Mol. Biol.
          <year>2013</year>
<volume>4</volume>
<fpage>179</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="pmid">24380022</pub-id>
</element-citation>
</ref>
<ref id="B10-biomolecules-10-00702">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kramer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sponholz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Slaba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wissuwa</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Claus</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Menzel</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Huse</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Platzer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Alternative 5′ untranslated regions are involved in expression regulation of human heme oxygenase-1</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e77224</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0077224</pub-id>
<pub-id pub-id-type="pmid">24098580</pub-id>
</element-citation>
</ref>
<ref id="B11-biomolecules-10-00702">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mulholland</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Cooperative activity of BRG1 and Z-DNA formation in chromatin remodeling</article-title>
<source/>Mol. Cell. Biol.
          <year>2006</year>
<volume>26</volume>
<fpage>2550</fpage>
<lpage>2559</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.26.7.2550-2559.2006</pub-id>
<pub-id pub-id-type="pmid">16537901</pub-id>
</element-citation>
</ref>
<ref id="B12-biomolecules-10-00702">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quilez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guilmatre</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Highnam</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gymrek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Erlich</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Mittelman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Polymorphic tandem repeats within gene promoters act as modifiers of gene expression and DNA methylation in humans</article-title>
<source/>Nucleic Acids Res.
          <year>2016</year>
<volume>44</volume>
<fpage>3750</fpage>
<lpage>3762</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkw219</pub-id>
<pub-id pub-id-type="pmid">27060133</pub-id>
</element-citation>
</ref>
<ref id="B13-biomolecules-10-00702">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellegren</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Microsatellite mutations in the germline: Implications for evolutionary inference</article-title>
<source/>Trends Genet.
          <year>2000</year>
<volume>16</volume>
<fpage>551</fpage>
<lpage>558</lpage>
<pub-id pub-id-type="doi">10.1016/S0168-9525(00)02139-9</pub-id>
<pub-id pub-id-type="pmid">11102705</pub-id>
</element-citation>
</ref>
<ref id="B14-biomolecules-10-00702">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chistiakov</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Hellemans</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Volckaert</surname>
<given-names>F.A.M.</given-names>
</name>
</person-group>
<article-title>Microsatellites and their genomic distribution, evolution, function and applications: A review with special reference to fish genetics</article-title>
<source/>Aquaculture
          <year>2006</year>
<volume>255</volume>
<fpage>1</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1016/j.aquaculture.2005.11.031</pub-id>
</element-citation>
</ref>
<ref id="B15-biomolecules-10-00702">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weissenbach</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Microsatellite polymorphisms and the genetic linkage map of the human genome</article-title>
<source/>Curr. Opin. Genet. Dev.
          <year>1993</year>
<volume>3</volume>
<fpage>414</fpage>
<lpage>417</lpage>
<pub-id pub-id-type="doi">10.1016/0959-437X(93)90114-5</pub-id>
<pub-id pub-id-type="pmid">8353415</pub-id>
</element-citation>
</ref>
<ref id="B16-biomolecules-10-00702">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>López Castel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cleary</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>C.E.</given-names>
</name>
</person-group>
<article-title>Repeat instability as the basis for human diseases and as a potential target for therapy</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2010</year>
<volume>11</volume>
<fpage>165</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1038/nrm2854</pub-id>
<pub-id pub-id-type="pmid">20177394</pub-id>
</element-citation>
</ref>
<ref id="B17-biomolecules-10-00702">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pearson</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Nichol Edamura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cleary</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Repeat instability: Mechanisms of dynamic mutations</article-title>
<source/>Nat. Rev. Genet.
          <year>2005</year>
<volume>6</volume>
<fpage>729</fpage>
<lpage>742</lpage>
<pub-id pub-id-type="doi">10.1038/nrg1689</pub-id>
<pub-id pub-id-type="pmid">16205713</pub-id>
</element-citation>
</ref>
<ref id="B18-biomolecules-10-00702">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gatchel</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>Diseases of unstable repeat expansion: Mechanisms and common principles</article-title>
<source/>Nat. Rev. Genet.
          <year>2005</year>
<volume>6</volume>
<fpage>743</fpage>
<lpage>755</lpage>
<pub-id pub-id-type="doi">10.1038/nrg1691</pub-id>
<pub-id pub-id-type="pmid">16205714</pub-id>
</element-citation>
</ref>
<ref id="B19-biomolecules-10-00702">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paulson</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Repeat expansion diseases</article-title>
<source/>Handb. Clin. Neurol.
          <year>2018</year>
<volume>147</volume>
<fpage>105</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-444-63233-3.00009-9</pub-id>
<pub-id pub-id-type="pmid">29325606</pub-id>
</element-citation>
</ref>
<ref id="B20-biomolecules-10-00702">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McInnis</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Anticipation: An old idea in new genes</article-title>
<source/>Am. J. Hum. Genet.
          <year>1996</year>
<volume>59</volume>
<fpage>973</fpage>
<lpage>979</lpage>
<pub-id pub-id-type="pmid">8900222</pub-id>
</element-citation>
</ref>
<ref id="B21-biomolecules-10-00702">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Mossevelde</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>van der Zee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gijselinck</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sleegers</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>De Bleecker</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sieben</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vandenberghe</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Van Langenhove</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Baets</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Deryck</surname>
<given-names>O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion</article-title>
<source/>JAMA Neurol.
          <year>2017</year>
<volume>74</volume>
<fpage>445</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2016.4847</pub-id>
<pub-id pub-id-type="pmid">28192553</pub-id>
</element-citation>
</ref>
<ref id="B22-biomolecules-10-00702">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paulson</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Fischbeck</surname>
<given-names>K.H.</given-names>
</name>
</person-group>
<article-title>Trinucleotide repeats in neurogenetic disorders</article-title>
<source/>Annu. Rev. Neurosci.
          <year>1996</year>
<volume>19</volume>
<fpage>79</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.ne.19.030196.000455</pub-id>
<pub-id pub-id-type="pmid">8833437</pub-id>
</element-citation>
</ref>
<ref id="B23-biomolecules-10-00702">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reetz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dogan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Dafotakis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fedosov</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Giunti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Parkinson</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Sweeney</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Mariotti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Panzeri</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Biological and clinical characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) cohort: A cross-sectional analysis of baseline data</article-title>
<source/>Lancet Neurol.
          <year>2015</year>
<volume>14</volume>
<fpage>174</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(14)70321-7</pub-id>
<pub-id pub-id-type="pmid">25566998</pub-id>
</element-citation>
</ref>
<ref id="B24-biomolecules-10-00702">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cook</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giunti</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Friedreich’s ataxia: Clinical features, pathogenesis and management</article-title>
<source/>Br. Med Bull.
          <year>2017</year>
<volume>124</volume>
<fpage>19</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1093/bmb/ldx034</pub-id>
<pub-id pub-id-type="pmid">29053830</pub-id>
</element-citation>
</ref>
<ref id="B25-biomolecules-10-00702">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrew</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>Y.P.</given-names>
</name>
<name>
<surname>Kremer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Telenius</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Theilmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Squitieri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kalchman</surname>
<given-names>M.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease</article-title>
<source/>Nat. Genet.
          <year>1993</year>
<volume>4</volume>
<fpage>398</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.1038/ng0893-398</pub-id>
<pub-id pub-id-type="pmid">8401589</pub-id>
</element-citation>
</ref>
<ref id="B26-biomolecules-10-00702">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Figueroa</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Coon</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Velazquez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mederos</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Pulst</surname>
<given-names>S.-M.</given-names>
</name>
</person-group>
<article-title>Genetic analysis of age at onset variation in spinocerebellar ataxia type 2</article-title>
<source/>Neurol. Genet.
          <year>2017</year>
<volume>3</volume>
<fpage>e155</fpage>
<pub-id pub-id-type="doi">10.1212/NXG.0000000000000155</pub-id>
<pub-id pub-id-type="pmid">28534046</pub-id>
</element-citation>
</ref>
<ref id="B27-biomolecules-10-00702">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Igarashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tanno</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Onodera</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Miyatani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nagashima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sahashi</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy</article-title>
<source/>Neurology
          <year>1992</year>
<volume>42</volume>
<fpage>2300</fpage>
<lpage>2302</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.42.12.2300</pub-id>
<pub-id pub-id-type="pmid">1461383</pub-id>
</element-citation>
</ref>
<ref id="B28-biomolecules-10-00702">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savić</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rakocvic-Stojanovic</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Keckarevic</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Culjkovic</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Stojkovic</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Mladenovic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Todorovic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Apostolski</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Romac</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>250 CTG repeats in DMPK is a threshold for correlation of expansion size and age at onset of juvenile-adult DM1</article-title>
<source/>Hum. Mutat.
          <year>2002</year>
<volume>19</volume>
<fpage>131</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1002/humu.10027</pub-id>
<pub-id pub-id-type="pmid">11793472</pub-id>
</element-citation>
</ref>
<ref id="B29-biomolecules-10-00702">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Goetz</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Lara</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FMR1 CGG repeat length predicts motor dysfunction in premutation carriers</article-title>
<source/>Neurology
          <year>2008</year>
<volume>70</volume>
<fpage>1397</fpage>
<lpage>1402</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000281692.98200.f5</pub-id>
<pub-id pub-id-type="pmid">18057320</pub-id>
</element-citation>
</ref>
<ref id="B30-biomolecules-10-00702">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delatycki</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Paris</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Nassif</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Storey</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>MacMillan</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Forrest</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Clinical and genetic study of Friedreich ataxia in an Australian population</article-title>
<source/>Am. J. Med. Genet.
          <year>1999</year>
<volume>87</volume>
<fpage>168</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19991119)87:2&lt;168::AID-AJMG8&gt;3.0.CO;2-2</pub-id>
<pub-id pub-id-type="pmid">10533031</pub-id>
</element-citation>
</ref>
<ref id="B31-biomolecules-10-00702">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cossée</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dürr</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Trouillas</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Allinson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kostrzewa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nivelon-Chevallier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gustavson</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Kohlschütter</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Friedreich’s ataxia: Point mutations and clinical presentation of compound heterozygotes</article-title>
<source/>Ann. Neurol.
          <year>1999</year>
<volume>45</volume>
<fpage>200</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.1002/1531-8249(199902)45:2&lt;200::AID-ANA10&gt;3.0.CO;2-U</pub-id>
<pub-id pub-id-type="pmid">9989622</pub-id>
</element-citation>
</ref>
<ref id="B32-biomolecules-10-00702">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Michele</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Perrone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Filla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mirante</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Placido</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Campanella</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich’s disease: A retrospective study on 119 patients</article-title>
<source/>Neurology
          <year>1996</year>
<volume>47</volume>
<fpage>1260</fpage>
<lpage>1264</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.47.5.1260</pub-id>
<pub-id pub-id-type="pmid">8909440</pub-id>
</element-citation>
</ref>
<ref id="B33-biomolecules-10-00702">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cnop</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mulder</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Igoillo-Esteve</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Diabetes in Friedreich ataxia</article-title>
<source/>J. Neurochem.
          <year>2013</year>
<volume>126</volume>
<issue>Suppl. 1</issue>
<fpage>94</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.12216</pub-id>
<pub-id pub-id-type="pmid">23859345</pub-id>
</element-citation>
</ref>
<ref id="B34-biomolecules-10-00702">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arsenault</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Prévost</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lescault</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Laberge</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Puymirat</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mathieu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions</article-title>
<source/>Neurology
          <year>2006</year>
<volume>66</volume>
<fpage>1248</fpage>
<lpage>1250</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000208513.48550.08</pub-id>
<pub-id pub-id-type="pmid">16636244</pub-id>
</element-citation>
</ref>
<ref id="B35-biomolecules-10-00702">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lokey</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Chastain</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Lakkis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Eberhart</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>S.T.</given-names>
</name>
</person-group>
<article-title>Translational suppression by trinucleotide repeat expansion at FMR1</article-title>
<source/>Science
          <year>1995</year>
<volume>268</volume>
<fpage>731</fpage>
<lpage>734</lpage>
<pub-id pub-id-type="doi">10.1126/science.7732383</pub-id>
<pub-id pub-id-type="pmid">7732383</pub-id>
</element-citation>
</ref>
<ref id="B36-biomolecules-10-00702">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campuzano</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Montermini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Molto</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Pianese</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cossee</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cavalcanti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Monros</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rodius</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Duclos</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Monticelli</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Friedreich’s ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion</article-title>
<source/>Science
          <year>1996</year>
<volume>271</volume>
<fpage>1423</fpage>
<lpage>1427</lpage>
<pub-id pub-id-type="doi">10.1126/science.271.5254.1423</pub-id>
<pub-id pub-id-type="pmid">8596916</pub-id>
</element-citation>
</ref>
<ref id="B37-biomolecules-10-00702">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Orr</surname>
<given-names>H.T.</given-names>
</name>
</person-group>
<article-title>Glutamine repeats and neurodegeneration</article-title>
<source/>Annu. Rev. Neurosci.
          <year>2000</year>
<volume>23</volume>
<fpage>217</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.neuro.23.1.217</pub-id>
<pub-id pub-id-type="pmid">10845064</pub-id>
</element-citation>
</ref>
<ref id="B38-biomolecules-10-00702">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nucifora</surname>
<given-names>F.C.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Sasaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tsuji</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Troncoso</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>V.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity</article-title>
<source/>Science
          <year>2001</year>
<volume>291</volume>
<fpage>2423</fpage>
<lpage>2428</lpage>
<pub-id pub-id-type="doi">10.1126/science.1056784</pub-id>
<pub-id pub-id-type="pmid">11264541</pub-id>
</element-citation>
</ref>
<ref id="B39-biomolecules-10-00702">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunah</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.-M.</given-names>
</name>
<name>
<surname>Standaert</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Hersch</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Mouradian</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Tanese</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Krainc</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Sp1 and TAFII130 transcriptional activity disrupted in early Huntington’s disease</article-title>
<source/>Science
          <year>2002</year>
<volume>296</volume>
<fpage>2238</fpage>
<lpage>2243</lpage>
<pub-id pub-id-type="doi">10.1126/science.1072613</pub-id>
<pub-id pub-id-type="pmid">11988536</pub-id>
</element-citation>
</ref>
<ref id="B40-biomolecules-10-00702">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciechanover</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brundin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg</article-title>
<source/>Neuron
          <year>2003</year>
<volume>40</volume>
<fpage>427</fpage>
<lpage>446</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(03)00606-8</pub-id>
<pub-id pub-id-type="pmid">14556719</pub-id>
</element-citation>
</ref>
<ref id="B41-biomolecules-10-00702">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahadevan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsilfidis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sabourin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shutler</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Amemiya</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Neville</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Narang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Barceló</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>O’Hoy</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Myotonic dystrophy mutation: An unstable CTG repeat in the 3′ untranslated region of the gene</article-title>
<source/>Science
          <year>1992</year>
<volume>255</volume>
<fpage>1253</fpage>
<lpage>1255</lpage>
<pub-id pub-id-type="doi">10.1126/science.1546325</pub-id>
<pub-id pub-id-type="pmid">1546325</pub-id>
</element-citation>
</ref>
<ref id="B42-biomolecules-10-00702">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranum</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>P.F.</given-names>
</name>
<name>
<surname>Benzow</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Koob</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Genetic mapping of a second myotonic dystrophy locus</article-title>
<source/>Nat. Genet.
          <year>1998</year>
<volume>19</volume>
<fpage>196</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="doi">10.1038/570</pub-id>
<pub-id pub-id-type="pmid">9620781</pub-id>
</element-citation>
</ref>
<ref id="B43-biomolecules-10-00702">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Des Portes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Jardini</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fragile X premutation tremor/ataxia syndrome: Molecular, clinical, and neuroimaging correlates</article-title>
<source/>Am. J. Hum. Genet.
          <year>2003</year>
<volume>72</volume>
<fpage>869</fpage>
<lpage>878</lpage>
<pub-id pub-id-type="doi">10.1086/374321</pub-id>
<pub-id pub-id-type="pmid">12638084</pub-id>
</element-citation>
</ref>
<ref id="B44-biomolecules-10-00702">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Echeverria</surname>
<given-names>G.V.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>Muscleblind-like 1 activates insulin receptor exon 11 inclusion by enhancing U2AF65 binding and splicing of the upstream intron</article-title>
<source/>Nucleic Acids Res.
          <year>2014</year>
<volume>42</volume>
<fpage>1893</fpage>
<lpage>1903</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkt1020</pub-id>
<pub-id pub-id-type="pmid">24185704</pub-id>
</element-citation>
</ref>
<ref id="B45-biomolecules-10-00702">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savkur</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Philips</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy</article-title>
<source/>Nat. Genet.
          <year>2001</year>
<volume>29</volume>
<fpage>40</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1038/ng704</pub-id>
<pub-id pub-id-type="pmid">11528389</pub-id>
</element-citation>
</ref>
<ref id="B46-biomolecules-10-00702">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mankodi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Bowers</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Moxley</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy</article-title>
<source/>Mol. Cell
          <year>2002</year>
<volume>10</volume>
<fpage>35</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/S1097-2765(02)00563-4</pub-id>
<pub-id pub-id-type="pmid">12150905</pub-id>
</element-citation>
</ref>
<ref id="B47-biomolecules-10-00702">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sellier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rau</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hukema</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Gattoni</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>D.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients</article-title>
<source/>EMBO J.
          <year>2010</year>
<volume>29</volume>
<fpage>1248</fpage>
<lpage>1261</lpage>
<pub-id pub-id-type="doi">10.1038/emboj.2010.21</pub-id>
<pub-id pub-id-type="pmid">20186122</pub-id>
</element-citation>
</ref>
<ref id="B48-biomolecules-10-00702">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>G.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Rhie</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The Role of Oxidative Stress in Neurodegenerative Diseases</article-title>
<source/>Exp. Neurobiol.
          <year>2015</year>
<volume>24</volume>
<fpage>325</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="doi">10.5607/en.2015.24.4.325</pub-id>
<pub-id pub-id-type="pmid">26713080</pub-id>
</element-citation>
</ref>
<ref id="B49-biomolecules-10-00702">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Dimitrion</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2017</year>
<volume>2017</volume>
<fpage>2525967</fpage>
<pub-id pub-id-type="doi">10.1155/2017/2525967</pub-id>
<pub-id pub-id-type="pmid">28785371</pub-id>
</element-citation>
</ref>
<ref id="B50-biomolecules-10-00702">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryter</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.P.</given-names>
</name>
<name>
<surname>Hoetzel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Nakahira</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Mechanisms of cell death in oxidative stress</article-title>
<source/>Antioxid. Redox Signal.
          <year>2007</year>
<volume>9</volume>
<fpage>49</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2007.9.49</pub-id>
<pub-id pub-id-type="pmid">17115887</pub-id>
</element-citation>
</ref>
<ref id="B51-biomolecules-10-00702">
<label>51.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Ghosh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chaffee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>C.K.</given-names>
</name>
</person-group>
<article-title>Chapter 4—Reactive Oxygen Species, Oxidative Damage and Cell Death</article-title>
<source/>Immunity and Inflammation in Health and Disease
          <person-group person-group-type="editor">
<name>
<surname>Chatterjee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jungraithmayr</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Bagchi</surname>
<given-names>D.</given-names>
</name>
</person-group>
<publisher-name>Academic Press</publisher-name>
<publisher-loc>Cambridge, MA, USA</publisher-loc>
<year>2018</year>
<fpage>45</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-12-805417-8.00004-4</pub-id>
</element-citation>
</ref>
<ref id="B52-biomolecules-10-00702">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birben</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sahiner</surname>
<given-names>U.M.</given-names>
</name>
<name>
<surname>Sackesen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Erzurum</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kalayci</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and antioxidant defense</article-title>
<source/>World Allergy Organ J.
          <year>2012</year>
<volume>5</volume>
<fpage>9</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1097/WOX.0b013e3182439613</pub-id>
<pub-id pub-id-type="pmid">23268465</pub-id>
</element-citation>
</ref>
<ref id="B53-biomolecules-10-00702">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thanan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Oikawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hiraku</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ohnishi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pinlaor</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yongvanit</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kawanishi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Murata</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and its significant roles in neurodegenerative diseases and cancer</article-title>
<source/>Int. J. Mol. Sci.
          <year>2014</year>
<volume>16</volume>
<fpage>193</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="doi">10.3390/ijms16010193</pub-id>
<pub-id pub-id-type="pmid">25547488</pub-id>
</element-citation>
</ref>
<ref id="B54-biomolecules-10-00702">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venditti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Di Stefano</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Di Meo</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Mitochondrial metabolism of reactive oxygen species</article-title>
<source/>Mitochondrion
          <year>2013</year>
<volume>13</volume>
<fpage>71</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/j.mito.2013.01.008</pub-id>
<pub-id pub-id-type="pmid">23376030</pub-id>
</element-citation>
</ref>
<ref id="B55-biomolecules-10-00702">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chakraborty</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dhama</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Oxidative stress, prooxidants, and antioxidants: The interplay</article-title>
<source/>Biomed. Res. Int.
          <year>2014</year>
<volume>2014</volume>
<fpage>761264</fpage>
<pub-id pub-id-type="doi">10.1155/2014/761264</pub-id>
<pub-id pub-id-type="pmid">24587990</pub-id>
</element-citation>
</ref>
<ref id="B56-biomolecules-10-00702">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ray</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>Tsuji</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling</article-title>
<source/>Cell Signal
          <year>2012</year>
<volume>24</volume>
<fpage>981</fpage>
<lpage>990</lpage>
<pub-id pub-id-type="doi">10.1016/j.cellsig.2012.01.008</pub-id>
<pub-id pub-id-type="pmid">22286106</pub-id>
</element-citation>
</ref>
<ref id="B57-biomolecules-10-00702">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schieber</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chandel</surname>
<given-names>N.S.</given-names>
</name>
</person-group>
<article-title>ROS function in redox signaling and oxidative stress</article-title>
<source/>Curr. Biol.
          <year>2014</year>
<volume>24</volume>
<fpage>R453</fpage>
<lpage>R462</lpage>
<pub-id pub-id-type="doi">10.1016/j.cub.2014.03.034</pub-id>
<pub-id pub-id-type="pmid">24845678</pub-id>
</element-citation>
</ref>
<ref id="B58-biomolecules-10-00702">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Autreaux</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Toledano</surname>
<given-names>M.B.</given-names>
</name>
</person-group>
<article-title>ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis</article-title>
<source/>Nat. Rev. Mol. Cell. Biol.
          <year>2007</year>
<volume>8</volume>
<fpage>813</fpage>
<lpage>824</lpage>
<pub-id pub-id-type="doi">10.1038/nrm2256</pub-id>
<pub-id pub-id-type="pmid">17848967</pub-id>
</element-citation>
</ref>
<ref id="B59-biomolecules-10-00702">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Younus</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Therapeutic potentials of superoxide dismutase</article-title>
<source/>Int. J. Health Sci.
          <year>2018</year>
<volume>12</volume>
<fpage>88</fpage>
<lpage>93</lpage>
</element-citation>
</ref>
<ref id="B60-biomolecules-10-00702">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nandi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>L.-J.</given-names>
</name>
<name>
<surname>Jana</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Role of Catalase in Oxidative Stress- and Age-Associated Degenerative Diseases</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2019</year>
<volume>2019</volume>
<fpage>9613090</fpage>
<pub-id pub-id-type="doi">10.1155/2019/9613090</pub-id>
<pub-id pub-id-type="pmid">31827713</pub-id>
</element-citation>
</ref>
<ref id="B61-biomolecules-10-00702">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brigelius-Flohé</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Maiorino</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Glutathione peroxidases</article-title>
<source/>Biochim. Biophys. Acta
          <year>2013</year>
<volume>1830</volume>
<fpage>3289</fpage>
<lpage>3303</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbagen.2012.11.020</pub-id>
<pub-id pub-id-type="pmid">23201771</pub-id>
</element-citation>
</ref>
<ref id="B62-biomolecules-10-00702">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirończuk-Chodakowska</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Witkowska</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Zujko</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>Endogenous non-enzymatic antioxidants in the human body</article-title>
<source/>Adv. Med. Sci.
          <year>2018</year>
<volume>63</volume>
<fpage>68</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1016/j.advms.2017.05.005</pub-id>
<pub-id pub-id-type="pmid">28822266</pub-id>
</element-citation>
</ref>
<ref id="B63-biomolecules-10-00702">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haenen</surname>
<given-names>G.R.M.M.</given-names>
</name>
<name>
<surname>Bast</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Glutathione revisited: A better scavenger than previously thought</article-title>
<source/>Front. Pharmacol.
          <year>2014</year>
<volume>5</volume>
<elocation-id>260</elocation-id>
<pub-id pub-id-type="doi">10.3389/fphar.2014.00260</pub-id>
<pub-id pub-id-type="pmid">25505886</pub-id>
</element-citation>
</ref>
<ref id="B64-biomolecules-10-00702">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aquilano</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Baldelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ciriolo</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Glutathione: New roles in redox signaling for an old antioxidant</article-title>
<source/>Front. Pharmacol.
          <year>2014</year>
<volume>5</volume>
<elocation-id>196</elocation-id>
<pub-id pub-id-type="doi">10.3389/fphar.2014.00196</pub-id>
<pub-id pub-id-type="pmid">25206336</pub-id>
</element-citation>
</ref>
<ref id="B65-biomolecules-10-00702">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brigelius-Flohé</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Tissue-specific functions of individual glutathione peroxidases</article-title>
<source/>Free Radic. Biol. Med.
          <year>1999</year>
<volume>27</volume>
<fpage>951</fpage>
<lpage>965</lpage>
<pub-id pub-id-type="doi">10.1016/S0891-5849(99)00173-2</pub-id>
<pub-id pub-id-type="pmid">10569628</pub-id>
</element-citation>
</ref>
<ref id="B66-biomolecules-10-00702">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheehan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Meade</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Dowd</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Structure, function and evolution of glutathione transferases: Implications for classification of non-mammalian members of an ancient enzyme superfamily</article-title>
<source/>Biochem. J.
          <year>2001</year>
<volume>360</volume>
<fpage>1</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1042/bj3600001</pub-id>
<pub-id pub-id-type="pmid">11695986</pub-id>
</element-citation>
</ref>
<ref id="B67-biomolecules-10-00702">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forman</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rinna</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Glutathione: Overview of its protective roles, measurement, and biosynthesis</article-title>
<source/>Mol. Asp. Med.
          <year>2009</year>
<volume>30</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.mam.2008.08.006</pub-id>
</element-citation>
</ref>
<ref id="B68-biomolecules-10-00702">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Njålsson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Norgren</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Physiological and pathological aspects of GSH metabolism</article-title>
<source/>Acta Paediatr.
          <year>2005</year>
<volume>94</volume>
<fpage>132</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1080/08035250410025285</pub-id>
<pub-id pub-id-type="pmid">15981742</pub-id>
</element-citation>
</ref>
<ref id="B69-biomolecules-10-00702">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tatara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mimura</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Regulation of Nrf2 by Mitochondrial Reactive Oxygen Species in Physiology and Pathology</article-title>
<source/>Biomolecules
          <year>2020</year>
<volume>10</volume>
<elocation-id>320</elocation-id>
<pub-id pub-id-type="doi">10.3390/biom10020320</pub-id>
</element-citation>
</ref>
<ref id="B70-biomolecules-10-00702">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Role of nrf2 in oxidative stress and toxicity</article-title>
<source/>Annu. Rev. Pharmacol. Toxicol.
          <year>2013</year>
<volume>53</volume>
<fpage>401</fpage>
<lpage>426</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-pharmtox-011112-140320</pub-id>
<pub-id pub-id-type="pmid">23294312</pub-id>
</element-citation>
</ref>
<ref id="B71-biomolecules-10-00702">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaw</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chattopadhyay</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Nrf2-ARE signaling in cellular protection: Mechanism of action and the regulatory mechanisms</article-title>
<source/>J. Cell. Physiol.
          <year>2019</year>
<volume>235</volume>
<fpage>3119</fpage>
<lpage>3130</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.29219</pub-id>
<pub-id pub-id-type="pmid">31549397</pub-id>
</element-citation>
</ref>
<ref id="B72-biomolecules-10-00702">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Rosa</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Piemonte</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>The NRF2 Signaling Network Defines Clinical Biomarkers and Therapeutic Opportunity in Friedreich’s Ataxia</article-title>
<source/>Int. J. Mol. Sci.
          <year>2020</year>
<volume>21</volume>
<elocation-id>916</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms21030916</pub-id>
<pub-id pub-id-type="pmid">32019240</pub-id>
</element-citation>
</ref>
<ref id="B73-biomolecules-10-00702">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Asunis</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>Y.W.</given-names>
</name>
</person-group>
<article-title>Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1994</year>
<volume>91</volume>
<fpage>9926</fpage>
<lpage>9930</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.91.21.9926</pub-id>
<pub-id pub-id-type="pmid">7937919</pub-id>
</element-citation>
</ref>
<ref id="B74-biomolecules-10-00702">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amoutzias</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Van de Peer</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Oliver</surname>
<given-names>S.G.</given-names>
</name>
</person-group>
<article-title>Choose your partners: Dimerization in eukaryotic transcription factors</article-title>
<source/>Trends Biochem. Sci.
          <year>2008</year>
<volume>33</volume>
<fpage>220</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="doi">10.1016/j.tibs.2008.02.002</pub-id>
<pub-id pub-id-type="pmid">18406148</pub-id>
</element-citation>
</ref>
<ref id="B75-biomolecules-10-00702">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Igarashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kataoka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nishizawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins</article-title>
<source/>Nature
          <year>1994</year>
<volume>367</volume>
<fpage>568</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="doi">10.1038/367568a0</pub-id>
<pub-id pub-id-type="pmid">8107826</pub-id>
</element-citation>
</ref>
<ref id="B76-biomolecules-10-00702">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itoh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chiba</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Oyake</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Satoh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hatayama</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>1997</year>
<volume>236</volume>
<fpage>313</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.1997.6943</pub-id>
<pub-id pub-id-type="pmid">9240432</pub-id>
</element-citation>
</ref>
<ref id="B77-biomolecules-10-00702">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wasserman</surname>
<given-names>W.W.</given-names>
</name>
<name>
<surname>Fahl</surname>
<given-names>W.E.</given-names>
</name>
</person-group>
<article-title>Functional antioxidant responsive elements</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1997</year>
<volume>94</volume>
<fpage>5361</fpage>
<lpage>5366</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.94.10.5361</pub-id>
<pub-id pub-id-type="pmid">9144242</pub-id>
</element-citation>
</ref>
<ref id="B78-biomolecules-10-00702">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rojo</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Cousin</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Rumsey</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Attucks</surname>
<given-names>O.C.</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Levonen</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Kensler</surname>
<given-names>T.W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2019</year>
<volume>18</volume>
<fpage>295</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1038/s41573-018-0008-x</pub-id>
<pub-id pub-id-type="pmid">30610225</pub-id>
</element-citation>
</ref>
<ref id="B79-biomolecules-10-00702">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corenblum</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Remley</surname>
<given-names>Q.W.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Harder</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Madhavan</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Reduced Nrf2 expression mediates the decline in neural stem cell function during a critical middle-age period</article-title>
<source/>Aging Cell
          <year>2016</year>
<volume>15</volume>
<fpage>725</fpage>
<lpage>736</lpage>
<pub-id pub-id-type="doi">10.1111/acel.12482</pub-id>
<pub-id pub-id-type="pmid">27095375</pub-id>
</element-citation>
</ref>
<ref id="B80-biomolecules-10-00702">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dodson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de la Vega</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Cholanians</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Schmidlin</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Modulating NRF2 in Disease: Timing Is Everything</article-title>
<source/>Annu. Rev. Pharmacol. Toxicol.
          <year>2019</year>
<volume>59</volume>
<fpage>555</fpage>
<lpage>575</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010818-021856</pub-id>
<pub-id pub-id-type="pmid">30256716</pub-id>
</element-citation>
</ref>
<ref id="B81-biomolecules-10-00702">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Rosa</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>D’Amico</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Petrillo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aquilano</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lettieri-Barbato</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Turchi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Piemonte</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Nrf2 Induction Re-establishes a Proper Neuronal Differentiation Program in Friedreich’s Ataxia Neural Stem Cells</article-title>
<source/>Front. Cell. Neurosci.
          <year>2019</year>
<volume>13</volume>
<fpage>356</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2019.00356</pub-id>
<pub-id pub-id-type="pmid">31417369</pub-id>
</element-citation>
</ref>
<ref id="B82-biomolecules-10-00702">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robledinos-Anton</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rojo</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Ferreiro</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nunez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Jaquet</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Transcription factor NRF2 controls the fate of neural stem cells in the subgranular zone of the hippocampus</article-title>
<source/>Redox Biol.
          <year>2017</year>
<volume>13</volume>
<fpage>393</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1016/j.redox.2017.06.010</pub-id>
<pub-id pub-id-type="pmid">28667908</pub-id>
</element-citation>
</ref>
<ref id="B83-biomolecules-10-00702">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turchi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tortolici</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Guidobaldi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Iacovelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Falconi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rufini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Faraonio</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Casagrande</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Federici</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Angelis</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frataxin deficiency induces lipid accumulation and affects thermogenesis in brown adipose tissue</article-title>
<source/>Cell Death Dis.
          <year>2020</year>
<volume>11</volume>
<fpage>51</fpage>
<pub-id pub-id-type="doi">10.1038/s41419-020-2253-2</pub-id>
<pub-id pub-id-type="pmid">31974344</pub-id>
</element-citation>
</ref>
<ref id="B84-biomolecules-10-00702">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tanji</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Engler</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Matsumiya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Role of the ISR-ATF4 pathway and its cross talk with Nrf2 in mitochondrial quality control</article-title>
<source/>J. Clin. Biochem. Nutr.
          <year>2019</year>
<volume>64</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.3164/jcbn.18-37</pub-id>
<pub-id pub-id-type="pmid">30705506</pub-id>
</element-citation>
</ref>
<ref id="B85-biomolecules-10-00702">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrillo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>D’Amico</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>La Rosa</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Piemonte</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs</article-title>
<source/>Int. J. Mol. Sci.
          <year>2019</year>
<volume>20</volume>
<elocation-id>5211</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms20205211</pub-id>
<pub-id pub-id-type="pmid">31640150</pub-id>
</element-citation>
</ref>
<ref id="B86-biomolecules-10-00702">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/beta-TrCP</article-title>
<source/>Free Radic. Biol. Med.
          <year>2015</year>
<volume>88</volume>
<fpage>147</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.04.029</pub-id>
<pub-id pub-id-type="pmid">25937177</pub-id>
</element-citation>
</ref>
<ref id="B87-biomolecules-10-00702">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Okawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ohtsuji</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zenke</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chiba</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2</article-title>
<source/>Mol. Cell. Biol.
          <year>2004</year>
<volume>24</volume>
<fpage>7130</fpage>
<lpage>7139</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.24.16.7130-7139.2004</pub-id>
<pub-id pub-id-type="pmid">15282312</pub-id>
</element-citation>
</ref>
<ref id="B88-biomolecules-10-00702">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kensler</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Motohashi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>The KEAP1-NRF2 System: A Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis</article-title>
<source/>Physiol. Rev.
          <year>2018</year>
<volume>98</volume>
<fpage>1169</fpage>
<lpage>1203</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00023.2017</pub-id>
<pub-id pub-id-type="pmid">29717933</pub-id>
</element-citation>
</ref>
<ref id="B89-biomolecules-10-00702">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rada</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rojo</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Chowdhry</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>SCF/beta-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner</article-title>
<source/>Mol. Cell. Biol.
          <year>2011</year>
<volume>31</volume>
<fpage>1121</fpage>
<lpage>1133</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.01204-10</pub-id>
<pub-id pub-id-type="pmid">21245377</pub-id>
</element-citation>
</ref>
<ref id="B90-biomolecules-10-00702">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Nrf2 in cancers: A double-edged sword</article-title>
<source/>Cancer Med.
          <year>2019</year>
<volume>8</volume>
<fpage>2252</fpage>
<lpage>2267</lpage>
<pub-id pub-id-type="doi">10.1002/cam4.2101</pub-id>
<pub-id pub-id-type="pmid">30929309</pub-id>
</element-citation>
</ref>
<ref id="B91-biomolecules-10-00702">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Caisova</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huynh</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Ghayee</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pacak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma</article-title>
<source/>Cancers
          <year>2020</year>
<volume>12</volume>
<elocation-id>280</elocation-id>
<pub-id pub-id-type="doi">10.3390/cancers12020280</pub-id>
</element-citation>
</ref>
<ref id="B92-biomolecules-10-00702">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Celiku</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Targeting IDH1-Mutated Malignancies with NRF2 Blockade</article-title>
<source/>J. Natl. Cancer Inst.
          <year>2019</year>
<volume>111</volume>
<fpage>1033</fpage>
<lpage>1041</lpage>
<pub-id pub-id-type="doi">10.1093/jnci/djy230</pub-id>
<pub-id pub-id-type="pmid">30759236</pub-id>
</element-citation>
</ref>
<ref id="B93-biomolecules-10-00702">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benarroch</surname>
<given-names>E.E.</given-names>
</name>
</person-group>
<article-title>Nrf2, cellular redox regulation, and neurologic implications</article-title>
<source/>Neurology
          <year>2017</year>
<volume>88</volume>
<fpage>1942</fpage>
<lpage>1950</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000003946</pub-id>
<pub-id pub-id-type="pmid">28424271</pub-id>
</element-citation>
</ref>
<ref id="B94-biomolecules-10-00702">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Kostov</surname>
<given-names>R.V.</given-names>
</name>
<name>
<surname>Kazantsev</surname>
<given-names>A.G.</given-names>
</name>
</person-group>
<article-title>The role of Nrf2 signaling in counteracting neurodegenerative diseases</article-title>
<source/>FEBS J.
          <year>2018</year>
<volume>285</volume>
<fpage>3576</fpage>
<lpage>3590</lpage>
<pub-id pub-id-type="doi">10.1111/febs.14379</pub-id>
<pub-id pub-id-type="pmid">29323772</pub-id>
</element-citation>
</ref>
<ref id="B95-biomolecules-10-00702">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdalkader</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lampinen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kanninen</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Malm</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Liddell</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration</article-title>
<source/>Front. Neurosci.
          <year>2018</year>
<volume>12</volume>
<fpage>466</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2018.00466</pub-id>
<pub-id pub-id-type="pmid">30042655</pub-id>
</element-citation>
</ref>
<ref id="B96-biomolecules-10-00702">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sadhukhan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sil</surname>
<given-names>P.C.</given-names>
</name>
</person-group>
<article-title>Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy</article-title>
<source/>Toxicol. Rep.
          <year>2017</year>
<volume>4</volume>
<fpage>306</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1016/j.toxrep.2017.06.002</pub-id>
<pub-id pub-id-type="pmid">28959654</pub-id>
</element-citation>
</ref>
<ref id="B97-biomolecules-10-00702">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menegon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Columbano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The Dual Roles of NRF2 in Cancer</article-title>
<source/>Trends Mol. Med.
          <year>2016</year>
<volume>22</volume>
<fpage>578</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmed.2016.05.002</pub-id>
<pub-id pub-id-type="pmid">27263465</pub-id>
</element-citation>
</ref>
<ref id="B98-biomolecules-10-00702">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The KEAP1-NRF2 System in Cancer</article-title>
<source/>Front. Oncol.
          <year>2017</year>
<volume>7</volume>
<fpage>85</fpage>
<pub-id pub-id-type="doi">10.3389/fonc.2017.00085</pub-id>
<pub-id pub-id-type="pmid">28523248</pub-id>
</element-citation>
</ref>
<ref id="B99-biomolecules-10-00702">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitamura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Motohashi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>NRF2 addiction in cancer cells</article-title>
<source/>Cancer Sci.
          <year>2018</year>
<volume>109</volume>
<fpage>900</fpage>
<lpage>911</lpage>
<pub-id pub-id-type="doi">10.1111/cas.13537</pub-id>
<pub-id pub-id-type="pmid">29450944</pub-id>
</element-citation>
</ref>
<ref id="B100-biomolecules-10-00702">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramsey</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Lindl</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Ritson</surname>
<given-names>G.P.</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Jordan-Sciutto</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>Expression of Nrf2 in neurodegenerative diseases</article-title>
<source/>J. Neuropathol. Exp. Neurol.
          <year>2007</year>
<volume>66</volume>
<fpage>75</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1097/nen.0b013e31802d6da9</pub-id>
<pub-id pub-id-type="pmid">17204939</pub-id>
</element-citation>
</ref>
<ref id="B101-biomolecules-10-00702">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarlette</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Krampfl</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Grothe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Neuhoff</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dengler</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Petri</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis</article-title>
<source/>J. Neuropathol. Exp. Neurol.
          <year>2008</year>
<volume>67</volume>
<fpage>1055</fpage>
<lpage>1062</lpage>
<pub-id pub-id-type="doi">10.1097/NEN.0b013e31818b4906</pub-id>
<pub-id pub-id-type="pmid">18957896</pub-id>
</element-citation>
</ref>
<ref id="B102-biomolecules-10-00702">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandes</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>N.E.</given-names>
</name>
</person-group>
<article-title>NRF2 as a Therapeutic Target in Neurodegenerative Diseases</article-title>
<source/>ASN Neuro
          <year>2020</year>
<volume>12</volume>
<fpage>1759091419899782</fpage>
<pub-id pub-id-type="doi">10.1177/1759091419899782</pub-id>
<pub-id pub-id-type="pmid">31964153</pub-id>
</element-citation>
</ref>
<ref id="B103-biomolecules-10-00702">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sbodio</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>B.D.</given-names>
</name>
</person-group>
<article-title>Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities</article-title>
<source/>Antioxid. Redox Signal.
          <year>2019</year>
<volume>30</volume>
<fpage>1450</fpage>
<lpage>1499</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2017.7321</pub-id>
<pub-id pub-id-type="pmid">29634350</pub-id>
</element-citation>
</ref>
<ref id="B104-biomolecules-10-00702">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cossée</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Campuzano</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Reutenauer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Moutou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Evolution of the Friedreich’s ataxia trinucleotide repeat expansion: Founder effect and premutations</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1997</year>
<volume>94</volume>
<fpage>7452</fpage>
<lpage>7457</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.94.14.7452</pub-id>
<pub-id pub-id-type="pmid">9207112</pub-id>
</element-citation>
</ref>
<ref id="B105-biomolecules-10-00702">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Napierala</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dent</surname>
<given-names>S.Y.</given-names>
</name>
</person-group>
<article-title>Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich’s ataxia</article-title>
<source/>Nucleic Acids Res.
          <year>2011</year>
<volume>39</volume>
<fpage>8366</fpage>
<lpage>8377</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkr542</pub-id>
<pub-id pub-id-type="pmid">21745819</pub-id>
</element-citation>
</ref>
<ref id="B106-biomolecules-10-00702">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koeppen</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>Friedreich’s ataxia: Pathology, pathogenesis, and molecular genetics</article-title>
<source/>J. Neurol. Sci.
          <year>2011</year>
<volume>303</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2011.01.010</pub-id>
<pub-id pub-id-type="pmid">21315377</pub-id>
</element-citation>
</ref>
<ref id="B107-biomolecules-10-00702">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandolfo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pastore</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The pathogenesis of Friedreich ataxia and the structure and function of frataxin</article-title>
<source/>J. Neurol.
          <year>2009</year>
<volume>256</volume>
<issue>Suppl. 1</issue>
<fpage>9</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-009-1003-2</pub-id>
<pub-id pub-id-type="pmid">19283345</pub-id>
</element-citation>
</ref>
<ref id="B108-biomolecules-10-00702">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parkinson</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Boesch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nachbauer</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mariotti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Giunti</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Clinical features of Friedreich’s ataxia: Classical and atypical phenotypes</article-title>
<source/>J. Neurochem.
          <year>2013</year>
<volume>126</volume>
<issue>Suppl. 1</issue>
<fpage>103</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.12317</pub-id>
<pub-id pub-id-type="pmid">23859346</pub-id>
</element-citation>
</ref>
<ref id="B109-biomolecules-10-00702">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puccio</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cossee</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Criqui-Filipe</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tiziano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Melki</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hindelang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Matyas</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rustin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits</article-title>
<source/>Nat. Genet.
          <year>2001</year>
<volume>27</volume>
<fpage>181</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1038/84818</pub-id>
<pub-id pub-id-type="pmid">11175786</pub-id>
</element-citation>
</ref>
<ref id="B110-biomolecules-10-00702">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anzovino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>Fixing frataxin: ‘ironing out’ the metabolic defect in Friedreich’s ataxia</article-title>
<source/>Br. J. Pharmacol.
          <year>2014</year>
<volume>171</volume>
<fpage>2174</fpage>
<lpage>2190</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12470</pub-id>
<pub-id pub-id-type="pmid">24138602</pub-id>
</element-citation>
</ref>
<ref id="B111-biomolecules-10-00702">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaubel</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Isaya</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia</article-title>
<source/>Mol. Cell. Neurosci.
          <year>2013</year>
<volume>55</volume>
<fpage>50</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2012.08.003</pub-id>
<pub-id pub-id-type="pmid">22917739</pub-id>
</element-citation>
</ref>
<ref id="B112-biomolecules-10-00702">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koenig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Deciphering the cause of Friedreich ataxia</article-title>
<source/>Curr. Opin. Neurobiol.
          <year>1997</year>
<volume>7</volume>
<fpage>689</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="doi">10.1016/S0959-4388(97)80090-6</pub-id>
<pub-id pub-id-type="pmid">9384553</pub-id>
</element-citation>
</ref>
<ref id="B113-biomolecules-10-00702">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomes</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Neurodegeneration in Friedreich’s ataxia: From defective frataxin to oxidative stress</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2013</year>
<volume>2013</volume>
<fpage>487534</fpage>
<pub-id pub-id-type="doi">10.1155/2013/487534</pub-id>
<pub-id pub-id-type="pmid">23936609</pub-id>
</element-citation>
</ref>
<ref id="B114-biomolecules-10-00702">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carletti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Piemonte</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Friedreich’s Ataxia: A Neuronal Point of View on the Oxidative Stress Hypothesis</article-title>
<source/>Antioxidants
          <year>2014</year>
<volume>3</volume>
<fpage>592</fpage>
<lpage>603</lpage>
<pub-id pub-id-type="doi">10.3390/antiox3030592</pub-id>
<pub-id pub-id-type="pmid">26785073</pub-id>
</element-citation>
</ref>
<ref id="B115-biomolecules-10-00702">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lupoli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Vannocci</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Niccolai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pastore</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The role of oxidative stress in Friedreich’s ataxia</article-title>
<source/>FEBS Lett.
          <year>2018</year>
<volume>592</volume>
<fpage>718</fpage>
<lpage>727</lpage>
<pub-id pub-id-type="doi">10.1002/1873-3468.12928</pub-id>
<pub-id pub-id-type="pmid">29197070</pub-id>
</element-citation>
</ref>
<ref id="B116-biomolecules-10-00702">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anzovino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>Molecular Alterations in a Mouse Cardiac Model of Friedreich Ataxia: An Impaired Nrf2 Response Mediated via Upregulation of Keap1 and Activation of the Gsk3β Axis</article-title>
<source/>Am. J. Pathol.
          <year>2017</year>
<volume>187</volume>
<fpage>2858</fpage>
<lpage>2875</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2017.08.021</pub-id>
<pub-id pub-id-type="pmid">28935570</pub-id>
</element-citation>
</ref>
<ref id="B117-biomolecules-10-00702">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paupe</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dassa</surname>
<given-names>E.P.</given-names>
</name>
<name>
<surname>Goncalves</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Auchere</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lonn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Holmgren</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rustin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia</article-title>
<source/>PLoS ONE
          <year>2009</year>
<volume>4</volume>
<elocation-id>e4253</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0004253</pub-id>
<pub-id pub-id-type="pmid">19158945</pub-id>
</element-citation>
</ref>
<ref id="B118-biomolecules-10-00702">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Oria</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Petrini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Travaglini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Priori</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Piermarini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Petrillo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carletti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Piemonte</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Frataxin deficiency leads to reduced expression and impaired translocation of NF-E2-related factor (Nrf2) in cultured motor neurons</article-title>
<source/>Int. J. Mol. Sci.
          <year>2013</year>
<volume>14</volume>
<fpage>7853</fpage>
<lpage>7865</lpage>
<pub-id pub-id-type="doi">10.3390/ijms14047853</pub-id>
<pub-id pub-id-type="pmid">23574943</pub-id>
</element-citation>
</ref>
<ref id="B119-biomolecules-10-00702">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Schoenfeld</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Napoli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Akiyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Iodi Carstens</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Carstens</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Pook</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Cortopassi</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich’s ataxia YG8R mouse model</article-title>
<source/>Antioxid. Redox Signal.
          <year>2013</year>
<volume>19</volume>
<fpage>1481</fpage>
<lpage>1493</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2012.4537</pub-id>
<pub-id pub-id-type="pmid">23350650</pub-id>
</element-citation>
</ref>
<ref id="B120-biomolecules-10-00702">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emond</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lepage</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vanasse</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pandolfo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Increased levels of plasma malondialdehyde in Friedreich ataxia</article-title>
<source/>Neurology
          <year>2000</year>
<volume>55</volume>
<fpage>1752</fpage>
<lpage>1753</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.55.11.1752</pub-id>
<pub-id pub-id-type="pmid">11113241</pub-id>
</element-citation>
</ref>
<ref id="B121-biomolecules-10-00702">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulz</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Dehmer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Schöls</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mende</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hardt</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vorgerd</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bürk</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Matson</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Dichgans</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>M.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress in patients with Friedreich ataxia</article-title>
<source/>Neurology
          <year>2000</year>
<volume>55</volume>
<fpage>1719</fpage>
<lpage>1721</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.55.11.1719</pub-id>
<pub-id pub-id-type="pmid">11113228</pub-id>
</element-citation>
</ref>
<ref id="B122-biomolecules-10-00702">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tozzi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nuccetelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lo Bello</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bernardini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bellincampi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ballerini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gaeta</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Casali</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pastore</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Federici</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antioxidant enzymes in blood of patients with Friedreich’s ataxia</article-title>
<source/>Arch. Dis. Child.
          <year>2002</year>
<volume>86</volume>
<fpage>376</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="doi">10.1136/adc.86.5.376</pub-id>
<pub-id pub-id-type="pmid">11970939</pub-id>
</element-citation>
</ref>
<ref id="B123-biomolecules-10-00702">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Wilson-Delfosse</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Mieyal</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Dysregulation of glutathione homeostasis in neurodegenerative diseases</article-title>
<source/>Nutrients
          <year>2012</year>
<volume>4</volume>
<fpage>1399</fpage>
<lpage>1440</lpage>
<pub-id pub-id-type="doi">10.3390/nu4101399</pub-id>
<pub-id pub-id-type="pmid">23201762</pub-id>
</element-citation>
</ref>
<ref id="B124-biomolecules-10-00702">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cotticelli</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Crabbe</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Shchepinov</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids</article-title>
<source/>Redox Biol.
          <year>2013</year>
<volume>1</volume>
<fpage>398</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="doi">10.1016/j.redox.2013.06.004</pub-id>
<pub-id pub-id-type="pmid">25499576</pub-id>
</element-citation>
</ref>
<ref id="B125-biomolecules-10-00702">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cotticelli</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Terrab</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wipf</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Huryn</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>R.B.</given-names>
</name>
</person-group>
<article-title>Ferroptosis as a Novel Therapeutic Target for Friedreich’s Ataxia</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2019</year>
<volume>369</volume>
<fpage>47</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.118.252759</pub-id>
<pub-id pub-id-type="pmid">30635474</pub-id>
</element-citation>
</ref>
<ref id="B126-biomolecules-10-00702">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abeti</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Parkinson</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Hargreaves</surname>
<given-names>I.P.</given-names>
</name>
<name>
<surname>Angelova</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Sandi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pook</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Giunti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Abramov</surname>
<given-names>A.Y.</given-names>
</name>
</person-group>
<article-title>‘Mitochondrial energy imbalance and lipid peroxidation cause cell death in Friedreich’s ataxia’</article-title>
<source/>Cell Death Dis.
          <year>2016</year>
<volume>7</volume>
<fpage>e2237</fpage>
<pub-id pub-id-type="doi">10.1038/cddis.2016.111</pub-id>
<pub-id pub-id-type="pmid">27228352</pub-id>
</element-citation>
</ref>
<ref id="B127-biomolecules-10-00702">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kajarabille</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Latunde-Dada</surname>
<given-names>G.O.</given-names>
</name>
</person-group>
<article-title>Programmed Cell-Death by Ferroptosis: Antioxidants as Mitigators</article-title>
<source/>Int. J. Mol. Sci.
          <year>2019</year>
<volume>20</volume>
<pub-id pub-id-type="doi">10.3390/ijms20194968</pub-id>
</element-citation>
</ref>
<ref id="B128-biomolecules-10-00702">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esteras</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Abramov</surname>
<given-names>A.Y.</given-names>
</name>
</person-group>
<article-title>Nrf2 activation in the treatment of neurodegenerative diseases: A focus on its role in mitochondrial bioenergetics and function</article-title>
<source/>Biol. Chem.
          <year>2016</year>
<volume>397</volume>
<fpage>383</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="doi">10.1515/hsz-2015-0295</pub-id>
<pub-id pub-id-type="pmid">26812787</pub-id>
</element-citation>
</ref>
<ref id="B129-biomolecules-10-00702">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kensler</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Biswal</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway</article-title>
<source/>Annu. Rev. Pharmacol. Toxicol.
          <year>2007</year>
<volume>47</volume>
<fpage>89</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.pharmtox.46.120604.141046</pub-id>
<pub-id pub-id-type="pmid">16968214</pub-id>
</element-citation>
</ref>
<ref id="B130-biomolecules-10-00702">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klomparens</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The neuroprotective mechanisms and effects of sulforaphane</article-title>
<source/>Brain Circ.
          <year>2019</year>
<volume>5</volume>
<fpage>74</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.4103/bc.bc_7_19</pub-id>
<pub-id pub-id-type="pmid">31334360</pub-id>
</element-citation>
</ref>
<ref id="B131-biomolecules-10-00702">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uddin</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Mamun</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Jakaria</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Thangapandiyan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Mathew</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Abdel-Daim</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Aleya</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders</article-title>
<source/>Sci. Total Environ.
          <year>2020</year>
<volume>707</volume>
<fpage>135624</fpage>
<pub-id pub-id-type="doi">10.1016/j.scitotenv.2019.135624</pub-id>
<pub-id pub-id-type="pmid">31784171</pub-id>
</element-citation>
</ref>
<ref id="B132-biomolecules-10-00702">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scannevin</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Chollate</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Shackett</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bista</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lukashev</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2012</year>
<volume>341</volume>
<fpage>274</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.111.190132</pub-id>
<pub-id pub-id-type="pmid">22267202</pub-id>
</element-citation>
</ref>
<ref id="B133-biomolecules-10-00702">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montes Diaz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hupperts</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fraussen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Somers</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies</article-title>
<source/>Autoimmun. Rev.
          <year>2018</year>
<volume>17</volume>
<fpage>1240</fpage>
<lpage>1250</lpage>
<pub-id pub-id-type="doi">10.1016/j.autrev.2018.07.001</pub-id>
<pub-id pub-id-type="pmid">30316988</pub-id>
</element-citation>
</ref>
<ref id="B134-biomolecules-10-00702">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranea-Robles</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Launay</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ruiz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Calingasan</surname>
<given-names>N.Y.</given-names>
</name>
<name>
<surname>Dumont</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Naudi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Portero-Otin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pamplona</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ferrer</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>M.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aberrant regulation of the GSK-3beta/NRF2 axis unveils a novel therapy for adrenoleukodystrophy</article-title>
<source/>EMBO Mol. Med.
          <year>2018</year>
<volume>10</volume>
<fpage>e8604</fpage>
<pub-id pub-id-type="doi">10.15252/emmm.201708604</pub-id>
<pub-id pub-id-type="pmid">29997171</pub-id>
</element-citation>
</ref>
<ref id="B135-biomolecules-10-00702">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrillo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Piermarini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pastore</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vasco</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schirinzi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Carrozzo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Piemonte</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia</article-title>
<source/>Int. J. Mol. Sci.
          <year>2017</year>
<volume>18</volume>
<elocation-id>2173</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms18102173</pub-id>
</element-citation>
</ref>
<ref id="B136-biomolecules-10-00702">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jasoliya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sacca</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sahdeo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chedin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pane</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brescia Morra</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Filla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pook</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cortopassi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia</article-title>
<source/>PLoS ONE
          <year>2019</year>
<volume>14</volume>
<elocation-id>e0217776</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0217776</pub-id>
<pub-id pub-id-type="pmid">31158268</pub-id>
</element-citation>
</ref>
<ref id="B137-biomolecules-10-00702">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahdeo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>McMackin</surname>
<given-names>M.Z.</given-names>
</name>
<name>
<surname>Jasoliya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wulff</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Pook</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Cortopassi</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich’s ataxia</article-title>
<source/>Hum. Mol. Genet.
          <year>2014</year>
<volume>23</volume>
<fpage>6848</fpage>
<lpage>6862</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu408</pub-id>
<pub-id pub-id-type="pmid">25113747</pub-id>
</element-citation>
</ref>
<ref id="B138-biomolecules-10-00702">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clay</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hearle</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schadt</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>New developments in pharmacotherapy for Friedreich ataxia</article-title>
<source/>Expert Opin. Pharmacother.
          <year>2019</year>
<volume>20</volume>
<fpage>1855</fpage>
<lpage>1867</lpage>
<pub-id pub-id-type="doi">10.1080/14656566.2019.1639671</pub-id>
<pub-id pub-id-type="pmid">31311349</pub-id>
</element-citation>
</ref>
<ref id="B139-biomolecules-10-00702">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hausse</surname>
<given-names>A.O.</given-names>
</name>
<name>
<surname>Aggoun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sidi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Munnich</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rotig</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rustin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia</article-title>
<source/>Heart
          <year>2002</year>
<volume>87</volume>
<fpage>346</fpage>
<lpage>349</lpage>
<pub-id pub-id-type="doi">10.1136/heart.87.4.346</pub-id>
<pub-id pub-id-type="pmid">11907009</pub-id>
</element-citation>
</ref>
<ref id="B140-biomolecules-10-00702">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Prospero</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jeffries</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fischbeck</surname>
<given-names>K.H.</given-names>
</name>
</person-group>
<article-title>Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: A randomised, placebo-controlled trial</article-title>
<source/>Lancet Neurol.
          <year>2007</year>
<volume>6</volume>
<fpage>878</fpage>
<lpage>886</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(07)70220-X</pub-id>
<pub-id pub-id-type="pmid">17826341</pub-id>
</element-citation>
</ref>
<ref id="B141-biomolecules-10-00702">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montenegro</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Turnaturi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Parenti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pasquinucci</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Idebenone: Novel Strategies to Improve Its Systemic and Local Efficacy</article-title>
<source/>Nanomaterials
          <year>2018</year>
<volume>8</volume>
<elocation-id>87</elocation-id>
<pub-id pub-id-type="doi">10.3390/nano8020087</pub-id>
<pub-id pub-id-type="pmid">29401722</pub-id>
</element-citation>
</ref>
<ref id="B142-biomolecules-10-00702">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.Q.</given-names>
</name>
<name>
<surname>Mesaros</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Boesch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Delatycki</surname>
<given-names>M.B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia</article-title>
<source/>Ann. Clin. Transl. Neurol.
          <year>2019</year>
<volume>6</volume>
<fpage>15</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1002/acn3.660</pub-id>
<pub-id pub-id-type="pmid">30656180</pub-id>
</element-citation>
</ref>
<ref id="B143-biomolecules-10-00702">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zesiewicz</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Salemi</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Isaacs</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gooch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>M.B.</given-names>
</name>
</person-group>
<article-title>Double-blind, randomized and controlled trial of EPI-743 in Friedreich’s ataxia</article-title>
<source/>Neurodegener. Dis. Manag.
          <year>2018</year>
<volume>8</volume>
<fpage>233</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.2217/nmt-2018-0013</pub-id>
<pub-id pub-id-type="pmid">30051753</pub-id>
</element-citation>
</ref>
<ref id="B144-biomolecules-10-00702">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hazlett</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Moine</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kooy</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gantois</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sonenberg</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>J.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fragile X syndrome</article-title>
<source/>Nat. Rev. Dis. Primers
          <year>2017</year>
<volume>3</volume>
<fpage>17065</fpage>
<pub-id pub-id-type="doi">10.1038/nrdp.2017.65</pub-id>
<pub-id pub-id-type="pmid">28960184</pub-id>
</element-citation>
</ref>
<ref id="B145-biomolecules-10-00702">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bell</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Hirst</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Nakahori</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>MacKinnon</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Roche</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Tommerup</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tranebjaerg</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Froster-Iskenius</surname>
<given-names>U.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Physical mapping across the fragile X: Hypermethylation and clinical expression of the fragile X syndrome</article-title>
<source/>Cell
          <year>1991</year>
<volume>64</volume>
<fpage>861</fpage>
<lpage>866</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(91)90514-Y</pub-id>
<pub-id pub-id-type="pmid">1997211</pub-id>
</element-citation>
</ref>
<ref id="B146-biomolecules-10-00702">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myrick</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Nakamoto-Kinoshita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lindor</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Kirmani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>S.T.</given-names>
</name>
</person-group>
<article-title>Fragile X syndrome due to a missense mutation</article-title>
<source/>Eur. J. Hum. Genet.
          <year>2014</year>
<volume>22</volume>
<fpage>1185</fpage>
<lpage>1189</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2013.311</pub-id>
<pub-id pub-id-type="pmid">24448548</pub-id>
</element-citation>
</ref>
<ref id="B147-biomolecules-10-00702">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quartier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Poquet</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gilbert-Dussardier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Casteleyn</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Portes</surname>
<given-names>V.D.</given-names>
</name>
<name>
<surname>Feger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nourisson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kuentz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Redin</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intragenic FMR1 disease-causing variants: A significant mutational mechanism leading to Fragile-X syndrome</article-title>
<source/>Eur. J. Hum. Genet.
          <year>2017</year>
<volume>25</volume>
<fpage>423</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2016.204</pub-id>
<pub-id pub-id-type="pmid">28176767</pub-id>
</element-citation>
</ref>
<ref id="B148-biomolecules-10-00702">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiraanont</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.-T.</given-names>
</name>
<name>
<surname>Espinal</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Chutabhakdikul</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Size and methylation mosaicism in males with Fragile X syndrome</article-title>
<source/>Expert Rev. Mol. Diagn.
          <year>2017</year>
<volume>17</volume>
<fpage>1023</fpage>
<lpage>1032</lpage>
<pub-id pub-id-type="doi">10.1080/14737159.2017.1377612</pub-id>
<pub-id pub-id-type="pmid">28929824</pub-id>
</element-citation>
</ref>
<ref id="B149-biomolecules-10-00702">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbeduto</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>McDuffie</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thurman</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>The fragile X syndrome-autism comorbidity: What do we really know?</article-title>
<source/>Front. Genet.
          <year>2014</year>
<volume>5</volume>
<elocation-id>355</elocation-id>
<pub-id pub-id-type="doi">10.3389/fgene.2014.00355</pub-id>
<pub-id pub-id-type="pmid">25360144</pub-id>
</element-citation>
</ref>
<ref id="B150-biomolecules-10-00702">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dyer-Friedman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Glaser</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Huffman</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wisbeck</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Reiss</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>Genetic and environmental influences on the cognitive outcomes of children with fragile X syndrome</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2002</year>
<volume>41</volume>
<fpage>237</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="doi">10.1097/00004583-200203000-00002</pub-id>
<pub-id pub-id-type="pmid">11886017</pub-id>
</element-citation>
</ref>
<ref id="B151-biomolecules-10-00702">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loesch</surname>
<given-names>D.Z.</given-names>
</name>
<name>
<surname>Huggins</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Phenotypic variation and FMRP levels in fragile X</article-title>
<source/>Ment. Retard. Dev. Disabil. Res. Rev.
          <year>2004</year>
<volume>10</volume>
<fpage>31</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1002/mrdd.20006</pub-id>
<pub-id pub-id-type="pmid">14994286</pub-id>
</element-citation>
</ref>
<ref id="B152-biomolecules-10-00702">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartholomay</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Lightbody</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Reiss</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>Closing the Gender Gap in Fragile X Syndrome: Review on Females with FXS and Preliminary Research Findings</article-title>
<source/>Brain Sci.
          <year>2019</year>
<volume>9</volume>
<elocation-id>11</elocation-id>
<pub-id pub-id-type="doi">10.3390/brainsci9010011</pub-id>
<pub-id pub-id-type="pmid">30642066</pub-id>
</element-citation>
</ref>
<ref id="B153-biomolecules-10-00702">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bardoni</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Schenck</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>J.-L.</given-names>
</name>
</person-group>
<article-title>The Fragile X mental retardation protein</article-title>
<source/>Brain Res. Bull.
          <year>2001</year>
<volume>56</volume>
<fpage>375</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.1016/S0361-9230(01)00647-5</pub-id>
<pub-id pub-id-type="pmid">11719275</pub-id>
</element-citation>
</ref>
<ref id="B154-biomolecules-10-00702">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devys</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lutz</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rouyer</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bellocq</surname>
<given-names>J.-P.</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>J.-L.</given-names>
</name>
</person-group>
<article-title>The FMR–1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation</article-title>
<source/>Nat. Genet.
          <year>1993</year>
<volume>4</volume>
<fpage>335</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="doi">10.1038/ng0893-335</pub-id>
<pub-id pub-id-type="pmid">8401578</pub-id>
</element-citation>
</ref>
<ref id="B155-biomolecules-10-00702">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gutekunst</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Eberhart</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Hersch</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Fragile X mental retardation protein: Nucleocytoplasmic shuttling and association with somatodendritic ribosomes</article-title>
<source/>J. Neurosci.
          <year>1997</year>
<volume>17</volume>
<fpage>1539</fpage>
<lpage>1547</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.17-05-01539.1997</pub-id>
<pub-id pub-id-type="pmid">9030614</pub-id>
</element-citation>
</ref>
<ref id="B156-biomolecules-10-00702">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrari</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mercaldo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Piccoli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sala</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cannata</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Achsel</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bagni</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines</article-title>
<source/>Mol. Cell. Neurosci.
          <year>2007</year>
<volume>34</volume>
<fpage>343</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2006.11.015</pub-id>
<pub-id pub-id-type="pmid">17254795</pub-id>
</element-citation>
</ref>
<ref id="B157-biomolecules-10-00702">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dictenberg</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Swanger</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Antar</surname>
<given-names>L.N.</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Bassell</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome</article-title>
<source/>Dev. Cell
          <year>2008</year>
<volume>14</volume>
<fpage>926</fpage>
<lpage>939</lpage>
<pub-id pub-id-type="doi">10.1016/j.devcel.2008.04.003</pub-id>
<pub-id pub-id-type="pmid">18539120</pub-id>
</element-citation>
</ref>
<ref id="B158-biomolecules-10-00702">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huber</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Gallagher</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Altered synaptic plasticity in a mouse model of fragile X mental retardation</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2002</year>
<volume>99</volume>
<fpage>7746</fpage>
<lpage>7750</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.122205699</pub-id>
<pub-id pub-id-type="pmid">12032354</pub-id>
</element-citation>
</ref>
<ref id="B159-biomolecules-10-00702">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nalavadi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Narayanan</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Bassell</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>S.T.</given-names>
</name>
</person-group>
<article-title>Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2007</year>
<volume>104</volume>
<fpage>15537</fpage>
<lpage>15542</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0707484104</pub-id>
<pub-id pub-id-type="pmid">17881561</pub-id>
</element-citation>
</ref>
<ref id="B160-biomolecules-10-00702">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eadie</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Cushman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kannangara</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Fanselow</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Christie</surname>
<given-names>B.R.</given-names>
</name>
</person-group>
<article-title>NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult Fmr1 knockout mice</article-title>
<source/>Hippocampus
          <year>2012</year>
<volume>22</volume>
<fpage>241</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1002/hipo.20890</pub-id>
<pub-id pub-id-type="pmid">21049485</pub-id>
</element-citation>
</ref>
<ref id="B161-biomolecules-10-00702">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Centonze</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mercaldo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Napoli</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ciotti</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>De Chiara</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Musella</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Prosperetti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Calabresi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bernardi</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome</article-title>
<source/>Biol. Psychiatry
          <year>2008</year>
<volume>63</volume>
<fpage>963</fpage>
<lpage>973</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2007.09.008</pub-id>
<pub-id pub-id-type="pmid">18028882</pub-id>
</element-citation>
</ref>
<ref id="B162-biomolecules-10-00702">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rajan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bagni</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>The FMRP regulon: From targets to disease convergence</article-title>
<source/>Front. Neurosci.
          <year>2013</year>
<volume>7</volume>
<fpage>191</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2013.00191</pub-id>
<pub-id pub-id-type="pmid">24167470</pub-id>
</element-citation>
</ref>
<ref id="B163-biomolecules-10-00702">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ceman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Darnell</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>O’Donnell</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Tenenbaum</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Keene</surname>
<given-names>J.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome</article-title>
<source/>Cell
          <year>2001</year>
<volume>107</volume>
<fpage>477</fpage>
<lpage>487</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(01)00568-2</pub-id>
<pub-id pub-id-type="pmid">11719188</pub-id>
</element-citation>
</ref>
<ref id="B164-biomolecules-10-00702">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napoli</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mercaldo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Boyl</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Eleuteri</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zalfa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>De Rubeis</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Di Marino</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mohr</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Massimi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Falconi</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP</article-title>
<source/>Cell
          <year>2008</year>
<volume>134</volume>
<fpage>1042</fpage>
<lpage>1054</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2008.07.031</pub-id>
<pub-id pub-id-type="pmid">18805096</pub-id>
</element-citation>
</ref>
<ref id="B165-biomolecules-10-00702">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narayanan</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Nalavadi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nakamoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pallas</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Ceman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bassell</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>S.T.</given-names>
</name>
</person-group>
<article-title>FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A</article-title>
<source/>J. Neurosci.
          <year>2007</year>
<volume>27</volume>
<fpage>14349</fpage>
<lpage>14357</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2969-07.2007</pub-id>
<pub-id pub-id-type="pmid">18160642</pub-id>
</element-citation>
</ref>
<ref id="B166-biomolecules-10-00702">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muddashetty</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Kelić</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bassell</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome</article-title>
<source/>J. Neurosci.
          <year>2007</year>
<volume>27</volume>
<fpage>5338</fpage>
<lpage>5348</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0937-07.2007</pub-id>
<pub-id pub-id-type="pmid">17507556</pub-id>
</element-citation>
</ref>
<ref id="B167-biomolecules-10-00702">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pelletier</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Perez Velazquez</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Carlen</surname>
<given-names>P.L.</given-names>
</name>
</person-group>
<article-title>Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency</article-title>
<source/>Mol. Cell. Neurosci.
          <year>2002</year>
<volume>19</volume>
<fpage>138</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="doi">10.1006/mcne.2001.1085</pub-id>
<pub-id pub-id-type="pmid">11860268</pub-id>
</element-citation>
</ref>
<ref id="B168-biomolecules-10-00702">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serrano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Reactive oxygen species and synaptic plasticity in the aging hippocampus</article-title>
<source/>Ageing Res. Rev.
          <year>2004</year>
<volume>3</volume>
<fpage>431</fpage>
<lpage>443</lpage>
<pub-id pub-id-type="doi">10.1016/j.arr.2004.05.002</pub-id>
<pub-id pub-id-type="pmid">15541710</pub-id>
</element-citation>
</ref>
<ref id="B169-biomolecules-10-00702">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sidorov</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Auerbach</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Fragile X mental retardation protein and synaptic plasticity</article-title>
<source/>Mol. Brain
          <year>2013</year>
<volume>6</volume>
<fpage>15</fpage>
<pub-id pub-id-type="doi">10.1186/1756-6606-6-15</pub-id>
<pub-id pub-id-type="pmid">23566911</pub-id>
</element-citation>
</ref>
<ref id="B170-biomolecules-10-00702">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chauhan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chauhan</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Oxidative stress in autism</article-title>
<source/>Pathophysiology
          <year>2006</year>
<volume>13</volume>
<fpage>171</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1016/j.pathophys.2006.05.007</pub-id>
<pub-id pub-id-type="pmid">16766163</pub-id>
</element-citation>
</ref>
<ref id="B171-biomolecules-10-00702">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gingrich</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Oxidative stress is the new stress</article-title>
<source/>Nat. Med.
          <year>2005</year>
<volume>11</volume>
<fpage>1281</fpage>
<lpage>1282</lpage>
<pub-id pub-id-type="doi">10.1038/nm1205-1281</pub-id>
<pub-id pub-id-type="pmid">16333265</pub-id>
</element-citation>
</ref>
<ref id="B172-biomolecules-10-00702">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bouayed</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rammal</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Soulimani</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and anxiety: Relationship and cellular pathways</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2009</year>
<volume>2</volume>
<fpage>63</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.4161/oxim.2.2.7944</pub-id>
<pub-id pub-id-type="pmid">20357926</pub-id>
</element-citation>
</ref>
<ref id="B173-biomolecules-10-00702">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tönnies</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Trushina</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2017</year>
<volume>57</volume>
<fpage>1105</fpage>
<lpage>1121</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-161088</pub-id>
<pub-id pub-id-type="pmid">28059794</pub-id>
</element-citation>
</ref>
<ref id="B174-biomolecules-10-00702">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Bekay</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Romero-Zerbo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Decara</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sanchez-Salido</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Del Arco-Herrera</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rodríguez-de Fonseca</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>de Diego-Otero</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome</article-title>
<source/>Eur. J. Neurosci.
          <year>2007</year>
<volume>26</volume>
<fpage>3169</fpage>
<lpage>3180</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2007.05939.x</pub-id>
<pub-id pub-id-type="pmid">18005058</pub-id>
</element-citation>
</ref>
<ref id="B175-biomolecules-10-00702">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyashiro</surname>
<given-names>K.Y.</given-names>
</name>
<name>
<surname>Beckel-Mitchener</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Purk</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>K.G.</given-names>
</name>
<name>
<surname>Barret</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Carbonetto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Weiler</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Greenough</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Eberwine</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice</article-title>
<source/>Neuron
          <year>2003</year>
<volume>37</volume>
<fpage>417</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(03)00034-5</pub-id>
<pub-id pub-id-type="pmid">12575950</pub-id>
</element-citation>
</ref>
<ref id="B176-biomolecules-10-00702">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bechara</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Didiot</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Melko</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Davidovic</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bensaid</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Castets</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pognonec</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Khandjian</surname>
<given-names>E.W.</given-names>
</name>
<name>
<surname>Moine</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel function for fragile X mental retardation protein in translational activation</article-title>
<source/>PLoS Biol.
          <year>2009</year>
<volume>7</volume>
<elocation-id>e16</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pbio.1000016</pub-id>
<pub-id pub-id-type="pmid">19166269</pub-id>
</element-citation>
</ref>
<ref id="B177-biomolecules-10-00702">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martín-Moldes</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lastres-Becker</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation</article-title>
<source/>J Biol. Chem.
          <year>2014</year>
<volume>289</volume>
<fpage>15244</fpage>
<lpage>15258</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M113.540633</pub-id>
<pub-id pub-id-type="pmid">24759106</pub-id>
</element-citation>
</ref>
<ref id="B178-biomolecules-10-00702">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marei</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Malliri</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms</article-title>
<source/>Small GTPases
          <year>2017</year>
<volume>8</volume>
<fpage>139</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="doi">10.1080/21541248.2016.1211398</pub-id>
<pub-id pub-id-type="pmid">27442895</pub-id>
</element-citation>
</ref>
<ref id="B179-biomolecules-10-00702">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Terada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ariyoshi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Morimoto</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Monocyte chemoattractant protein-1/CC chemokine ligand 2 enhances apoptotic cell removal by macrophages through Rac1 activation</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2010</year>
<volume>399</volume>
<fpage>677</fpage>
<lpage>682</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2010.07.141</pub-id>
<pub-id pub-id-type="pmid">20691665</pub-id>
</element-citation>
</ref>
<ref id="B180-biomolecules-10-00702">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>MEKK3 regulates IFN-gamma production in T cells through the Rac1/2-dependent MAPK cascades</article-title>
<source/>J. Immunol.
          <year>2011</year>
<volume>186</volume>
<fpage>5791</fpage>
<lpage>5800</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1002127</pub-id>
<pub-id pub-id-type="pmid">21471448</pub-id>
</element-citation>
</ref>
<ref id="B181-biomolecules-10-00702">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salazar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rojo</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Velasco</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>de Sagarra</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2</article-title>
<source/>J. Biol. Chem.
          <year>2006</year>
<volume>281</volume>
<fpage>14841</fpage>
<lpage>14851</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M513737200</pub-id>
<pub-id pub-id-type="pmid">16551619</pub-id>
</element-citation>
</ref>
<ref id="B182-biomolecules-10-00702">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beitel</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Alvarado</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mokhtar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Paliouras</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trifiro</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Mechanisms Mediating Spinal and Bulbar Muscular Atrophy: Investigations into Polyglutamine-Expanded Androgen Receptor Function and Dysfunction</article-title>
<source/>Front. Neurol.
          <year>2013</year>
<volume>4</volume>
<fpage>53</fpage>
<pub-id pub-id-type="doi">10.3389/fneur.2013.00053</pub-id>
<pub-id pub-id-type="pmid">23720649</pub-id>
</element-citation>
</ref>
<ref id="B183-biomolecules-10-00702">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rhodes</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>B.K.</given-names>
</name>
<name>
<surname>Auh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kokkinis</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>La Pean</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lehky</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Shrader</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>E.W.</given-names>
</name>
<name>
<surname>Harris-Love</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical features of spinal and bulbar muscular atrophy</article-title>
<source/>Brain J. Neurol.
          <year>2009</year>
<volume>132</volume>
<fpage>3242</fpage>
<lpage>3251</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awp258</pub-id>
<pub-id pub-id-type="pmid">19846582</pub-id>
</element-citation>
</ref>
<ref id="B184-biomolecules-10-00702">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dejager</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bry-Gauillard</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bruckert</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Salachas</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>LeGuern</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tardieu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chadarevian</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Giral</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Turpin</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>A comprehensive endocrine description of Kennedy’s disease revealing androgen insensitivity linked to CAG repeat length</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2002</year>
<volume>87</volume>
<fpage>3893</fpage>
<lpage>3901</lpage>
<pub-id pub-id-type="doi">10.1210/jcem.87.8.8780</pub-id>
<pub-id pub-id-type="pmid">12161529</pub-id>
</element-citation>
</ref>
<ref id="B185-biomolecules-10-00702">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antonini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gragnani</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Romaniello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pennisi</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Morino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ceschin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Santoro</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cruccu</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Sensory involvement in spinal-bulbar muscular atrophy (Kennedy’s disease)</article-title>
<source/>Muscle Nerve
          <year>2000</year>
<volume>23</volume>
<fpage>252</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1097-4598(200002)23:2&lt;252::AID-MUS17&gt;3.0.CO;2-P</pub-id>
<pub-id pub-id-type="pmid">10639619</pub-id>
</element-citation>
</ref>
<ref id="B186-biomolecules-10-00702">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Spada</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Lubahn</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Fischbeck</surname>
<given-names>K.H.</given-names>
</name>
</person-group>
<article-title>Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy</article-title>
<source/>Nature
          <year>1991</year>
<volume>352</volume>
<fpage>77</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1038/352077a0</pub-id>
<pub-id pub-id-type="pmid">2062380</pub-id>
</element-citation>
</ref>
<ref id="B187-biomolecules-10-00702">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pellegrini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bulzomi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lecis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Campesi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Franconi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Endocrine Disruptors Differently Influence Estrogen Receptor β and Androgen Receptor in Male and Female Rat VSMC</article-title>
<source/>J. Cell. Physiol.
          <year>2014</year>
<volume>229</volume>
<fpage>1061</fpage>
<lpage>1068</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.24530</pub-id>
<pub-id pub-id-type="pmid">24347325</pub-id>
</element-citation>
</ref>
<ref id="B188-biomolecules-10-00702">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rusmini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sau</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Crippa</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Palazzolo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Simonini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Onesto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Martini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Poletti</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Aggregation and proteasome: The case of elongated polyglutamine aggregation in spinal and bulbar muscular atrophy</article-title>
<source/>Neurobiol. Aging
          <year>2007</year>
<volume>28</volume>
<fpage>1099</fpage>
<lpage>1111</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.05.015</pub-id>
<pub-id pub-id-type="pmid">16781019</pub-id>
</element-citation>
</ref>
<ref id="B189-biomolecules-10-00702">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schindler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fabre</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>de Weille</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Carreau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mersel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bakalara</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Disruption of Nongenomic Testosterone Signaling in a Model of Spinal and Bulbar Muscular Atrophy</article-title>
<source/>Mol. Endocrinol.
          <year>2012</year>
<volume>26</volume>
<fpage>1102</fpage>
<lpage>1116</lpage>
<pub-id pub-id-type="doi">10.1210/me.2011-1367</pub-id>
<pub-id pub-id-type="pmid">22570336</pub-id>
</element-citation>
</ref>
<ref id="B190-biomolecules-10-00702">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davies</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Watt</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>McEwan</surname>
<given-names>I.J.</given-names>
</name>
</person-group>
<article-title>Consequences of poly-glutamine repeat length for the conformation and folding of the androgen receptor amino-terminal domain</article-title>
<source/>J. Mol. Endocrinol.
          <year>2008</year>
<volume>41</volume>
<fpage>301</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1677/JME-08-0042</pub-id>
<pub-id pub-id-type="pmid">18762554</pub-id>
</element-citation>
</ref>
<ref id="B191-biomolecules-10-00702">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lieberman</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Harmison</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Strand</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Fischbeck</surname>
<given-names>K.H.</given-names>
</name>
</person-group>
<article-title>Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor</article-title>
<source/>Hum. Mol. Genet.
          <year>2002</year>
<volume>11</volume>
<fpage>1967</fpage>
<lpage>1976</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/11.17.1967</pub-id>
<pub-id pub-id-type="pmid">12165558</pub-id>
</element-citation>
</ref>
<ref id="B192-biomolecules-10-00702">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCampbell</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Taye</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Robitschek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Walcott</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Merry</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sobue</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CREB-binding protein sequestration by expanded polyglutamine</article-title>
<source/>Hum. Mol. Genet.
          <year>2000</year>
<volume>9</volume>
<fpage>2197</fpage>
<lpage>2202</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/9.14.2197</pub-id>
<pub-id pub-id-type="pmid">10958659</pub-id>
</element-citation>
</ref>
<ref id="B193-biomolecules-10-00702">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Allingham-Hawkins</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Spriggs</surname>
<given-names>E.L.</given-names>
</name>
</person-group>
<article-title>Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women</article-title>
<source/>Neurology
          <year>2002</year>
<volume>59</volume>
<fpage>770</fpage>
<lpage>772</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.59.5.770</pub-id>
<pub-id pub-id-type="pmid">12221177</pub-id>
</element-citation>
</ref>
<ref id="B194-biomolecules-10-00702">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeyama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tanimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Furutani</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kanuka</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Miura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tabata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila</article-title>
<source/>Neuron
          <year>2002</year>
<volume>35</volume>
<fpage>855</fpage>
<lpage>864</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(02)00875-9</pub-id>
<pub-id pub-id-type="pmid">12372281</pub-id>
</element-citation>
</ref>
<ref id="B195-biomolecules-10-00702">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katsuno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Adachi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kume</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nakagomi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Niwa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Doyu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sobue</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy</article-title>
<source/>Neuron
          <year>2002</year>
<volume>35</volume>
<fpage>843</fpage>
<lpage>854</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(02)00834-6</pub-id>
<pub-id pub-id-type="pmid">12372280</pub-id>
</element-citation>
</ref>
<ref id="B196-biomolecules-10-00702">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cary</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>La Spada</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>Androgen Receptor Function in Motor Neuron Survival and Degeneration</article-title>
<source/>Phys. Med. Rehabil. Clin. N. Am.
          <year>2008</year>
<volume>19</volume>
<fpage>479</fpage>
<lpage>494</lpage>
<pub-id pub-id-type="doi">10.1016/j.pmr.2008.03.002</pub-id>
<pub-id pub-id-type="pmid">18625411</pub-id>
</element-citation>
</ref>
<ref id="B197-biomolecules-10-00702">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mitsuma</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Inukai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mitsuma</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sobue</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Expression of GDNF and GDNFR-alpha mRNAs in muscles of patients with motor neuron diseases</article-title>
<source/>Neurochem. Res.
          <year>1999</year>
<volume>24</volume>
<fpage>785</fpage>
<lpage>790</lpage>
<pub-id pub-id-type="doi">10.1023/A:1020739831778</pub-id>
<pub-id pub-id-type="pmid">10447463</pub-id>
</element-citation>
</ref>
<ref id="B198-biomolecules-10-00702">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Dadgar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Albertelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gruis</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Robins</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>A.P.</given-names>
</name>
</person-group>
<article-title>Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model</article-title>
<source/>J. Clin. Investig.
          <year>2006</year>
<volume>116</volume>
<fpage>2663</fpage>
<lpage>2672</lpage>
<pub-id pub-id-type="doi">10.1172/JCI28773</pub-id>
<pub-id pub-id-type="pmid">16981011</pub-id>
</element-citation>
</ref>
<ref id="B199-biomolecules-10-00702">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sopher</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>P.S.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>LaFevre-Bernt</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Holm</surname>
<given-names>I.E.</given-names>
</name>
<name>
<surname>Wilke</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Ware</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>L.W.</given-names>
</name>
<name>
<surname>Libby</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Ellerby</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>La Spada</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration</article-title>
<source/>Neuron
          <year>2004</year>
<volume>41</volume>
<fpage>687</fpage>
<lpage>699</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(04)00082-0</pub-id>
<pub-id pub-id-type="pmid">15003169</pub-id>
</element-citation>
</ref>
<ref id="B200-biomolecules-10-00702">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranganathan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Harmison</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Meyertholen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pennuto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Burnett</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Fischbeck</surname>
<given-names>K.H.</given-names>
</name>
</person-group>
<article-title>Mitochondrial abnormalities in spinal and bulbar muscular atrophy</article-title>
<source/>Hum. Mol. Genet.
          <year>2009</year>
<volume>18</volume>
<fpage>27</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddn310</pub-id>
<pub-id pub-id-type="pmid">18824496</pub-id>
</element-citation>
</ref>
<ref id="B201-biomolecules-10-00702">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finsterer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wakil</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pennuto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soraru</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Mitochondrial implications in bulbospinal muscular atrophy (Kennedy disease)</article-title>
<source/>Amyotroph. Lateral Scler. Frontotemporal Degener.
          <year>2015</year>
<volume>17</volume>
<fpage>112</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.3109/21678421.2015.1089910</pub-id>
<pub-id pub-id-type="pmid">26428534</pub-id>
</element-citation>
</ref>
<ref id="B202-biomolecules-10-00702">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gavrilova-Jordan</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>T.M.</given-names>
</name>
</person-group>
<article-title>Actions of steroids in mitochondria</article-title>
<source/>Semin. Reprod. Med.
          <year>2007</year>
<volume>25</volume>
<fpage>154</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="doi">10.1055/s-2007-973428</pub-id>
<pub-id pub-id-type="pmid">17447205</pub-id>
</element-citation>
</ref>
<ref id="B203-biomolecules-10-00702">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stenoien</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>H.P.</given-names>
</name>
<name>
<surname>Mancini</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>DeMartino</surname>
<given-names>G.N.</given-names>
</name>
<name>
<surname>Marcelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weigel</surname>
<given-names>N.L.</given-names>
</name>
<name>
<surname>Mancini</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone</article-title>
<source/>Hum. Mol. Genet.
          <year>1999</year>
<volume>8</volume>
<fpage>731</fpage>
<lpage>741</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/8.5.731</pub-id>
<pub-id pub-id-type="pmid">10196362</pub-id>
</element-citation>
</ref>
<ref id="B204-biomolecules-10-00702">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simeoni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mancini</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Stenoien</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Marcelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weigel</surname>
<given-names>N.L.</given-names>
</name>
<name>
<surname>Zanisi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Poletti</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract</article-title>
<source/>Hum. Mol. Genet.
          <year>2000</year>
<volume>9</volume>
<fpage>133</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/9.1.133</pub-id>
<pub-id pub-id-type="pmid">10587588</pub-id>
</element-citation>
</ref>
<ref id="B205-biomolecules-10-00702">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sisodia</surname>
<given-names>S.S.</given-names>
</name>
</person-group>
<article-title>Nuclear inclusions in glutamine repeat disorders: Are they pernicious, coincidental, or beneficial?</article-title>
<source/>Cell
          <year>1998</year>
<volume>95</volume>
<fpage>1</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81743-2</pub-id>
<pub-id pub-id-type="pmid">9778239</pub-id>
</element-citation>
</ref>
<ref id="B206-biomolecules-10-00702">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piccioni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pinton</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Simeoni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pozzi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fascio</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Vismara</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Martini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rizzuto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Poletti</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Androgen receptor with elongated polyglutamine tract forms aggregates that alter axonal trafficking and mitochondrial distribution in motor neuronal processes</article-title>
<source/>FASEB J.
          <year>2002</year>
<volume>16</volume>
<fpage>1418</fpage>
<lpage>1420</lpage>
<pub-id pub-id-type="doi">10.1096/fj.01-1035fje</pub-id>
<pub-id pub-id-type="pmid">12205033</pub-id>
</element-citation>
</ref>
<ref id="B207-biomolecules-10-00702">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beauchemin</surname>
<given-names>A.M.J.</given-names>
</name>
<name>
<surname>Gottlieb</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Beitel</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Elhaji</surname>
<given-names>Y.A.</given-names>
</name>
<name>
<surname>Pinsky</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Trifiro</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Cytochrome c oxidase subunit Vb interacts with human androgen receptor: A potential mechanism for neurotoxicity in spinobulbar muscular atrophy</article-title>
<source/>Brain Res. Bull.
          <year>2001</year>
<volume>56</volume>
<fpage>285</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1016/S0361-9230(01)00583-4</pub-id>
<pub-id pub-id-type="pmid">11719263</pub-id>
</element-citation>
</ref>
<ref id="B208-biomolecules-10-00702">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malik</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Devine</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Patani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>La Spada</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Greensmith</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Gene expression analysis reveals early dysregulation of disease pathways and links Chmp7 to pathogenesis of spinal and bulbar muscular atrophy</article-title>
<source/>Sci. Rep.
          <year>2019</year>
<volume>9</volume>
<fpage>3539</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-019-40118-3</pub-id>
<pub-id pub-id-type="pmid">30837566</pub-id>
</element-citation>
</ref>
<ref id="B209-biomolecules-10-00702">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alavez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vantipalli</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Zucker</surname>
<given-names>D.J.S.</given-names>
</name>
<name>
<surname>Klang</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Lithgow</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan</article-title>
<source/>Nature
          <year>2011</year>
<volume>472</volume>
<fpage>226</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="doi">10.1038/nature09873</pub-id>
<pub-id pub-id-type="pmid">21451522</pub-id>
</element-citation>
</ref>
<ref id="B210-biomolecules-10-00702">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calamini</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Madoux</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hutt</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chalfant</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Saldanha</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Hodder</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tait</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Garza</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Small-molecule proteostasis regulators for protein conformational diseases</article-title>
<source/>Nat. Chem. Biol.
          <year>2012</year>
<volume>8</volume>
<fpage>185</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="doi">10.1038/nchembio.763</pub-id>
</element-citation>
</ref>
<ref id="B211-biomolecules-10-00702">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porat</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Abramowitz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gazit</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism</article-title>
<source/>Chem. Biol. Drug Des.
          <year>2006</year>
<volume>67</volume>
<fpage>27</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1111/j.1747-0285.2005.00318.x</pub-id>
<pub-id pub-id-type="pmid">16492146</pub-id>
</element-citation>
</ref>
<ref id="B212-biomolecules-10-00702">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Massiah</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Bozak</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Hicks</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Talalay</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2001</year>
<volume>98</volume>
<fpage>3404</fpage>
<lpage>3409</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.051632198</pub-id>
<pub-id pub-id-type="pmid">11248091</pub-id>
</element-citation>
</ref>
<ref id="B213-biomolecules-10-00702">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mishra</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Paital</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jena</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Swain</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Chainy</surname>
<given-names>G.B.N.</given-names>
</name>
<name>
<surname>Samanta</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Possible activation of NRF2 by Vitamin E/Curcumin against altered thyroid hormone induced oxidative stress via NFκB/AKT/mTOR/KEAP1 signalling in rat heart</article-title>
<source/>Sci. Rep.
          <year>2019</year>
<volume>9</volume>
<fpage>7408</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-019-43320-5</pub-id>
<pub-id pub-id-type="pmid">31092832</pub-id>
</element-citation>
</ref>
<ref id="B214-biomolecules-10-00702">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y.-J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C.-C.</given-names>
</name>
<name>
<surname>Miyamoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Merry</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Sobue</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.-M.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>S.-S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor</article-title>
<source/>Nat. Med.
          <year>2007</year>
<volume>13</volume>
<fpage>348</fpage>
<lpage>353</lpage>
<pub-id pub-id-type="doi">10.1038/nm1547</pub-id>
<pub-id pub-id-type="pmid">17334372</pub-id>
</element-citation>
</ref>
<ref id="B215-biomolecules-10-00702">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bott</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Badders</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Harmison</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Bautista</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Katsuno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sobue</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Dantuma</surname>
<given-names>N.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy</article-title>
<source/>Hum. Mol. Genet.
          <year>2016</year>
<volume>25</volume>
<fpage>1979</fpage>
<lpage>1989</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddw073</pub-id>
<pub-id pub-id-type="pmid">26962150</pub-id>
</element-citation>
</ref>
<ref id="B216-biomolecules-10-00702">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furtado</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Suchowersky</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Rewcastle</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Klimek</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Garber</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Relationship between trinucleotide repeats and neuropathological changes in Huntington’s disease</article-title>
<source/>Ann. Neurol.
          <year>1996</year>
<volume>39</volume>
<fpage>132</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410390120</pub-id>
<pub-id pub-id-type="pmid">8572659</pub-id>
</element-citation>
</ref>
<ref id="B217-biomolecules-10-00702">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snell</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>MacMillan</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Cheadle</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Fenton</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lazarou</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Gusella</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington’s disease</article-title>
<source/>Nat. Genet.
          <year>1993</year>
<volume>4</volume>
<fpage>393</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="doi">10.1038/ng0893-393</pub-id>
<pub-id pub-id-type="pmid">8401588</pub-id>
</element-citation>
</ref>
<ref id="B218-biomolecules-10-00702">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>The Huntington’s Disease Collaborative Research Group</collab>
</person-group>
<article-title>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes</article-title>
<source/>Cell
          <year>1993</year>
<volume>72</volume>
<fpage>971</fpage>
<lpage>983</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(93)90585-e</pub-id>
<pub-id pub-id-type="pmid">8458085</pub-id>
</element-citation>
</ref>
<ref id="B219-biomolecules-10-00702">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ravina</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Romer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Constantinescu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Biglan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Brocht</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kieburtz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shoulson</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>The relationship between CAG repeat length and clinical progression in Huntington’s disease</article-title>
<source/>Mov. Disord.
          <year>2008</year>
<volume>23</volume>
<fpage>1223</fpage>
<lpage>1227</lpage>
<pub-id pub-id-type="doi">10.1002/mds.21988</pub-id>
<pub-id pub-id-type="pmid">18512767</pub-id>
</element-citation>
</ref>
<ref id="B220-biomolecules-10-00702">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>F.O.</given-names>
</name>
</person-group>
<article-title>Huntington’s disease</article-title>
<source/>Lancet
          <year>2007</year>
<volume>369</volume>
<fpage>218</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60111-1</pub-id>
<pub-id pub-id-type="pmid">17240289</pub-id>
</element-citation>
</ref>
<ref id="B221-biomolecules-10-00702">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ochaba</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lukacsovich</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Csikos</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Margulis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Salazar</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Yeung</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Humbert</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Potential function for the Huntingtin protein as a scaffold for selective autophagy</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2014</year>
<volume>111</volume>
<fpage>16889</fpage>
<lpage>16894</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1420103111</pub-id>
<pub-id pub-id-type="pmid">25385587</pub-id>
</element-citation>
</ref>
<ref id="B222-biomolecules-10-00702">
<label>222.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rui</surname>
<given-names>Y.N.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tito</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>David</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Stimming</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Bellen</surname>
<given-names>H.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Huntingtin functions as a scaffold for selective macroautophagy</article-title>
<source/>Nat. Cell Biol.
          <year>2015</year>
<volume>17</volume>
<fpage>262</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="doi">10.1038/ncb3101</pub-id>
<pub-id pub-id-type="pmid">25686248</pub-id>
</element-citation>
</ref>
<ref id="B223-biomolecules-10-00702">
<label>223.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shacham</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lederkremer</surname>
<given-names>G.Z.</given-names>
</name>
</person-group>
<article-title>Protein Misfolding and ER Stress in Huntington’s Disease</article-title>
<source/>Front. Mol. Biosci.
          <year>2019</year>
<volume>6</volume>
<fpage>20</fpage>
<pub-id pub-id-type="doi">10.3389/fmolb.2019.00020</pub-id>
<pub-id pub-id-type="pmid">31001537</pub-id>
</element-citation>
</ref>
<ref id="B224-biomolecules-10-00702">
<label>224.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallardo-Orihuela</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hervás-Corpión</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hierro-Bujalance</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sanchez-Sotano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jiménez-Gómez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mora-López</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Campos-Caro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garcia-Alloza</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Valor</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>Transcriptional correlates of the pathological phenotype in a Huntington’s disease mouse model</article-title>
<source/>Sci. Rep.
          <year>2019</year>
<volume>9</volume>
<fpage>18696</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-019-55177-9</pub-id>
<pub-id pub-id-type="pmid">31822756</pub-id>
</element-citation>
</ref>
<ref id="B225-biomolecules-10-00702">
<label>225.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Baranov</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Baranova</surname>
<given-names>O.V.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yablonska</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carlisle</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Ferrante</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Friedlander</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Inhibition of mitochondrial protein import by mutant huntingtin</article-title>
<source/>Nat. Neurosci.
          <year>2014</year>
<volume>17</volume>
<fpage>822</fpage>
<lpage>831</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3721</pub-id>
<pub-id pub-id-type="pmid">24836077</pub-id>
</element-citation>
</ref>
<ref id="B226-biomolecules-10-00702">
<label>226.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stack</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Matson</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Ferrante</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Evidence of oxidant damage in Huntington’s disease: Translational strategies using antioxidants</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <year>2008</year>
<volume>1147</volume>
<fpage>79</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1196/annals.1427.008</pub-id>
<pub-id pub-id-type="pmid">19076433</pub-id>
</element-citation>
</ref>
<ref id="B227-biomolecules-10-00702">
<label>227.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agrawal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Novel proteomic changes in brain mitochondria provide insights into mitochondrial dysfunction in mouse models of Huntington’s disease</article-title>
<source/>Mitochondrion
          <year>2019</year>
<volume>47</volume>
<fpage>318</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="doi">10.1016/j.mito.2019.03.004</pub-id>
<pub-id pub-id-type="pmid">30902619</pub-id>
</element-citation>
</ref>
<ref id="B228-biomolecules-10-00702">
<label>228.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogdanov</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Ferrante</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Kuemmerle</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Klivenyi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington’s disease</article-title>
<source/>J. Neurochem.
          <year>1998</year>
<volume>71</volume>
<fpage>2642</fpage>
<lpage>2644</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1998.71062642.x</pub-id>
<pub-id pub-id-type="pmid">9832167</pub-id>
</element-citation>
</ref>
<ref id="B229-biomolecules-10-00702">
<label>229.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brouillet</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>The 3-NP Model of Striatal Neurodegeneration</article-title>
<source/>Curr. Protoc. Neurosci.
          <year>2014</year>
<volume>67</volume>
<fpage>9.48.1</fpage>
<lpage>9.48.14</lpage>
<pub-id pub-id-type="doi">10.1002/0471142301.ns0948s67</pub-id>
</element-citation>
</ref>
<ref id="B230-biomolecules-10-00702">
<label>230.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenstock</surname>
<given-names>T.R.</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Jurkiewicz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Frussa-Filho</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Smaili</surname>
<given-names>S.S.</given-names>
</name>
</person-group>
<article-title>Mitochondrial calcium, oxidative stress and apoptosis in a neurodegenerative disease model induced by 3-nitropropionic acid</article-title>
<source/>J. Neurochem.
          <year>2004</year>
<volume>88</volume>
<fpage>1220</fpage>
<lpage>1228</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.02250.x</pub-id>
<pub-id pub-id-type="pmid">15009678</pub-id>
</element-citation>
</ref>
<ref id="B231-biomolecules-10-00702">
<label>231.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Browne</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Oxidative damage in Huntington’s disease pathogenesis</article-title>
<source/>Antioxid. Redox Signal.
          <year>2006</year>
<volume>8</volume>
<fpage>2061</fpage>
<lpage>2073</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2006.8.2061</pub-id>
<pub-id pub-id-type="pmid">17034350</pub-id>
</element-citation>
</ref>
<ref id="B232-biomolecules-10-00702">
<label>232.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maiuri</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bowie</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Truant</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>DNA Repair Signaling of Huntingtin: The Next Link Between Late-Onset Neurodegenerative Disease and Oxidative DNA Damage</article-title>
<source/>DNA Cell Biol.
          <year>2019</year>
<volume>38</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1089/dna.2018.4476</pub-id>
<pub-id pub-id-type="pmid">30481056</pub-id>
</element-citation>
</ref>
<ref id="B233-biomolecules-10-00702">
<label>233.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.R.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>Soong</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>D.T.</given-names>
</name>
</person-group>
<article-title>Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2007</year>
<volume>359</volume>
<fpage>335</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2007.05.093</pub-id>
<pub-id pub-id-type="pmid">17543886</pub-id>
</element-citation>
</ref>
<ref id="B234-biomolecules-10-00702">
<label>234.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sánchez-López</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tasset</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Agüera</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Feijóo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fernández-Bolaños</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sánchez</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Ruiz</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Gascón</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Túnez</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and inflammation biomarkers in the blood of patients with Huntington’s disease</article-title>
<source/>Neurol. Res.
          <year>2012</year>
<volume>34</volume>
<fpage>721</fpage>
<lpage>724</lpage>
<pub-id pub-id-type="doi">10.1179/1743132812Y.0000000073</pub-id>
<pub-id pub-id-type="pmid">22889672</pub-id>
</element-citation>
</ref>
<ref id="B235-biomolecules-10-00702">
<label>235.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agrawal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Thyagarajan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Brain mitochondrial iron accumulates in Huntington’s disease, mediates mitochondrial dysfunction, and can be removed pharmacologically</article-title>
<source/>Free Radic. Biol. Med.
          <year>2018</year>
<volume>120</volume>
<fpage>317</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2018.04.002</pub-id>
<pub-id pub-id-type="pmid">29625173</pub-id>
</element-citation>
</ref>
<ref id="B236-biomolecules-10-00702">
<label>236.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peyser</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Folstein</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chase</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Starkstein</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brandt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cockrell</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Bylsma</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>McHugh</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Folstein</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>Trial of d-alpha-tocopherol in Huntington’s disease</article-title>
<source/>Am. J. Psychiatry
          <year>1995</year>
<volume>152</volume>
<fpage>1771</fpage>
<lpage>1775</lpage>
<pub-id pub-id-type="doi">10.1176/ajp.152.12.1771</pub-id>
<pub-id pub-id-type="pmid">8526244</pub-id>
</element-citation>
</ref>
<ref id="B237-biomolecules-10-00702">
<label>237.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasparová</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sumbalová</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Bystrický</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kucharská</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liptaj</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mlynárik</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gvozdjáková</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington’s disease</article-title>
<source/>Neurochem. Int.
          <year>2006</year>
<volume>48</volume>
<fpage>93</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2005.09.002</pub-id>
<pub-id pub-id-type="pmid">16290265</pub-id>
</element-citation>
</ref>
<ref id="B238-biomolecules-10-00702">
<label>238.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rebec</surname>
<given-names>G.V.</given-names>
</name>
<name>
<surname>Barton</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Marseilles</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Ascorbate treatment attenuates the Huntington behavioral phenotype in mice</article-title>
<source/>Neuroreport
          <year>2003</year>
<volume>14</volume>
<fpage>1263</fpage>
<lpage>1265</lpage>
<pub-id pub-id-type="doi">10.1097/00001756-200307010-00015</pub-id>
<pub-id pub-id-type="pmid">12824772</pub-id>
</element-citation>
</ref>
<ref id="B239-biomolecules-10-00702">
<label>239.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Finkelstein</surname>
<given-names>D.I.</given-names>
</name>
<name>
<surname>Crouch</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Pow</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>T.Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>Z.M.</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Renoir</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington’s disease</article-title>
<source/>Hum. Mol. Genet.
          <year>2016</year>
<volume>25</volume>
<fpage>2923</fpage>
<lpage>2933</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddw144</pub-id>
<pub-id pub-id-type="pmid">27179791</pub-id>
</element-citation>
</ref>
<ref id="B240-biomolecules-10-00702">
<label>240.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Renoir</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>Z.M.</given-names>
</name>
<name>
<surname>Frazier</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Thorburn</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>McGee</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Hannan</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>L.J.</given-names>
</name>
</person-group>
<article-title>N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington’s disease</article-title>
<source/>Transl. Psychiatry
          <year>2015</year>
<volume>5</volume>
<fpage>e492</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2014.131</pub-id>
<pub-id pub-id-type="pmid">25562842</pub-id>
</element-citation>
</ref>
<ref id="B241-biomolecules-10-00702">
<label>241.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandhir</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sood</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mehrotra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kamboj</surname>
<given-names>S.S.</given-names>
</name>
</person-group>
<article-title>N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington’s disease</article-title>
<source/>Neurodegener. Dis.
          <year>2012</year>
<volume>9</volume>
<fpage>145</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1159/000334273</pub-id>
<pub-id pub-id-type="pmid">22327485</pub-id>
</element-citation>
</ref>
<ref id="B242-biomolecules-10-00702">
<label>242.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreassen</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>Ferrante</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Dedeoglu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Lipoic acid improves survival in transgenic mouse models of Huntington’s disease</article-title>
<source/>Neuroreport
          <year>2001</year>
<volume>12</volume>
<fpage>3371</fpage>
<lpage>3373</lpage>
<pub-id pub-id-type="doi">10.1097/00001756-200110290-00044</pub-id>
<pub-id pub-id-type="pmid">11711888</pub-id>
</element-citation>
</ref>
<ref id="B243-biomolecules-10-00702">
<label>243.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hettinger</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rezvani</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington’s disease</article-title>
<source/>J. Neurochem.
          <year>2014</year>
<volume>129</volume>
<fpage>539</fpage>
<lpage>547</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.12647</pub-id>
<pub-id pub-id-type="pmid">24383989</pub-id>
</element-citation>
</ref>
<ref id="B244-biomolecules-10-00702">
<label>244.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quinti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dayalan Naidu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Träger</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kegel-Gleason</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Llères</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Connolly</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chopra</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moniot</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington’s disease patients</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2017</year>
<volume>114</volume>
<fpage>E4676</fpage>
<lpage>E4685</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1614943114</pub-id>
<pub-id pub-id-type="pmid">28533375</pub-id>
</element-citation>
</ref>
<ref id="B245-biomolecules-10-00702">
<label>245.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Orman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Linkermann</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models</article-title>
<source/>J. Am. Chem. Soc.
          <year>2014</year>
<volume>136</volume>
<fpage>4551</fpage>
<lpage>4556</lpage>
<pub-id pub-id-type="doi">10.1021/ja411006a</pub-id>
<pub-id pub-id-type="pmid">24592866</pub-id>
</element-citation>
</ref>
<ref id="B246-biomolecules-10-00702">
<label>246.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dodson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Castro-Portuguez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis</article-title>
<source/>Redox Biol.
          <year>2019</year>
<volume>23</volume>
<fpage>101107</fpage>
<pub-id pub-id-type="doi">10.1016/j.redox.2019.101107</pub-id>
<pub-id pub-id-type="pmid">30692038</pub-id>
</element-citation>
</ref>
<ref id="B247-biomolecules-10-00702">
<label>247.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellrichmann</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Petrasch-Parwez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Reick</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Arning</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Saft</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Linker</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington’s disease</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<elocation-id>e16172</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0016172</pub-id>
<pub-id pub-id-type="pmid">21297955</pub-id>
</element-citation>
</ref>
<ref id="B248-biomolecules-10-00702">
<label>248.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Nah</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>I.H.</given-names>
</name>
</person-group>
<article-title>Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington’s disease: Activation of the Nrf2 pathway through lysophosphatidic acid receptors</article-title>
<source/>Brain Behav. Immun.
          <year>2019</year>
<volume>80</volume>
<fpage>146</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2019.03.001</pub-id>
<pub-id pub-id-type="pmid">30853569</pub-id>
</element-citation>
</ref>
<ref id="B249-biomolecules-10-00702">
<label>249.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taroni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>DiDonato</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Pathways to motor incoordination: The inherited ataxias</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2004</year>
<volume>5</volume>
<fpage>641</fpage>
<lpage>655</lpage>
<pub-id pub-id-type="doi">10.1038/nrn1474</pub-id>
<pub-id pub-id-type="pmid">15263894</pub-id>
</element-citation>
</ref>
<ref id="B250-biomolecules-10-00702">
<label>250.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koeppen</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>The pathogenesis of spinocerebellar ataxia</article-title>
<source/>Cerebellum
          <year>2005</year>
<volume>4</volume>
<fpage>62</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1080/14734220510007950</pub-id>
<pub-id pub-id-type="pmid">15895563</pub-id>
</element-citation>
</ref>
<ref id="B251-biomolecules-10-00702">
<label>251.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paulson</surname>
<given-names>H.L.</given-names>
</name>
</person-group>
<article-title>The spinocerebellar ataxias</article-title>
<source/>J. Neuroophthalmol.
          <year>2009</year>
<volume>29</volume>
<fpage>227</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="doi">10.1097/WNO0b013e3181b416de</pub-id>
<pub-id pub-id-type="pmid">19726947</pub-id>
</element-citation>
</ref>
<ref id="B252-biomolecules-10-00702">
<label>252.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harding</surname>
<given-names>A.E.</given-names>
</name>
</person-group>
<article-title>Clinical features and classification of inherited ataxias</article-title>
<source/>Adv. Neurol.
          <year>1993</year>
<volume>61</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">8421960</pub-id>
</element-citation>
</ref>
<ref id="B253-biomolecules-10-00702">
<label>253.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duenas</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Goold</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Giunti</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Molecular pathogenesis of spinocerebellar ataxias</article-title>
<source/>Brain
          <year>2006</year>
<volume>129</volume>
<fpage>1357</fpage>
<lpage>1370</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awl081</pub-id>
<pub-id pub-id-type="pmid">16613893</pub-id>
</element-citation>
</ref>
<ref id="B254-biomolecules-10-00702">
<label>254.</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Bird</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Hereditary Ataxia Overview</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.geneclinics.org/servlet/access?db=geneclinics&amp;site=gt&amp;id=8888891&amp;key=Fkx-A35oEHZ2G&amp;gry=&amp;fcn=y&amp;fw=g8bn&amp;filename=/profiles/ataxias/index.html">http://www.geneclinics.org/servlet/access?db=geneclinics&amp;site=gt&amp;id=8888891&amp;key=Fkx-A35oEHZ2G&amp;gry=&amp;fcn=y&amp;fw=g8bn&amp;filename=/profiles/ataxias/index.html</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2020-02-01">(accessed on 1 February 2020)</date-in-citation>
</element-citation>
</ref>
<ref id="B255-biomolecules-10-00702">
<label>255.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashizawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Oz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>H.L.</given-names>
</name>
</person-group>
<article-title>Spinocerebellar ataxias: Prospects and challenges for therapy development</article-title>
<source/>Nat. Rev. Neurol.
          <year>2018</year>
<volume>14</volume>
<fpage>590</fpage>
<lpage>605</lpage>
<pub-id pub-id-type="doi">10.1038/s41582-018-0051-6</pub-id>
<pub-id pub-id-type="pmid">30131520</pub-id>
</element-citation>
</ref>
<ref id="B256-biomolecules-10-00702">
<label>256.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paulson</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Machado-Joseph disease/spinocerebellar ataxia type 3</article-title>
<source/>Handb. Clin. Neurol.
          <year>2012</year>
<volume>103</volume>
<fpage>437</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="doi">10.1016/b978-0-444-51892-7.00027-9</pub-id>
<pub-id pub-id-type="pmid">21827905</pub-id>
</element-citation>
</ref>
<ref id="B257-biomolecules-10-00702">
<label>257.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.-J.</given-names>
</name>
</person-group>
<article-title>Structural basis of the phosphorylation dependent complex formation of neurodegenerative disease protein Ataxin-1 and RBM17</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2014</year>
<volume>449</volume>
<fpage>399</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2014.05.063</pub-id>
<pub-id pub-id-type="pmid">24858692</pub-id>
</element-citation>
</ref>
<ref id="B258-biomolecules-10-00702">
<label>258.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carrillo-Rosas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fievet</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Messaddeq</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Karam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Trottier</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Loss of zebrafish Ataxin-7, a SAGA subunit responsible for SCA7 retinopathy, causes ocular coloboma and malformation of photoreceptors</article-title>
<source/>Hum. Mol. Genet.
          <year>2018</year>
<volume>28</volume>
<fpage>912</fpage>
<lpage>927</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddy401</pub-id>
</element-citation>
</ref>
<ref id="B259-biomolecules-10-00702">
<label>259.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Dubeau</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>The TATA-binding protein as a regulator of cellular transformation</article-title>
<source/>Cell Cycle
          <year>2003</year>
<volume>2</volume>
<fpage>442</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="doi">10.4161/cc.2.5.493</pub-id>
<pub-id pub-id-type="pmid">12963838</pub-id>
</element-citation>
</ref>
<ref id="B260-biomolecules-10-00702">
<label>260.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>C.-C.</given-names>
</name>
</person-group>
<article-title>Atrophin proteins: An overview of a new class of nuclear receptor corepressors</article-title>
<source/>Nucl. Recept Signal
          <year>2008</year>
<volume>6</volume>
<fpage>e009</fpage>
<pub-id pub-id-type="doi">10.1621/nrs.06009</pub-id>
<pub-id pub-id-type="pmid">19043594</pub-id>
</element-citation>
</ref>
<ref id="B261-biomolecules-10-00702">
<label>261.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lastres-Becker</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Nonis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Eich</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Klinkenberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gorospe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kotter</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Kedersha</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Auburger</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K/mTOR and is induced by starvation</article-title>
<source/>Biochim. Biophys. Acta
          <year>2016</year>
<volume>1862</volume>
<fpage>1558</fpage>
<lpage>1569</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2016.05.017</pub-id>
<pub-id pub-id-type="pmid">27240544</pub-id>
</element-citation>
</ref>
<ref id="B262-biomolecules-10-00702">
<label>262.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blount</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Tsou</surname>
<given-names>W.-L.</given-names>
</name>
<name>
<surname>Ristic</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Burr</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Galante</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Scaglione</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Todi</surname>
<given-names>S.V.</given-names>
</name>
</person-group>
<article-title>Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23</article-title>
<source/>Nat. Commun.
          <year>2014</year>
<volume>5</volume>
<elocation-id>4638</elocation-id>
<pub-id pub-id-type="doi">10.1038/ncomms5638</pub-id>
<pub-id pub-id-type="pmid">25144244</pub-id>
</element-citation>
</ref>
<ref id="B263-biomolecules-10-00702">
<label>263.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kordasiewicz</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Molecular pathogenesis of spinocerebellar ataxia type 6</article-title>
<source/>Neurotherapeutics
          <year>2007</year>
<volume>4</volume>
<fpage>285</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="doi">10.1016/j.nurt.2007.01.003</pub-id>
<pub-id pub-id-type="pmid">17395139</pub-id>
</element-citation>
</ref>
<ref id="B264-biomolecules-10-00702">
<label>264.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crespo-Barreto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Orr</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis</article-title>
<source/>PLoS Genet.
          <year>2010</year>
<volume>6</volume>
<elocation-id>e1001021</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1001021</pub-id>
<pub-id pub-id-type="pmid">20628574</pub-id>
</element-citation>
</ref>
<ref id="B265-biomolecules-10-00702">
<label>265.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Szabo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rual</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Fisk</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Smolyar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>D.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration</article-title>
<source/>Cell
          <year>2006</year>
<volume>125</volume>
<fpage>801</fpage>
<lpage>814</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.03.032</pub-id>
<pub-id pub-id-type="pmid">16713569</pub-id>
</element-citation>
</ref>
<ref id="B266-biomolecules-10-00702">
<label>266.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lindenberg</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Krebs</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schols</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Laccone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Herms</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rechsteiner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Riess</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Landwehrmeyer</surname>
<given-names>G.B.</given-names>
</name>
</person-group>
<article-title>Protein surveillance machinery in brains with spinocerebellar ataxia type 3: Redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions</article-title>
<source/>Ann. Neurol.
          <year>2002</year>
<volume>51</volume>
<fpage>302</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1002/ana.10101</pub-id>
<pub-id pub-id-type="pmid">11891825</pub-id>
</element-citation>
</ref>
<ref id="B267-biomolecules-10-00702">
<label>267.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Mancini</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Antalffy</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>DeFranco</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Orr</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1</article-title>
<source/>Nat. Genet.
          <year>1998</year>
<volume>19</volume>
<fpage>148</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1038/502</pub-id>
<pub-id pub-id-type="pmid">9620770</pub-id>
</element-citation>
</ref>
<ref id="B268-biomolecules-10-00702">
<label>268.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product</article-title>
<source/>Mol. Cells
          <year>2005</year>
<volume>19</volume>
<fpage>23</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">15750336</pub-id>
</element-citation>
</ref>
<ref id="B269-biomolecules-10-00702">
<label>269.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.-J.</given-names>
</name>
<name>
<surname>Ka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>USP7, a Ubiquitin-Specific Protease, Interacts with Ataxin-1, the SCA1 Gene Product</article-title>
<source/>Mol. Cell. Neurosci.
          <year>2002</year>
<volume>20</volume>
<fpage>298</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="doi">10.1006/mcne.2002.1103</pub-id>
<pub-id pub-id-type="pmid">12093161</pub-id>
</element-citation>
</ref>
<ref id="B270-biomolecules-10-00702">
<label>270.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ajayi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boga</surname>
<given-names>N.R.</given-names>
</name>
<name>
<surname>Ström</surname>
<given-names>A.-L.</given-names>
</name>
</person-group>
<article-title>Differential degradation of full-length and cleaved ataxin-7 fragments in a novel stable inducible SCA7 model</article-title>
<source/>J. Mol. Neurosci.
          <year>2012</year>
<volume>47</volume>
<fpage>219</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-012-9722-8</pub-id>
<pub-id pub-id-type="pmid">22367614</pub-id>
</element-citation>
</ref>
<ref id="B271-biomolecules-10-00702">
<label>271.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Berke</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>H.L.</given-names>
</name>
</person-group>
<article-title>Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways</article-title>
<source/>J. Biol. Chem.
          <year>2004</year>
<volume>279</volume>
<fpage>3605</fpage>
<lpage>3611</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M310939200</pub-id>
<pub-id pub-id-type="pmid">14602712</pub-id>
</element-citation>
</ref>
<ref id="B272-biomolecules-10-00702">
<label>272.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Zeviani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Simonati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bindoff</surname>
<given-names>L.A.</given-names>
</name>
</person-group>
<article-title>Chapter 22—Ataxia in mitochondrial disorders</article-title>
<source/>Handbook of Clinical Neurology
          <person-group person-group-type="editor">
<name>
<surname>Subramony</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Dürr</surname>
<given-names>A.</given-names>
</name>
</person-group>
<publisher-name>Elsevier</publisher-name>
<publisher-loc>Amsterdam, The Netherlands</publisher-loc>
<year>2012</year>
<volume>Volume 103</volume>
<fpage>359</fpage>
<lpage>372</lpage>
</element-citation>
</ref>
<ref id="B273-biomolecules-10-00702">
<label>273.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stucki</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Ruegsegger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Radecke</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Zuber</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Saxena</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Mitochondrial impairments contribute to Spinocerebellar ataxia type 1 progression and can be ameliorated by the mitochondria-targeted antioxidant MitoQ</article-title>
<source/>Free Radic. Biol. Med.
          <year>2016</year>
<volume>97</volume>
<fpage>427</fpage>
<lpage>440</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.07.005</pub-id>
<pub-id pub-id-type="pmid">27394174</pub-id>
</element-citation>
</ref>
<ref id="B274-biomolecules-10-00702">
<label>274.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qi</surname>
<given-names>M.-L.</given-names>
</name>
<name>
<surname>Tagawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Enokido</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yoshimura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>Y.-I.</given-names>
</name>
<name>
<surname>Watase</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ishiura</surname>
<given-names>S.-I.</given-names>
</name>
<name>
<surname>Kanazawa</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Botas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Saitoe</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases</article-title>
<source/>Nat. Cell Biol.
          <year>2007</year>
<volume>9</volume>
<fpage>402</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="doi">10.1038/ncb1553</pub-id>
<pub-id pub-id-type="pmid">17384639</pub-id>
</element-citation>
</ref>
<ref id="B275-biomolecules-10-00702">
<label>275.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ito</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tagawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Homma</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sasabe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Muramatsu</surname>
<given-names>S.-i.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>HMGB1 facilitates repair of mitochondrial DNA damage and extends the lifespan of mutant ataxin-1 knock-in mice</article-title>
<source/>EMBO Mol. Med.
          <year>2015</year>
<volume>7</volume>
<fpage>78</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.15252/emmm.201404392</pub-id>
<pub-id pub-id-type="pmid">25510912</pub-id>
</element-citation>
</ref>
<ref id="B276-biomolecules-10-00702">
<label>276.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Mitochondrial-targeted antioxidant MitoQ provides neuroprotection and reduces neuronal apoptosis in experimental traumatic brain injury possibly via the Nrf2-ARE pathway</article-title>
<source/>Am. J. Transl. Res.
          <year>2018</year>
<volume>10</volume>
<fpage>1887</fpage>
<lpage>1899</lpage>
<pub-id pub-id-type="pmid">30018728</pub-id>
</element-citation>
</ref>
<ref id="B277-biomolecules-10-00702">
<label>277.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cornelius</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wardman</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Hargreaves</surname>
<given-names>I.P.</given-names>
</name>
<name>
<surname>Neergheen</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bie</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Tumer</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>T.T.</given-names>
</name>
</person-group>
<article-title>Evidence of oxidative stress and mitochondrial dysfunction in spinocerebellar ataxia type 2 (SCA2) patient fibroblasts: Effect of coenzyme Q10 supplementation on these parameters</article-title>
<source/>Mitochondrion
          <year>2017</year>
<volume>34</volume>
<fpage>103</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.mito.2017.03.001</pub-id>
<pub-id pub-id-type="pmid">28263872</pub-id>
</element-citation>
</ref>
<ref id="B278-biomolecules-10-00702">
<label>278.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>R.Y.</given-names>
</name>
<name>
<surname>Figueroa</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Pulst</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wilmot</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schmahmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shakkottai</surname>
<given-names>V.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Coenzyme Q10 and spinocerebellar ataxias</article-title>
<source/>Mov. Disord.
          <year>2015</year>
<volume>30</volume>
<fpage>214</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26088</pub-id>
<pub-id pub-id-type="pmid">25449974</pub-id>
</element-citation>
</ref>
<ref id="B279-biomolecules-10-00702">
<label>279.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paulson</surname>
<given-names>H.L.</given-names>
</name>
</person-group>
<article-title>Dominantly inherited ataxias: Lessons learned from Machado-Joseph disease/spinocerebellar ataxia type 3</article-title>
<source/>Semin. Neurol.
          <year>2007</year>
<volume>27</volume>
<fpage>133</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.1055/s-2007-971172</pub-id>
<pub-id pub-id-type="pmid">17390258</pub-id>
</element-citation>
</ref>
<ref id="B280-biomolecules-10-00702">
<label>280.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease</article-title>
<source/>J. Neurosci. Res.
          <year>2009</year>
<volume>87</volume>
<fpage>1884</fpage>
<lpage>1891</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.22011</pub-id>
<pub-id pub-id-type="pmid">19185026</pub-id>
</element-citation>
</ref>
<ref id="B281-biomolecules-10-00702">
<label>281.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laço</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Rego</surname>
<given-names>A.C.</given-names>
</name>
</person-group>
<article-title>Compromised mitochondrial complex II in models of Machado–Joseph disease</article-title>
<source/>Biochim. Biophys. Acta (BBA) Mol. Basis Dis.
          <year>2012</year>
<volume>1822</volume>
<fpage>139</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2011.10.010</pub-id>
</element-citation>
</ref>
<ref id="B282-biomolecules-10-00702">
<label>282.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pacheco</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>da Silveira</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Trott</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Houenou</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Algarve</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Belló</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lenz</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Mânica-Cattani</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>da Cruz</surname>
<given-names>I.B.M.</given-names>
</name>
</person-group>
<article-title>Association between Machado–Joseph disease and oxidative stress biomarkers</article-title>
<source/>Mutat. Res. Genet. Toxicol. Environ. Mutagenesis
          <year>2013</year>
<volume>757</volume>
<fpage>99</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1016/j.mrgentox.2013.06.023</pub-id>
</element-citation>
</ref>
<ref id="B283-biomolecules-10-00702">
<label>283.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Assis</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Saute</surname>
<given-names>J.A.M.</given-names>
</name>
<name>
<surname>Longoni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Haas</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Torrez</surname>
<given-names>V.R.</given-names>
</name>
<name>
<surname>Brochier</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>G.N.</given-names>
</name>
<name>
<surname>Furtado</surname>
<given-names>G.V.</given-names>
</name>
<name>
<surname>Gheno</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peripheral Oxidative Stress Biomarkers in Spinocerebellar Ataxia Type 3/Machado-Joseph Disease</article-title>
<source/>Front. Neurol.
          <year>2017</year>
<volume>8</volume>
<fpage>485</fpage>
<pub-id pub-id-type="doi">10.3389/fneur.2017.00485</pub-id>
<pub-id pub-id-type="pmid">28979235</pub-id>
</element-citation>
</ref>
<ref id="B284-biomolecules-10-00702">
<label>284.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reina</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pittman</surname>
<given-names>R.N.</given-names>
</name>
</person-group>
<article-title>Proteotoxic stress increases nuclear localization of ataxin-3</article-title>
<source/>Hum. Mol. Genet.
          <year>2009</year>
<volume>19</volume>
<fpage>235</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddp482</pub-id>
<pub-id pub-id-type="pmid">19843543</pub-id>
</element-citation>
</ref>
<ref id="B285-biomolecules-10-00702">
<label>285.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saudou</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Finkbeiner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Devys</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions</article-title>
<source/>Cell
          <year>1998</year>
<volume>95</volume>
<fpage>55</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81782-1</pub-id>
<pub-id pub-id-type="pmid">9778247</pub-id>
</element-citation>
</ref>
<ref id="B286-biomolecules-10-00702">
<label>286.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peters</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Nucifora</surname>
<given-names>F.C.</given-names>
</name>
<name>
<surname>Kushi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Seaman</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Herring</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Nuclear Targeting of Mutant Huntingtin Increases Toxicity</article-title>
<source/>Mol. Cell. Neurosci.
          <year>1999</year>
<volume>14</volume>
<fpage>121</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1006/mcne.1999.0773</pub-id>
<pub-id pub-id-type="pmid">10479410</pub-id>
</element-citation>
</ref>
<ref id="B287-biomolecules-10-00702">
<label>287.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujigasaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Uchihara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Koyano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Iwabuchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yagishita</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Makifuchi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Toru</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains</article-title>
<source/>Exp. Neurol.
          <year>2000</year>
<volume>165</volume>
<fpage>248</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="doi">10.1006/exnr.2000.7479</pub-id>
<pub-id pub-id-type="pmid">10993685</pub-id>
</element-citation>
</ref>
<ref id="B288-biomolecules-10-00702">
<label>288.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nucifora</surname>
<given-names>F.C.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Ellerby</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Wellington</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Herring</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hayden</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity</article-title>
<source/>J. Biol. Chem.
          <year>2003</year>
<volume>278</volume>
<fpage>13047</fpage>
<lpage>13055</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M211224200</pub-id>
<pub-id pub-id-type="pmid">12464607</pub-id>
</element-citation>
</ref>
<ref id="B289-biomolecules-10-00702">
<label>289.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bichelmeier</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hübener</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Boy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rüttiger</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Häbig</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Poths</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bonin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Knipper</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>W.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: In vivo evidence</article-title>
<source/>J. Neurosci.
          <year>2007</year>
<volume>27</volume>
<fpage>7418</fpage>
<lpage>7428</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4540-06.2007</pub-id>
<pub-id pub-id-type="pmid">17626202</pub-id>
</element-citation>
</ref>
<ref id="B290-biomolecules-10-00702">
<label>290.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liguori</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Curcio</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bulli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Aran</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Della-Morte</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gargiulo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Testa</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cacciatore</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bonaduce</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress, aging, and diseases</article-title>
<source/>Clin. Interv. Aging
          <year>2018</year>
<volume>13</volume>
<fpage>757</fpage>
<lpage>772</lpage>
<pub-id pub-id-type="doi">10.2147/CIA.S158513</pub-id>
<pub-id pub-id-type="pmid">29731617</pub-id>
</element-citation>
</ref>
<ref id="B291-biomolecules-10-00702">
<label>291.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klotz</surname>
<given-names>L.-O.</given-names>
</name>
<name>
<surname>Sánchez-Ramos</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Prieto-Arroyo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Urbánek</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Steinbrenner</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Monsalve</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Redox regulation of FoxO transcription factors</article-title>
<source/>Redox Biol.
          <year>2015</year>
<volume>6</volume>
<fpage>51</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1016/j.redox.2015.06.019</pub-id>
<pub-id pub-id-type="pmid">26184557</pub-id>
</element-citation>
</ref>
<ref id="B292-biomolecules-10-00702">
<label>292.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Araujo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Breuer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dieringer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krauss</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dorn</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pfeifer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klockgether</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wuellner</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Evert</surname>
<given-names>B.O.</given-names>
</name>
</person-group>
<article-title>FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3</article-title>
<source/>Hum. Mol. Genet.
          <year>2011</year>
<volume>20</volume>
<fpage>2928</fpage>
<lpage>2941</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr197</pub-id>
<pub-id pub-id-type="pmid">21536589</pub-id>
</element-citation>
</ref>
<ref id="B293-biomolecules-10-00702">
<label>293.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C.-M.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>Y.-T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.-L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T.-H.</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.-H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>L.-C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.-Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.-R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aqueous extract of Glycyrrhiza inflata inhibits aggregation by upregulating PPARGC1A and NFE2L2–ARE pathways in cell models of spinocerebellar ataxia 3</article-title>
<source/>Free Radic. Biol. Med.
          <year>2014</year>
<volume>71</volume>
<fpage>339</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.03.023</pub-id>
<pub-id pub-id-type="pmid">24675225</pub-id>
</element-citation>
</ref>
<ref id="B294-biomolecules-10-00702">
<label>294.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.-L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.-R.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T.-H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.-C.</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>L.-C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.-C.</given-names>
</name>
<name>
<surname>Lee-Chen</surname>
<given-names>G.-J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aqueous extract of Gardenia jasminoides targeting oxidative stress to reduce polyQ aggregation in cell models of spinocerebellar ataxia 3</article-title>
<source/>Neuropharmacology
          <year>2014</year>
<volume>81</volume>
<fpage>166</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.01.032</pub-id>
<pub-id pub-id-type="pmid">24486383</pub-id>
</element-citation>
</ref>
<ref id="B295-biomolecules-10-00702">
<label>295.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>W.Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>Caffeic acid and resveratrol ameliorate cellular damage in cell and Drosophila models of spinocerebellar ataxia type 3 through upregulation of Nrf2 pathway</article-title>
<source/>Free Radic. Biol. Med.
          <year>2018</year>
<volume>115</volume>
<fpage>309</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2017.12.011</pub-id>
<pub-id pub-id-type="pmid">29247688</pub-id>
</element-citation>
</ref>
<ref id="B296-biomolecules-10-00702">
<label>296.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ajayi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lindberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Langel</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Ström</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model</article-title>
<source/>BMC Neurosci.
          <year>2012</year>
<volume>13</volume>
<elocation-id>86</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2202-13-86</pub-id>
<pub-id pub-id-type="pmid">22827889</pub-id>
</element-citation>
</ref>
<ref id="B297-biomolecules-10-00702">
<label>297.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boukhtouche</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Vodjdani</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jarvis</surname>
<given-names>C.I.</given-names>
</name>
<name>
<surname>Bakouche</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Staels</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mariani</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lemaigre-Dubreuil</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Brugg</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Human retinoic acid receptor-related orphan receptor alpha1 overexpression protects neurones against oxidative stress-induced apoptosis</article-title>
<source/>J. Neurochem.
          <year>2006</year>
<volume>96</volume>
<fpage>1778</fpage>
<lpage>1789</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03708.x</pub-id>
<pub-id pub-id-type="pmid">16539693</pub-id>
</element-citation>
</ref>
<ref id="B298-biomolecules-10-00702">
<label>298.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Z.H.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.J.</given-names>
</name>
</person-group>
<article-title>Polyglutamine domain modulates the TBP-TFIIB interaction: Implications for its normal function and neurodegeneration</article-title>
<source/>Nat. Neurosci.
          <year>2007</year>
<volume>10</volume>
<fpage>1519</fpage>
<lpage>1528</lpage>
<pub-id pub-id-type="doi">10.1038/nn2011</pub-id>
<pub-id pub-id-type="pmid">17994014</pub-id>
</element-citation>
</ref>
<ref id="B299-biomolecules-10-00702">
<label>299.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wyttenbach</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sauvageot</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Carmichael</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Diaz-Latoud</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Arrigo</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Rubinsztein</surname>
<given-names>D.C.</given-names>
</name>
</person-group>
<article-title>Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin</article-title>
<source/>Hum. Mol. Genet.
          <year>2002</year>
<volume>11</volume>
<fpage>1137</fpage>
<lpage>1151</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/11.9.1137</pub-id>
<pub-id pub-id-type="pmid">11978772</pub-id>
</element-citation>
</ref>
<ref id="B300-biomolecules-10-00702">
<label>300.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C.-M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>L.-C.</given-names>
</name>
<name>
<surname>Soong</surname>
<given-names>B.-W.</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>H.-C.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>W.-C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>P.-Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.-J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F.-L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Lee-Chen</surname>
<given-names>G.-J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SCA17 repeat expansion: Mildly expanded CAG/CAA repeat alleles in neurological disorders and the functional implications</article-title>
<source/>Clin. Chim. Acta
          <year>2010</year>
<volume>411</volume>
<fpage>375</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1016/j.cca.2009.12.002</pub-id>
<pub-id pub-id-type="pmid">20004653</pub-id>
</element-citation>
</ref>
<ref id="B301-biomolecules-10-00702">
<label>301.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.R.</given-names>
</name>
<name>
<surname>Soong</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Lee-Chen</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Downregulation of proteins involved in the endoplasmic reticulum stress response and Nrf2-ARE signaling in lymphoblastoid cells of spinocerebellar ataxia type 17</article-title>
<source/>J. Neural Transm.
          <year>2014</year>
<volume>121</volume>
<fpage>601</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="doi">10.1007/s00702-013-1157-z</pub-id>
<pub-id pub-id-type="pmid">24413982</pub-id>
</element-citation>
</ref>
<ref id="B302-biomolecules-10-00702">
<label>302.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koriyama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chiba</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Muramoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Long-acting genipin derivative protects retinal ganglion cells from oxidative stress models in vitro and in vivo through the Nrf2/antioxidant response element signaling pathway</article-title>
<source/>J. Neurochem.
          <year>2010</year>
<volume>115</volume>
<fpage>79</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06903.x</pub-id>
<pub-id pub-id-type="pmid">20681953</pub-id>
</element-citation>
</ref>
<ref id="B303-biomolecules-10-00702">
<label>303.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyata</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tanuma</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shioda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fukatsu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mizutani</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Oxidative stress in neurodegeneration in dentatorubral-pallidoluysian atrophy</article-title>
<source/>J. Neurol. Sci.
          <year>2008</year>
<volume>264</volume>
<fpage>133</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2007.08.025</pub-id>
<pub-id pub-id-type="pmid">17949751</pub-id>
</element-citation>
</ref>
<ref id="B304-biomolecules-10-00702">
<label>304.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orr</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>Trinucleotide repeat disorders</article-title>
<source/>Annu. Rev. Neurosci.
          <year>2007</year>
<volume>30</volume>
<fpage>575</fpage>
<lpage>621</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.neuro.29.051605.113042</pub-id>
<pub-id pub-id-type="pmid">17417937</pub-id>
</element-citation>
</ref>
<ref id="B305-biomolecules-10-00702">
<label>305.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Coffey</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Seritan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Olichney</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems</article-title>
<source/>Clin. Interv. Aging
          <year>2008</year>
<volume>3</volume>
<fpage>251</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.2147/CIA.S1794</pub-id>
<pub-id pub-id-type="pmid">18686748</pub-id>
</element-citation>
</ref>
<ref id="B306-biomolecules-10-00702">
<label>306.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: Two faces of FMR1</article-title>
<source/>Lancet Neurol.
          <year>2007</year>
<volume>6</volume>
<fpage>45</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(06)70676-7</pub-id>
<pub-id pub-id-type="pmid">17166801</pub-id>
</element-citation>
</ref>
<ref id="B307-biomolecules-10-00702">
<label>307.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jardini</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gane</surname>
<given-names>L.W.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>S.W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population</article-title>
<source/>JAMA
          <year>2004</year>
<volume>291</volume>
<fpage>460</fpage>
<lpage>469</lpage>
<pub-id pub-id-type="doi">10.1001/jama.291.4.460</pub-id>
<pub-id pub-id-type="pmid">14747503</pub-id>
</element-citation>
</ref>
<ref id="B308-biomolecules-10-00702">
<label>308.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Chamberlain</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Transcription of the FMR1 gene in individuals with fragile X syndrome</article-title>
<source/>Am. J. Med. Genet.
          <year>2000</year>
<volume>97</volume>
<fpage>195</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1002/1096-8628(200023)97:3&lt;195::AID-AJMG1037&gt;3.0.CO;2-R</pub-id>
<pub-id pub-id-type="pmid">11449488</pub-id>
</element-citation>
</ref>
<ref id="B309-biomolecules-10-00702">
<label>309.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chudley</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Del Bigio</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers</article-title>
<source/>Brain
          <year>2002</year>
<volume>125</volume>
<fpage>1760</fpage>
<lpage>1771</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awf184</pub-id>
<pub-id pub-id-type="pmid">12135967</pub-id>
</element-citation>
</ref>
<ref id="B310-biomolecules-10-00702">
<label>310.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Iwahashi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>
<source/>RNA Biol.
          <year>2004</year>
<volume>1</volume>
<fpage>103</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.4161/rna.1.2.1035</pub-id>
<pub-id pub-id-type="pmid">17179750</pub-id>
</element-citation>
</ref>
<ref id="B311-biomolecules-10-00702">
<label>311.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwahashi</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Yasui</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nannen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Babineau</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lebrilla</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Protein composition of the intranuclear inclusions of FXTAS</article-title>
<source/>Brain
          <year>2006</year>
<volume>129</volume>
<fpage>256</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awh650</pub-id>
<pub-id pub-id-type="pmid">16246864</pub-id>
</element-citation>
</ref>
<ref id="B312-biomolecules-10-00702">
<label>312.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Qurashi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rosser</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>S.T.</given-names>
</name>
</person-group>
<article-title>Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome</article-title>
<source/>Neuron
          <year>2007</year>
<volume>55</volume>
<fpage>556</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2007.07.020</pub-id>
<pub-id pub-id-type="pmid">17698009</pub-id>
</element-citation>
</ref>
<ref id="B313-biomolecules-10-00702">
<label>313.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sofola</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>de Haro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Botas</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS</article-title>
<source/>Neuron
          <year>2007</year>
<volume>55</volume>
<fpage>565</fpage>
<lpage>571</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2007.07.021</pub-id>
<pub-id pub-id-type="pmid">17698010</pub-id>
</element-citation>
</ref>
<ref id="B314-biomolecules-10-00702">
<label>314.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Herren</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Espinal</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Randol</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Martinez-Cerdeno</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>I.N.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Composition of the Intranuclear Inclusions of Fragile X-associated Tremor/Ataxia Syndrome</article-title>
<source/>Acta Neuropathol. Commun.
          <year>2019</year>
<volume>7</volume>
<fpage>143</fpage>
<pub-id pub-id-type="doi">10.1186/s40478-019-0796-1</pub-id>
<pub-id pub-id-type="pmid">31481131</pub-id>
</element-citation>
</ref>
<ref id="B315-biomolecules-10-00702">
<label>315.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iijima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Witte</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hanno-Iijima</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Glatter</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Scheiffele</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>SAM68 regulates neuronal activity-dependent alternative splicing of neurexin-1</article-title>
<source/>Cell
          <year>2011</year>
<volume>147</volume>
<fpage>1601</fpage>
<lpage>1614</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2011.11.028</pub-id>
<pub-id pub-id-type="pmid">22196734</pub-id>
</element-citation>
</ref>
<ref id="B316-biomolecules-10-00702">
<label>316.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iijima</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ayukawa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ohtsuka</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SAM68-Specific Splicing Is Required for Proper Selection of Alternative 3′ UTR Isoforms in the Nervous System</article-title>
<source/>iScience
          <year>2019</year>
<volume>22</volume>
<fpage>318</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1016/j.isci.2019.11.028</pub-id>
<pub-id pub-id-type="pmid">31805436</pub-id>
</element-citation>
</ref>
<ref id="B317-biomolecules-10-00702">
<label>317.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Rosa</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bielli</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Compagnucci</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cesari</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Volpe</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Farioli Vecchioli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sette</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Sam68 promotes self-renewal and glycolytic metabolism in mouse neural progenitor cells by modulating Aldh1a3 pre-mRNA 3′-end processing</article-title>
<source/>Elife
          <year>2016</year>
<volume>5</volume>
<pub-id pub-id-type="doi">10.7554/eLife.20750</pub-id>
<pub-id pub-id-type="pmid">27845622</pub-id>
</element-citation>
</ref>
<ref id="B318-biomolecules-10-00702">
<label>318.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvarez-Mora</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Rodriguez-Revenga</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Madrigal</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Guitart-Mampel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garrabou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mila</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Impaired Mitochondrial Function and Dynamics in the Pathogenesis of FXTAS</article-title>
<source/>Mol. Neurobiol.
          <year>2017</year>
<volume>54</volume>
<fpage>6896</fpage>
<lpage>6902</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-016-0194-7</pub-id>
<pub-id pub-id-type="pmid">27771901</pub-id>
</element-citation>
</ref>
<ref id="B319-biomolecules-10-00702">
<label>319.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Espinal</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Hulsizer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>I.N.</given-names>
</name>
</person-group>
<article-title>Calcium dysregulation and Cdk5-ATM pathway involved in a mouse model of fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Hum. Mol. Genet.
          <year>2017</year>
<volume>26</volume>
<fpage>2649</fpage>
<lpage>2666</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddx148</pub-id>
<pub-id pub-id-type="pmid">28444183</pub-id>
</element-citation>
</ref>
<ref id="B320-biomolecules-10-00702">
<label>320.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross-Inta</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Omanska-Klusek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barrow</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Garcia-Arocena</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Iwahashi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Giulivi</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Biochem. J.
          <year>2010</year>
<volume>429</volume>
<fpage>545</fpage>
<lpage>552</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20091960</pub-id>
<pub-id pub-id-type="pmid">20513237</pub-id>
</element-citation>
</ref>
<ref id="B321-biomolecules-10-00702">
<label>321.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Napoli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giulivi</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Altered redox mitochondrial biology in the neurodegenerative disorder fragile X-tremor/ataxia syndrome: Use of antioxidants in precision medicine</article-title>
<source/>Mol. Med.
          <year>2016</year>
<volume>22</volume>
<fpage>548</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="doi">10.2119/molmed.2016.00122</pub-id>
<pub-id pub-id-type="pmid">27385396</pub-id>
</element-citation>
</ref>
<ref id="B322-biomolecules-10-00702">
<label>322.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napoli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ross-Inta</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Omanska-Klusek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barrow</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Iwahashi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Garcia-Arocena</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sakaguchi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Hum. Mol. Genet.
          <year>2011</year>
<volume>20</volume>
<fpage>3079</fpage>
<lpage>3092</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr211</pub-id>
<pub-id pub-id-type="pmid">21558427</pub-id>
</element-citation>
</ref>
<ref id="B323-biomolecules-10-00702">
<label>323.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaplan</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hulsizer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Pessah</surname>
<given-names>I.N.</given-names>
</name>
</person-group>
<article-title>Early mitochondrial abnormalities in hippocampal neurons cultured from Fmr1 pre-mutation mouse model</article-title>
<source/>J. Neurochem.
          <year>2012</year>
<volume>123</volume>
<fpage>613</fpage>
<lpage>621</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07936.x</pub-id>
<pub-id pub-id-type="pmid">22924671</pub-id>
</element-citation>
</ref>
<ref id="B324-biomolecules-10-00702">
<label>324.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hatch</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Gurel</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Higgs</surname>
<given-names>H.N.</given-names>
</name>
</person-group>
<article-title>Novel roles for actin in mitochondrial fission</article-title>
<source/>J. Cell. Sci.
          <year>2014</year>
<volume>127</volume>
<fpage>4549</fpage>
<lpage>4560</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.153791</pub-id>
<pub-id pub-id-type="pmid">25217628</pub-id>
</element-citation>
</ref>
<ref id="B325-biomolecules-10-00702">
<label>325.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pastore</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tozzi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gaeta</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Serafini</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Di Cesare</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bonetto</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Casoni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Carrozzo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Federici</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Actin glutathionylation increases in fibroblasts of patients with Friedreich’s ataxia: A potential role in the pathogenesis of the disease</article-title>
<source/>J. Biol. Chem.
          <year>2003</year>
<volume>278</volume>
<fpage>42588</fpage>
<lpage>42595</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M301872200</pub-id>
<pub-id pub-id-type="pmid">12915401</pub-id>
</element-citation>
</ref>
<ref id="B326-biomolecules-10-00702">
<label>326.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2004</year>
<volume>101</volume>
<fpage>2046</fpage>
<lpage>2051</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0308347100</pub-id>
<pub-id pub-id-type="pmid">14764898</pub-id>
</element-citation>
</ref>
<ref id="B327-biomolecules-10-00702">
<label>327.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gakh</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Cavadini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Isaya</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Mitochondrial processing peptidases</article-title>
<source/>Biochim. Biophys. Acta (BBA) Mol. Cell Res.
          <year>2002</year>
<volume>1592</volume>
<fpage>63</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1016/S0167-4889(02)00265-3</pub-id>
</element-citation>
</ref>
<ref id="B328-biomolecules-10-00702">
<label>328.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Condò</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ventura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Malisan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Rufini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tomassini</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Testi</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>In vivo maturation of human frataxin</article-title>
<source/>Hum. Mol. Genet.
          <year>2007</year>
<volume>16</volume>
<fpage>1534</fpage>
<lpage>1540</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddm102</pub-id>
<pub-id pub-id-type="pmid">17468497</pub-id>
</element-citation>
</ref>
<ref id="B329-biomolecules-10-00702">
<label>329.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Dancis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pain</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Maturation of Frataxin Within Mammalian and Yeast Mitochondria: One-Step Processing by Matrix Processing Peptidase</article-title>
<source/>Hum. Mol. Genet.
          <year>1999</year>
<volume>8</volume>
<fpage>2255</fpage>
<lpage>2262</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/8.12.2255</pub-id>
<pub-id pub-id-type="pmid">10545606</pub-id>
</element-citation>
</ref>
<ref id="B330-biomolecules-10-00702">
<label>330.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoser</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Timchenko</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Myotonic dystrophies 1 and 2: Complex diseases with complex mechanisms</article-title>
<source/>Curr. Genom.
          <year>2010</year>
<volume>11</volume>
<fpage>77</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.2174/138920210790886844</pub-id>
</element-citation>
</ref>
<ref id="B331-biomolecules-10-00702">
<label>331.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winblad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Samuelsson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lindberg</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meola</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Cognition in myotonic dystrophy type 1: A 5-year follow-up study</article-title>
<source/>Eur. J. Neurol.
          <year>2016</year>
<volume>23</volume>
<fpage>1471</fpage>
<lpage>1476</lpage>
<pub-id pub-id-type="doi">10.1111/ene.13062</pub-id>
<pub-id pub-id-type="pmid">27323306</pub-id>
</element-citation>
</ref>
<ref id="B332-biomolecules-10-00702">
<label>332.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sansone</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gandossini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cotelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Calabria</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zanetti</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Meola</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Cognitive impairment in adult myotonic dystrophies: A longitudinal study</article-title>
<source/>Neurol. Sci.
          <year>2007</year>
<volume>28</volume>
<fpage>9</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1007/s10072-007-0742-z</pub-id>
<pub-id pub-id-type="pmid">17385090</pub-id>
</element-citation>
</ref>
<ref id="B333-biomolecules-10-00702">
<label>333.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schara</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Schoser</surname>
<given-names>B.G.</given-names>
</name>
</person-group>
<article-title>Myotonic dystrophies type 1 and 2: A summary on current aspects</article-title>
<source/>Semin. Pediatr. Neurol.
          <year>2006</year>
<volume>13</volume>
<fpage>71</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1016/j.spen.2006.06.002</pub-id>
<pub-id pub-id-type="pmid">17027856</pub-id>
</element-citation>
</ref>
<ref id="B334-biomolecules-10-00702">
<label>334.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machuca-Tzili</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Brook</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hilton-Jones</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Clinical and molecular aspects of the myotonic dystrophies: A review</article-title>
<source/>Muscle Nerve
          <year>2005</year>
<volume>32</volume>
<fpage>1</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1002/mus.20301</pub-id>
<pub-id pub-id-type="pmid">15770660</pub-id>
</element-citation>
</ref>
<ref id="B335-biomolecules-10-00702">
<label>335.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liquori</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Ricker</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Moseley</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Jacobsen</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Kress</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Naylor</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Ranum</surname>
<given-names>L.P.</given-names>
</name>
</person-group>
<article-title>Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9</article-title>
<source/>Science
          <year>2001</year>
<volume>293</volume>
<fpage>864</fpage>
<lpage>867</lpage>
<pub-id pub-id-type="doi">10.1126/science.1062125</pub-id>
<pub-id pub-id-type="pmid">11486088</pub-id>
</element-citation>
</ref>
<ref id="B336-biomolecules-10-00702">
<label>336.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Day</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Ricker</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jacobsen</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Kress</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Beilman</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>A.R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Myotonic dystrophy type 2: Molecular, diagnostic and clinical spectrum</article-title>
<source/>Neurology
          <year>2003</year>
<volume>60</volume>
<fpage>657</fpage>
<lpage>664</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000054481.84978.F9</pub-id>
<pub-id pub-id-type="pmid">12601109</pub-id>
</element-citation>
</ref>
<ref id="B337-biomolecules-10-00702">
<label>337.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yum</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>E.T.</given-names>
</name>
<name>
<surname>Kalsotra</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Myotonic dystrophy: Disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes</article-title>
<source/>Curr. Opin. Genet. Dev.
          <year>2017</year>
<volume>44</volume>
<fpage>30</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.gde.2017.01.007</pub-id>
<pub-id pub-id-type="pmid">28213156</pub-id>
</element-citation>
</ref>
<ref id="B338-biomolecules-10-00702">
<label>338.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ricker</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Grimm</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kress</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Reimers</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Meinck</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Reiners</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Toyka</surname>
<given-names>K.V.</given-names>
</name>
</person-group>
<article-title>Proximal myotonic myopathy: Evidence for anticipation in families with linkage to chromosome 3q</article-title>
<source/>Neurology
          <year>2000</year>
<volume>55</volume>
<fpage>383</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.55.3.383</pub-id>
<pub-id pub-id-type="pmid">10932272</pub-id>
</element-citation>
</ref>
<ref id="B339-biomolecules-10-00702">
<label>339.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reddy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Rich</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Leferovich</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Reilly</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rayburn</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cros</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy</article-title>
<source/>Nat. Genet.
          <year>1996</year>
<volume>13</volume>
<fpage>325</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1038/ng0796-325</pub-id>
<pub-id pub-id-type="pmid">8673132</pub-id>
</element-citation>
</ref>
<ref id="B340-biomolecules-10-00702">
<label>340.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pegoraro</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Menegazzo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gennarelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hoop</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Angelini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>E.P.</given-names>
</name>
</person-group>
<article-title>Myotonic dystrophy: Evidence for a possible dominant-negative RNA mutation</article-title>
<source/>Hum. Mol. Genet.
          <year>1995</year>
<volume>4</volume>
<fpage>599</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/4.4.599</pub-id>
<pub-id pub-id-type="pmid">7543316</pub-id>
</element-citation>
</ref>
<ref id="B341-biomolecules-10-00702">
<label>341.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warf</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Berglund</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T</article-title>
<source/>RNA
          <year>2007</year>
<volume>13</volume>
<fpage>2238</fpage>
<lpage>2251</lpage>
<pub-id pub-id-type="doi">10.1261/rna.610607</pub-id>
<pub-id pub-id-type="pmid">17942744</pub-id>
</element-citation>
</ref>
<ref id="B342-biomolecules-10-00702">
<label>342.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagliarini</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>La Rosa</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sette</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Faulty RNA splicing: Consequences and therapeutic opportunities in brain and muscle disorders</article-title>
<source/>Hum. Genet.
          <year>2017</year>
<volume>136</volume>
<fpage>1215</fpage>
<lpage>1235</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-017-1802-y</pub-id>
<pub-id pub-id-type="pmid">28434044</pub-id>
</element-citation>
</ref>
<ref id="B343-biomolecules-10-00702">
<label>343.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuyumcu-Martinez</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation</article-title>
<source/>Mol. Cell
          <year>2007</year>
<volume>28</volume>
<fpage>68</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2007.07.027</pub-id>
<pub-id pub-id-type="pmid">17936705</pub-id>
</element-citation>
</ref>
<ref id="B344-biomolecules-10-00702">
<label>344.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charlet</surname>
<given-names>B.N.</given-names>
</name>
<name>
<surname>Savkur</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Philips</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Grice</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing</article-title>
<source/>Mol. Cell
          <year>2002</year>
<volume>10</volume>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1016/S1097-2765(02)00572-5</pub-id>
<pub-id pub-id-type="pmid">12150906</pub-id>
</element-citation>
</ref>
<ref id="B345-biomolecules-10-00702">
<label>345.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mateos-Aierdi</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Goicoechea</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aiastui</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fernández-Torrón</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Garcia-Puga</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Matheu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>López de Munain</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Muscle wasting in myotonic dystrophies: A model of premature aging</article-title>
<source/>Front. Aging Neurosci.
          <year>2015</year>
<volume>7</volume>
<elocation-id>125</elocation-id>
<pub-id pub-id-type="doi">10.3389/fnagi.2015.00125</pub-id>
<pub-id pub-id-type="pmid">26217220</pub-id>
</element-citation>
</ref>
<ref id="B346-biomolecules-10-00702">
<label>346.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Usuki</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ishiura</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Expanded CTG repeats in myotonin protein kinase increase susceptibility to oxidative stress</article-title>
<source/>Neuroreport
          <year>1998</year>
<volume>9</volume>
<fpage>2291</fpage>
<lpage>2296</lpage>
<pub-id pub-id-type="doi">10.1097/00001756-199807130-00027</pub-id>
<pub-id pub-id-type="pmid">9694217</pub-id>
</element-citation>
</ref>
<ref id="B347-biomolecules-10-00702">
<label>347.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Usuki</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sasagawa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ishiura</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Differential signaling pathways following oxidative stress in mutant myotonin protein kinase cDNA-transfected C2C12 cell lines</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2000</year>
<volume>267</volume>
<fpage>739</fpage>
<lpage>743</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.1999.2026</pub-id>
<pub-id pub-id-type="pmid">10673361</pub-id>
</element-citation>
</ref>
<ref id="B348-biomolecules-10-00702">
<label>348.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ihara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hayabara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Namba</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nobukuni</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Miyata</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Edamatsu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Free radicals, lipid peroxides and antioxidants in blood of patients with myotonic dystrophy</article-title>
<source/>J. Neurol.
          <year>1995</year>
<volume>242</volume>
<fpage>119</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1007/BF00936882</pub-id>
<pub-id pub-id-type="pmid">7751852</pub-id>
</element-citation>
</ref>
<ref id="B349-biomolecules-10-00702">
<label>349.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Head</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Oxidative damage and cognitive dysfunction: Antioxidant treatments to promote healthy brain aging</article-title>
<source/>Neurochem. Res.
          <year>2009</year>
<volume>34</volume>
<fpage>670</fpage>
<lpage>678</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-008-9808-4</pub-id>
<pub-id pub-id-type="pmid">18683046</pub-id>
</element-citation>
</ref>
<ref id="B350-biomolecules-10-00702">
<label>350.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baierle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Moro</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Brucker</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Freitas</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gauer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Durgante</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bordignon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zibetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trentini</surname>
<given-names>C.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Relationship between inflammation and oxidative stress and cognitive decline in the institutionalized elderly</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2015</year>
<volume>2015</volume>
<fpage>804198</fpage>
<pub-id pub-id-type="doi">10.1155/2015/804198</pub-id>
<pub-id pub-id-type="pmid">25874023</pub-id>
</element-citation>
</ref>
<ref id="B351-biomolecules-10-00702">
<label>351.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michel</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Pülschen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thome</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The role of oxidative stress in depressive disorders</article-title>
<source/>Curr. Pharm. Des.
          <year>2012</year>
<volume>18</volume>
<fpage>5890</fpage>
<lpage>5899</lpage>
<pub-id pub-id-type="doi">10.2174/138161212803523554</pub-id>
<pub-id pub-id-type="pmid">22681168</pub-id>
</element-citation>
</ref>
<ref id="B352-biomolecules-10-00702">
<label>352.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rawdin</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Mellon</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Dhabhar</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Epel</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Puterman</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Reus</surname>
<given-names>V.I.</given-names>
</name>
<name>
<surname>Rosser</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>S.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dysregulated relationship of inflammation and oxidative stress in major depression</article-title>
<source/>Brain Behav. Immun.
          <year>2013</year>
<volume>31</volume>
<fpage>143</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2012.11.011</pub-id>
<pub-id pub-id-type="pmid">23201587</pub-id>
</element-citation>
</ref>
<ref id="B353-biomolecules-10-00702">
<label>353.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramon-Duaso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gener</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Consegal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fernández-Avilés</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gallego</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Castarlenas</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>de la Torre</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Maldonado</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Puig</surname>
<given-names>M.V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Methylphenidate Attenuates the Cognitive and Mood Alterations Observed in Mbnl2 Knockout Mice and Reduces Microglia Overexpression</article-title>
<source/>Cereb. Cortex
          <year>2018</year>
<volume>29</volume>
<fpage>2978</fpage>
<lpage>2997</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bhy164</pub-id>
</element-citation>
</ref>
<ref id="B354-biomolecules-10-00702">
<label>354.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruna</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lobos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Herrera-Molina</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hidalgo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Paula-Lima</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Adasme</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>The signaling pathways underlying BDNF-induced Nrf2 hippocampal nuclear translocation involve ROS, RyR-Mediated Ca<sup>2+</sup> signals, ERK and PI3K</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2018</year>
<volume>505</volume>
<fpage>201</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2018.09.080</pub-id>
<pub-id pub-id-type="pmid">30243728</pub-id>
</element-citation>
</ref>
<ref id="B355-biomolecules-10-00702">
<label>355.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Ishima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Suganuma</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice</article-title>
<source/>Sci. Rep.
          <year>2016</year>
<volume>6</volume>
<fpage>30659</fpage>
<pub-id pub-id-type="doi">10.1038/srep30659</pub-id>
<pub-id pub-id-type="pmid">27470577</pub-id>
</element-citation>
</ref>
<ref id="B356-biomolecules-10-00702">
<label>356.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.-C.</given-names>
</name>
<name>
<surname>Ishima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Honda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Antidepressant effects of TBE-31 and MCE-1, the novel Nrf2 activators, in an inflammation model of depression</article-title>
<source/>Eur. J. Pharmacol.
          <year>2016</year>
<volume>793</volume>
<fpage>21</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2016.10.037</pub-id>
<pub-id pub-id-type="pmid">27815170</pub-id>
</element-citation>
</ref>
<ref id="B357-biomolecules-10-00702">
<label>357.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winblad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Månsson</surname>
<given-names>J.-E.</given-names>
</name>
<name>
<surname>Samuelsson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lindberg</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Depression in Myotonic Dystrophy type 1: Clinical and neuronal correlates</article-title>
<source/>Behav. Brain Funct.
          <year>2010</year>
<volume>6</volume>
<elocation-id>25</elocation-id>
<pub-id pub-id-type="doi">10.1186/1744-9081-6-25</pub-id>
<pub-id pub-id-type="pmid">20482818</pub-id>
</element-citation>
</ref>
<ref id="B358-biomolecules-10-00702">
<label>358.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wegner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Araszkiewicz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Piorunska-Stolzmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wierusz-Wysocka</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zozulinska-Ziolkiewicz</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications</article-title>
<source/>Inflammation
          <year>2013</year>
<volume>36</volume>
<fpage>723</fpage>
<lpage>728</lpage>
<pub-id pub-id-type="doi">10.1007/s10753-013-9598-y</pub-id>
<pub-id pub-id-type="pmid">23371411</pub-id>
</element-citation>
</ref>
<ref id="B359-biomolecules-10-00702">
<label>359.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Anticipation in hereditary disease: The history of a biomedical concept</article-title>
<source/>Hum. Genet.
          <year>2011</year>
<volume>130</volume>
<fpage>705</fpage>
<lpage>714</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-011-1022-9</pub-id>
<pub-id pub-id-type="pmid">21667285</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="biomolecules-10-00702-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Putative location and sequence of DNA expansions in repeat disorders. Schematic representation of an ideal gene showing DNA repeat expansions that cause diseases. Name of the relative disorder, number of pathogenic repeats, and its sequence are reported in the gene region were the repeats stem in the pathology. The grey arrow represents pathology where oxidative stress has been poorly investigated. Blue arrows characterize diseases with oxidative stress contributions. Red arrows identify pathologies in which NF-E2 p45-related factor 2 (NRF2) involvement has been reported. (FXTAS, fragile X–associated tremor ataxia syndrome; FXS, fragile X syndrome; FA, Friedreich’s ataxia; DM1/DM2 myotonic dystrophy; HD, Huntington’s disease; SCAs, spinocerebellar ataxias; SBMA, spinobulbar muscular atrophy).</p>
</caption>
<graphic xlink:href="biomolecules-10-00702-g001"></graphic>
</fig>
<fig id="biomolecules-10-00702-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Representative model of the NRF2 signaling pathway activation in Friedreich’s Ataxia (FA), based on literature evidences. NRF2 inducers determine the activation of antioxidant genes transcription and the upregulation of enzymes involved in the regulation of glutathione (GSH) expression, rebalancing the unpaired GSH/GSSG ratio and reducing oxidative stress and lipid peroxidation. Importantly, NRF2 also increases frataxin (FXN) levels, thus partially rescuing the mitochondrial defects observed in FA pathology.</p>
</caption>
<graphic xlink:href="biomolecules-10-00702-g002"></graphic>
</fig>
<fig id="biomolecules-10-00702-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Representative model of the NRF2 signaling pathway activation in spinocerebellar ataxia 3 (SCA3), based on literature evidences. As a consequence of NRF2-mediated activation of the antioxidant response, reduction of cellular and mitochondrial ROS production is observed, thus inactivating the apoptotic pathway. In addition, NRF2 increases cellular levels of p62, which shuttles the mutant ataxin 3 aggregates to the autophagosomes, reducing their cellular concentration. At the same time, p62 interferes with the KEAP-1/NRF2 complexes, thus blocking the KEAP-1 mediated NRF2 degradation and sustaining its activity.</p>
</caption>
<graphic xlink:href="biomolecules-10-00702-g003"></graphic>
</fig>
<fig id="biomolecules-10-00702-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Representative model of the NRF2 signaling pathway activation in myotonic dystrophy 1 (DM1), based on literature evidences. Brain-derived neurotrophic factor (BDNF) activation of PI3K/AKT pathway determines the inhibitory phosphorylation of GSK3β by blocking NRF2/KEAP-1-indipendent degradation. As BDNF is a NRF2 target, this can start a positive feedback contributing to NRF2 activation. At the same time, the transcription of NRF2 antioxidant target genes reduces oxidative stress in DM1 cells and the pro-inflammatory cytokine IL-1β levels.</p>
</caption>
<graphic xlink:href="biomolecules-10-00702-g004"></graphic>
</fig>
<table-wrap id="biomolecules-10-00702-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">biomolecules-10-00702-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Table summarizing findings on antioxidant drugs/NRF2-activating compounds and their main effects in DNA repeat expansion disorders.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#A6A6A6" valign="middle">Disease</td>
<td align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#A6A6A6" valign="middle">Compound</td>
<td align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#A6A6A6" valign="middle">Model</td>
<td align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#A6A6A6" valign="middle">Effect of Treatment</td>
<td align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#A6A6A6" valign="middle">Ref.</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">FA</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">SFN, DMF, NAC, EPI-743, RTA408, Idebenone</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">FA patients’ fibroblasts</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">Increase of GSH content; enhancement of <italic>FXN</italic>, NRF2 and down-stream genes mRNA.</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">[<xref ref-type="bibr" rid="B111-biomolecules-10-00702">111</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">
</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">SFN, DMF</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">shFXN NSC34 motor neurons</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">Rebalance of GSH/GSSG ratio; increase of FXN, NRF2 and down-stream genes expression.</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">[<xref ref-type="bibr" rid="B124-biomolecules-10-00702">124</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">
</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">Idebenone</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">Patients</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">Reduction of cardiac hypertrophy.</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">[<xref ref-type="bibr" rid="B128-biomolecules-10-00702">128</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">
</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">EPI-743</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">Patients</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">Improvement of neurological functions.</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">[<xref ref-type="bibr" rid="B132-biomolecules-10-00702">132</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">SBMA</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">ASC-J9</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">AR-112Q PC12 cells; AR-97Q mice</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">Reduction of AR aggregates; rescue of motor defects and muscular atrophy; increase of VEGF expression.</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">[<xref ref-type="bibr" rid="B203-biomolecules-10-00702">203</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">
</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">ASC-J17</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">SBMA patients’ fibroblasts; AR97Q mouse; AR52Q drosophila</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">Increase of NRF2 down-stream genes; suppression of polyQ toxicity in mutant flies; amelioration of mutant mice phenotype and decrease of mutant AR accumulation.</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">[<xref ref-type="bibr" rid="B204-biomolecules-10-00702">204</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">HD</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">SFN</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">mHtt-94Q Hek293</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">Increase of mHtt degradation and reduction of mHtt-induced toxicity.</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">[<xref ref-type="bibr" rid="B232-biomolecules-10-00702">232</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">
</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">MIND4-17</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">HD patients’ primary monocytes</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">Reduction of inflammatory cytokines expression.</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">[<xref ref-type="bibr" rid="B233-biomolecules-10-00702">233</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">
</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">DMF</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">R6/2 and YAC128 mice</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">Increased survival and motor functions; preservation of striatal neurons morphology; increase of NRF2 expression.</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">[<xref ref-type="bibr" rid="B236-biomolecules-10-00702">236</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">SCA1</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">MitoQ</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">Sca1 154Q/2Q mice</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">Improvement of motor coordination defects; reduction of mitochondrial morphological abnormalities and ETC activity defects.</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">[<xref ref-type="bibr" rid="B262-biomolecules-10-00702">262</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">SCA3</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle"><italic>Glycyrrhiza inflata</italic> extract, AMGZ, Licochalcone A</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">ATXN3/Q75-GFP Hek293 and SH-SY5Y cells</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">Decrease of Ataxin3 aggregates; up-regulation of NRF2 and down-stream genes; reduction of GSSG and ROS levels.</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">[<xref ref-type="bibr" rid="B282-biomolecules-10-00702">282</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">
</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle"><italic>Gardenia jasminoides</italic> extract, genipin, geniposide, crocin</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">ATXN3/Q75-GFP Hek293 and SH-SY5Y cells</td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">Reduction of Ataxin3 aggregates and Caspase3 activity; increase of NRF2 and its target genes; decrease of ROS concentration. </td>
<td align="left" colspan="1" rowspan="1" style="background:#BFBFBF" valign="middle">[<xref ref-type="bibr" rid="B283-biomolecules-10-00702">283</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">SCA17</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">Resveratrol, genipin</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">SCA17 lynfoblastoid cells</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">Increase of NRF2 antioxidant target genes and cell viability; decrease of ROS.</td>
<td align="left" colspan="1" rowspan="1" style="background:#F2F2F2" valign="middle">[<xref ref-type="bibr" rid="B290-biomolecules-10-00702">290</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#BFBFBF" valign="middle">DM1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#BFBFBF" valign="middle">MPH</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#BFBFBF" valign="middle">Mbnl2 KO mice.</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#BFBFBF" valign="middle">Increase of <italic>NRF2</italic> and <italic>BDNF</italic> expression; rescue of behavioral deficits; decrease of inflammation.</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#BFBFBF" valign="middle">[<xref ref-type="bibr" rid="B344-biomolecules-10-00702">344</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>